96. クローン病 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
( L ) ASCORBATO DI CALCIO   
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2019-001866-14-IT   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
-aminosalicylic acid   
   University of Vermont
      1995   -   NCT00004423   -
0,25 mg RPC1063   
   Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
      2015   Phase 2   EUCTR2015-002025-19-HU   Canada;Hungary;Italy;Poland;Ukraine;United States;
00000   
   CELLTRION INC.
      2019   Phase 3   EUCTR2019-001087-30-IT   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
0114-0006B   
   Novo Nordisk A/S
      2013   -   EUCTR2012-002432-93-SK   Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2013   -   EUCTR2012-002432-93-PL   Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2013   -   EUCTR2012-002432-93-CZ   Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2013   -   EUCTR2012-002432-93-BG   Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2012   -   EUCTR2012-002432-93-HU   Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
      2012   -   EUCTR2012-002432-93-ES   Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
1000 IU D3   
   Cedars-Sinai Medical Center
      2018   Early Phase 1   NCT03615378   United States;
13-valent pneumococcal conjugated vaccine (PCV13)   
   Klara M. Pósfay Barbe
      2014   Phase 4   NCT01908283   Switzerland;
14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration   
   Celgene International II Sàrl
      2016   Phase 1   EUCTR2016-003073-18-GB   United Kingdom;
18F-FDG   
   Peking Union Medical College Hospital
      2020   Phase 2   NCT04502303   -
2'-Fucosyllactose   
   Children's Hospital Medical Center, Cincinnati
      2019   Phase 1/Phase 2   NCT03847467   United States;
23-valent polysaccharide pneumococcal vaccine   
   Kyunghee University Medical Center
      2011   Phase 4   NCT01505855   Korea, Republic of;
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)   
   Cedars-Sinai Medical Center
      2005   -   NCT00829595   United States;
3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III)   
   Iron Therapeutics (Switzerland) AG
      2012   -   EUCTR2010-023589-39-DE   Austria;Germany;Hungary;United Kingdom;
      2011   Phase 3   EUCTR2010-023589-39-GB   Austria;Germany;Hungary;United Kingdom;
      2011   -   EUCTR2010-023589-39-AT   Austria;Germany;Hungary;United Kingdom;
      -   -   EUCTR2010-023589-39-HU   Austria;Germany;Hungary;United Kingdom;
331731-18-1   
   AbbVie GK
      -   -   EUCTR2015-004121-13-Outside-EU/EEA   Japan;
   Abbott Deutschland GmbH & Co. KG
      -   -   EUCTR2014-004560-38-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-004531-39-Outside-EU/EEA   Japan;
4-Aminosalicylic acid   
   Jacobus Pharmaceutical
      2007   Phase 2   NCT00417690   Israel;United States;
4-Aminosalicylic acid extended release granules   
   Jacobus Pharmaceutical
      2007   Phase 2   NCT00495521   Israel;United States;
42942019   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy;
5-ASA   
   Alimentiv Inc.
      2017   Phase 4   NCT03261206   Canada;Italy;Ukraine;United Kingdom;
5-Aminosalicyl acid   
   Dr. Falk Pharma GmbH
      2007   -   EUCTR2004-001213-34-GB   Czech Republic;United Kingdom;
5-HTP   
   University Hospital, Ghent
      2018   Phase 2   NCT03574948   Belgium;
5-aminolevulinic acid   
   University Hospital, Akershus
      2019   Phase 1/Phase 2   NCT04164849   Norway;
5-aminosalicylate (Pentasa, Ferring)   
   VU University Medical Center
      2005   Phase 4   NCT00167882   Netherlands;
5-aminosalicylic acid   
   Lower GI disease, Hyogo College of Medicine
      2007   Phase 2,3   JPRN-UMIN000004427   Japan;
5000 IU D3   
   Cedars-Sinai Medical Center
      2018   Early Phase 1   NCT03615378   United States;
549-0261/F02-01   
   F. Hoffmann-La Roche Ltd
      2018   Phase 1   EUCTR2017-003649-10-GB   Belgium;Germany;Poland;Spain;United Kingdom;
      2018   Phase 1   EUCTR2017-003649-10-DE   Belgium;Germany;Poland;Spain;United Kingdom;United States;
      2018   Phase 1   EUCTR2017-003649-10-BE   Belgium;Germany;Poland;Spain;United Kingdom;
      -   Phase 1   EUCTR2017-003649-10-PL   Belgium;Germany;Poland;Spain;United Kingdom;United States;
6 Mercaptopurine   
   Tel-Aviv Sourasky Medical Center
      2012   Phase 3   NCT01629628   Israel;
6 mercaptopurine   
   Indiana University
      2015   -   NCT02413047   United States;
6-Mercaptopurine   
   PIBD net
      2018   Phase 4   EUCTR2016-000522-18-GB   Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
6-Mercaptopurine (Puri-Nethol)   
   University of Edinburgh
      2007   Phase 4   EUCTR2006-005800-15-GB   United Kingdom;
6-Mercaptopurine (Puri-nethol)   
   University of Edinburgh
      2007   Phase 4   EUCTR2006-005800-15-GB   United Kingdom;
6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine   
   Centocor B.V.
      2005   Phase 3   EUCTR2004-002815-10-GB   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002815-10-ES   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-SE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DK   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-AT   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
683699   
   GlaxoSmithKline
      2004   Phase 2   NCT00101946   Canada;United States;
99mTc-S-HYNIC Certolizumab pegol   
   Ghent University Hospital
      2012   Phase 3   EUCTR2009-017998-37-BE   Belgium;
?-3 polyunsaturated fatty acid   
   Sir Run Run Shaw Hospital
      2019   Phase 4   NCT03901937   China;
A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine   
   RedHill Biopharma Limited
      2017   Phase 3   NCT03009396   Canada;Czechia;Israel;New Zealand;Poland;Serbia;United States;
A-1293543.74   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2015   Phase 2   EUCTR2014-003240-12-IT   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2014-003240-12-SK   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-PL   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-NO   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-NL   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-HU   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-ES   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-DK   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-DE   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-BE   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AB1010   
   AB Science
      2015   Phase 2;Phase 3   EUCTR2012-004222-25-GR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Morocco;Poland;Romania;Russian Federation;Slovakia;Spain;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-004222-25-SK   Belgium;Czech Republic;France;Greece;India;Morocco;Slovakia;Spain;Tunisia;
      2013   Phase 3   EUCTR2012-004222-25-BE   Belgium;Canada;Central African Republic;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Romania;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
ABBV-066   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2020-002674-26-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2020-002674-26-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002674-26-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002674-26-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002674-26-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-002674-26-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-002674-26-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-002674-26-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-002674-26-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-003191-50-FR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-003190-17-FR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-SE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003191-50-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003190-17-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003190-17-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003190-17-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003190-17-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003190-17-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003123-32-SE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003123-32-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003123-32-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003123-32-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003123-32-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003123-32-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003123-32-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-EE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003191-50-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-EE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003190-17-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-EE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003123-32-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-003191-50-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-003191-50-NO   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-003190-17-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-003123-32-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-003123-32-NO   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-003123-32-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2016-003123-32-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
ABBV-154   
   AbbVie
      2022   Phase 2   NCT05068284   Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2022   Phase 2   EUCTR2021-002869-18-GR   Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-002869-18-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-002869-18-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-002869-18-BE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;United Kingdom;United States;
ABR-215062 sodium salt   
   Teva Pharmaceutical Industries Ltd.
      2008   Phase 2   EUCTR2008-004276-49-GB   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-004276-49-FR   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-004276-49-ES   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-004276-49-BE   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2008-004276-49-NL   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
ABT 494   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2015   Phase 2   EUCTR2014-003240-12-IT   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2014-003240-12-SK   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-PL   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-NO   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-NL   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-HU   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-ES   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-DK   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-DE   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003240-12-BE   Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
ABT Humira   
   Abbott GmbH & Co. KG
      2007   -   EUCTR2006-002078-23-SE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
ABT-494   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2018   Phase 3   EUCTR2017-001240-35-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   AbbVie
      2016   Phase 2   NCT02782663   Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Romania;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 2   NCT02365649   Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 3   EUCTR2017-001240-35-FR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001240-35-SI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001240-35-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001226-18-SI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001226-18-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001225-41-SI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001225-41-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-NL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-LV   Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-001240-35-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-HR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-ES   Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Israel;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-001240-35-EE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001240-35-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-HR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-EE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001226-18-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-NL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-LV   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-HR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-ES   Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-001225-41-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001225-41-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2015-003759-23-NO   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-003759-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-003759-23-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003759-23-SK   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003759-23-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003759-23-GB   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003759-23-ES   Australia;Canada;Israel;New Zealand;Puerto Rico;Spain;United States;
      2016   Phase 2   EUCTR2015-003759-23-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003759-23-DE   Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003759-23-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
ABT-874   
   Abbott
      2009   -   EUCTR2008-004919-36-SE   Austria;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-DK   Austria;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-BE   Austria;Belgium;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-AT   Austria;Denmark;Sweden;
      2007   Phase 2   NCT00562887   Australia;Austria;Belgium;Canada;Denmark;Germany;Puerto Rico;United States;
ABX464   
   Abivax S.A.
      2020   Phase 2   NCT03905109   Belgium;
ADSVF   
   ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
      2019   Phase 2   EUCTR2019-001948-21-FR   France;
AIN457   
   Novartis Pharma Services AG
      2010   -   EUCTR2009-011621-14-DE   Austria;Germany;
      2009   -   EUCTR2009-011621-14-AT   Austria;Germany;
      2009   -   EUCTR2008-008359-40-PL   Austria;Germany;Poland;
      2009   -   EUCTR2008-008359-40-DE   Austria;Germany;Poland;
      2009   -   EUCTR2008-008359-40-AT   Austria;Germany;Poland;
   Novartis Pharmaceuticals
      2009   Phase 2   NCT01009281   Austria;Canada;Germany;Poland;United States;
      2008   Phase 2   NCT00584740   Canada;Germany;United States;
ALBUMINE HUMAINE   
   ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
      2019   Phase 2   EUCTR2019-001948-21-FR   France;
ALLO-ASC   
   Anterogen Co., Ltd.
      2015   Phase 1   NCT02580617   Korea, Republic of;
ALLO-ASC-CD   
   Anterogen Co., Ltd.
      2016   -   NCT03183661   -
ALLOPURINOL SODIUM   
   Marianne Kiszka-Kanowitz
      2013   Phase 3   EUCTR2013-001503-37-DK   Denmark;
ALX-0600   
   Shire
      2003   Phase 2   NCT00072839   Canada;United States;
AMG 139   
   AstraZeneca
      2011   Phase 1   NCT01258205   Australia;United States;
AMG 181   
   Amgen
      2011   Phase 1   NCT01290042   Australia;United States;
   Amgen Inc
      2013   Phase 2   EUCTR2012-000529-31-NL   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000529-31-HU   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000529-31-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000529-31-DK   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000529-31-DE   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000529-31-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000529-31-BE   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-000529-31-AT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
AMG 827   
   Amgen
      2010   Phase 2   NCT01199302   Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
      2010   Phase 2   NCT01150890   Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
   Amgen Inc
      2011   Phase 2   EUCTR2010-020881-53-BE   Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
      2011   -   EUCTR2010-020881-53-NL   Belgium;Netherlands;Spain;
      2011   -   EUCTR2010-020881-53-ES   Belgium;Netherlands;Spain;
      2011   -   EUCTR2010-019544-39-NL   Belgium;France;Netherlands;Spain;
      2010   Phase 2   EUCTR2010-019544-39-BE   Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
      2010   -   EUCTR2010-019544-39-FR   Belgium;France;Netherlands;Spain;
      2010   -   EUCTR2010-019544-39-ES   Belgium;France;Netherlands;Spain;
AMGEVITA (Adalimumab biosimilar )   
   Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
      2019   Phase 4   EUCTR2019-000717-37-ES   Spain;
AMGEVITA®   
   Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
      2019   Phase 4   EUCTR2019-000717-37-ES   Spain;
AN100226   
   Elan Pharma Ltd.
      2005   -   EUCTR2004-003839-31-DK   Denmark;
APD334   
   ARENA PHARMACEUTICALS, INC.
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-IT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Arena Pharmaceuticals Inc.
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-PT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-NO   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-NL   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-LT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-HU   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-GR   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-GB   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-FR   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-ES   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-CZ   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-BG   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Arena Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003797-40-DE   Belgium;Germany;United States;
      2017   Phase 2   EUCTR2016-003797-40-BE   Belgium;Germany;United States;
APD371   
   Arena Pharmaceuticals
      2017   Phase 2   NCT03155945   United States;
AR401959 L-arginine   
   ARENA PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-002895-14-IT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Arena Pharmaceuticals Inc.
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-PT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-NO   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-NL   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-LT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-HU   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-GR   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-GB   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-FR   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-ES   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-CZ   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-BG   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
ASCs: Adipose derived Stem Cells   
   CELLERIX S.A.
      2009   -   EUCTR2008-004286-25-DE   Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
      2009   -   EUCTR2008-004286-25-BE   Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
AST-120   
   Ocera Therapeutics, Inc.
      2007   -   EUCTR2005-005363-28-HU   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2007   -   EUCTR2005-005363-28-AT   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   Phase 3   EUCTR2005-005363-28-GB   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-005363-28-DE   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-005363-28-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-005363-28-BE   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
ATG   
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
AVB-114   
   Avobis Bio, LLC
      2021   Phase 2   NCT04847739   United States;
AZA   
   Merck Sharp & Dohme Corp.
      2003   Phase 3   NCT00796250   -
AZA capsules   
   Centre Hospitalier Universitaire, Amiens
      2021   Phase 3   NCT05040464   France;
AZATHIOPRINE or METHOTREXATE   
   Prof. Arie Levine
      2013   Phase 4   NCT01802593   Israel;
AZATIOPRINA ASPEN - 50 COMPRESSE   
   UMBERTO I - POLICLINICO DI ROMA
      2017   Phase 4   EUCTR2016-000522-18-IT   Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
AZD9056   
   AstraZeneca AB
      2006   -   EUCTR2005-002319-26-HU   Austria;Belgium;Germany;Hungary;
      2006   -   EUCTR2005-002319-26-AT   Austria;Belgium;Germany;Hungary;
      2005   -   EUCTR2005-002319-26-DE   Austria;Belgium;Germany;Hungary;
      2005   -   EUCTR2005-002319-26-BE   Austria;Belgium;Germany;Hungary;
Abatacept   
   Bristol-Myers Squibb
      2006   Phase 3   NCT00406653   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;South Africa;Spain;Switzerland;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2006-003371-13-IE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2008   -   EUCTR2006-003371-13-PL   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2008   -   EUCTR2006-003371-13-CZ   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   Phase 3   EUCTR2006-003371-13-FR   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-NL   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-IT   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-GB   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
Abrilumab   
   Amgen
      2012   Phase 2   NCT01696396   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Netherlands;Switzerland;United Kingdom;United States;
Accelerated 1 hour-infusion   
   Asan Medical Center
      2011   Phase 4   NCT01346826   Korea, Republic of;
Accelerated 30 minutes-infusion   
   Asan Medical Center
      2011   Phase 4   NCT01346826   Korea, Republic of;
Acetaminophen   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
Adalimumab   
   AbbVie
      2016   -   NCT02750800   Hungary;
      2015   Phase 3   NCT02499783   China;
      2014   Phase 4   NCT02148718   Spain;
      2014   Phase 3   NCT02185014   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   NCT02065570   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   NCT01958827   Japan;
      2013   Phase 2   NCT02015793   China;
      2013   -   NCT01768858   Austria;
   AbbVie (prior sponsor, Abbott)
      2011   Phase 3   NCT01235689   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2008   Phase 3   NCT00686374   Belgium;Canada;Czech Republic;Czechia;France;Netherlands;Poland;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 3   EUCTR2013-004034-15-IT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004034-15-GB   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004034-15-FR   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004034-15-DK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2015   Phase 3   EUCTR2013-004034-15-DE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2015   Phase 3   EUCTR2013-004034-15-BE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2015   Phase 3   EUCTR2013-001746-33-FR   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2015   Phase 3   EUCTR2013-001746-33-BE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-004034-15-SK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004034-15-HU   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2014   Phase 3   EUCTR2013-004034-15-ES   Austria;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2014   Phase 3   EUCTR2013-004034-15-AT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001746-33-SK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-NL   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-IT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-ES   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-DK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-DE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-AT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   -   EUCTR2013-001746-33-HU   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
      2009   Phase 3   EUCTR2007-006494-90-CZ   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   AbbVie GK
      2013   Phase 3   JPRN-JapicCTI-142426   -
   Abbott
      2007   Phase 3   NCT00427921   United States;
      2007   Phase 3   NCT00409682   Belgium;Canada;Czech Republic;France;Italy;Netherlands;Poland;United Kingdom;United States;
      2007   Phase 2/Phase 3   NCT00445939   Japan;
      2007   Phase 2/Phase 3   NCT00445432   Japan;
      2006   Phase 3   NCT00409617   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Norway;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2006   Phase 3   NCT00348283   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Sweden;United States;
      2006   Phase 3   NCT00338650   United States;
      2004   Phase 3   NCT00195715   Australia;Belgium;Canada;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
      2004   Phase 3   NCT00105300   Belgium;Canada;France;United States;
      2003   Phase 3   NCT00077779   United States;
   Abbott GmBH Co KG
      2005   -   EUCTR2004-002163-24-IT   Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
   Abbott GmBH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Abbott GmbH Co.KG
      2006   -   EUCTR2005-005291-32-IT   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
   Abbott GmbH & Co. K.G.
      2009   Phase 3   EUCTR2007-006494-90-GB   Belgium;Czech Republic;United Kingdom;
      -   -   EUCTR2007-006494-90-Outside-EU/EEA   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   Abbott GmbH & Co. KG
      2009   -   EUCTR2006-004814-41-GB   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2006-004814-41-NL   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2006-004814-41-IT   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2006-004814-41-CZ   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2006-004814-41-BE   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2004-002163-24-GB   Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-004814-41-FR   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2005-005291-32-SE   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-NL   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-DE   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-BE   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-AT   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2005   -   EUCTR2004-002934-20-BE   Belgium;
      2005   -   EUCTR2004-002163-24-DE   Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
      2004   -   EUCTR2004-002163-24-SE   Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-002163-24-ES   Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-002163-24-DK   Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-004814-41-Outside-EU/EEA   -
   Abbott GmbH & Co. KG (Abbott)
      2006   -   EUCTR2006-002078-23-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   Abbott GmbH & co. KG
      2004   -   EUCTR2004-002163-24-BE   Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
   Abbott Japan Co., Ltd.
      2007   Phase 2-3   JPRN-JapicCTI-070367   -
      2007   Phase 2-3   JPRN-JapicCTI-070366   -
   Abbott Laboratories
      2004   -   EUCTR2004-002163-24-HU   Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
   Abbvie Deutschland GmbH & Co. K.G.
      2008   Phase 3   EUCTR2007-006494-90-BE   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   Academic Medical Center
      2019   Phase 4   EUCTR2018-002064-15-NL   Netherlands;
      2013   Phase 4   EUCTR2013-002932-25-NL   Netherlands;
   Biogen
      2019   -   NCT04089514   Belgium;Germany;Ireland;Italy;Spain;United Kingdom;
      2018   -   NCT03662919   France;
   Children's Hospital Medical Center, Cincinnati
      2019   -   NCT04131504   United States;
   Department of Internal Medicine, School of Medicine, Keio University
      2013   -   JPRN-UMIN000009596   Japan;
      2011   Phase 4   JPRN-UMIN000005146   Japan;
   Department of Lower Gastroenterology, Hyogo College of Medicine
      2012   Phase 4   JPRN-UMIN000006882   Japan;
   Foundation for Liver Research
      2008   Phase 3   NCT00736983   Netherlands;
   Fukuoka University Chikushi Hospital
      2016   -   JPRN-UMIN000023871   Japan;
   GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
      2015   Phase 4   EUCTR2013-003199-11-BE   Belgium;France;
   GETECCU
      2011   -   EUCTR2011-000885-36-ES   Spain;
   Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
      2012   Phase 3   NCT01564823   Spain;
   Hospital Universitari Vall d'Hebron Research Institute
      2014   -   NCT02539849   Spain;
   ISTITUTO CLINICO HUMANITAS
      2009   -   EUCTR2009-011763-37-IT   Italy;
   Innovaderm Research Inc.
      2012   Phase 4   NCT01556672   Canada;
   Iwate Medical UniversityKochi Medical School HospitalKeio University School of Medicine
      2016   -   JPRN-UMIN000019958   Japan;
   Janssen Research & Development, LLC
      2021   Phase 2   NCT04655807   Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
   Kenji Watanabe
      2010   -   JPRN-UMIN000005762   Japan;
      2010   -   JPRN-UMIN000005761   Japan;
   Landos Biopharma Inc.
      2021   Phase 2   NCT05057273   -
   Maastricht University Medical Center
      2019   Phase 4   NCT03917303   Netherlands;
   McMaster University
      2018   Phase 4   NCT03059849   -
   Mikami Yohei
      2019   -   JPRN-jRCT1031190056   Japan;
   Nagoya University Gradeate School of MedicineDepartment of Gastroenterology
      2012   Phase 2   JPRN-UMIN000007514   Japan;
   Numaguchi Hirotaka
      2021   Phase 2   JPRN-jRCT2031200406   Canada;France;Germany;Italy;Japan;Spain;United States Of America;
   PIBD-Net
      2017   Phase 4   NCT02852694   France;
   Radboud University
      2017   Phase 4   NCT03172377   Netherlands;
   Royal Liverpool University Hospital
      2012   -   EUCTR2011-006084-22-GB   United Kingdom;
   Saitama Medical Center
      2016   -   JPRN-UMIN000022270   Japan;
   Saitama Medical Center, Saitama Medical University
      2016   -   JPRN-UMIN000023735   Japan;
   Sakura Medical Center,Toho university
      2012   Phase 2   JPRN-UMIN000009284   Japan;
   Sakura medical center, Toho university
      2015   -   JPRN-UMIN000032485   Japan;
   Sara Varea
      2014   Phase 3   NCT01986127   Spain;
   Schneider Children's Medical Center, Israel
      2015   Phase 4   NCT02256462   Israel;
   Takeda
      2017   Phase 4   NCT02764762   Canada;United States;
   Tel-Aviv Sourasky Medical Center
      2012   Phase 3   NCT01629628   Israel;
   Toho University Medical Center Sakura Hospital
      2016   -   JPRN-UMIN000024566   Japan;
   Tohoku University Graduate School of Medicine (Tohoku University Hospital)
      2012   -   JPRN-UMIN000007343   Japan;
   UCB Biopharma SRL
      2021   Phase 3   NCT04643483   -
   Universitaire Ziekenhuizen Leuven
      2012   -   NCT02450513   Belgium;
   University Hospital Southampton NHS Foundation Trust
      2019   Phase 4   EUCTR2018-004967-30-GB   United Kingdom;
   University Medical Center Groningen
      2021   Phase 4   NCT04646187   Belgium;Netherlands;Spain;
   University of Alberta
      2009   Phase 4   NCT00972218   Canada;
   University of Western Ontario, Canada
      2014   Phase 4   NCT01960426   United States;
   Vanderbilt University Medical Center
      2008   Phase 4   NCT00517296   United States;
   Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      2021   Phase 4   ChiCTR2000036845   China;
   Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology
      2011   -   JPRN-UMIN000007047   Japan;
   waqqas.afif
      2017   -   NCT03261102   Canada;
Adalimumab (40 mg)   
   Janssen Scientific Affairs, LLC
      2018   Phase 3   NCT03464136   Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab (D2E7)   
   Abbott
      2002   Phase 2   NCT00055523   United States;
Adalimumab 40 mg eow or ew   
   Abbott
      2002   Phase 3   NCT01070303   United States;
Adalimumab Injection   
   St Vincent's Hospital Melbourne
      2017   Phase 4   NCT03220841   Australia;
Adalimumab PRN   
   Peter Higgins
      2013   Phase 3   NCT01674413   United States;
Adalimumab and Infliximab   
   University Hospital, Ghent
      2011   -   NCT01338740   Belgium;
Adult human mesenchymal stem cells   
   Mesoblast, Inc.
      2010   Phase 3   NCT01233960   Australia;New Zealand;United States;
Agri-King Synbiotic (AKSB)   
   Mayo Clinic
      2006   Phase 1/Phase 2   NCT00587041   United States;
Albendazole (Eskazole)   
   academic medical centre
      2018   Phase 4   EUCTR2017-001737-85-NL   Netherlands;
Alemtuzumab   
   Northwestern University
      2019   Phase 2   NCT04154735   United States;
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
Alequel   
   Hadassah Medical Organization
      2008   Phase 1/Phase 2   NCT02185183   -
Alfacalcidol   
   Nagoya University Hospital
      2017   -   JPRN-UMIN000025961   Japan;
   Nakamura Masanao
      2017   Phase 2   JPRN-jRCTs041180126   Japan;
Alicaforsen   
   Isis Pharmaceuticals
      2002   Phase 3   NCT00048295   Belgium;Czech Republic;Germany;Italy;Poland;Spain;
      2001   Phase 3   NCT00048113   Canada;United States;
Alicalm (polymeric liquid formula)   
   University Hospital Birmingham
      2008   Phase 4   NCT00609752   United Kingdom;
Allogeneic Bone Marrow Transplantation   
   Fred Hutchinson Cancer Research Center
      2012   Phase 2   NCT01570348   United States;
Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)   
   Joshua M Hare
      2019   Phase 1   NCT02677350   United States;
Allogeneic Stem Cell Therapy   
   Northwestern University
      2010   Phase 1/Phase 2   NCT01288053   United States;
Allogenic eASCs 5 milion cells/ml suspension for injection. Cx601   
   CELLERIX S.A.
      2012   Phase 3   EUCTR2011-006064-43-IT   Austria;Belgium;Germany;Israel;Italy;Netherlands;Spain;
Allogenic eASCs 5 million cells/ml suspension for injection CX601   
   TIGENIX S.A.U
      2018   Phase 3   EUCTR2017-000725-12-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   TiGenix, S.A.U.
      2021   Phase 3   EUCTR2017-000725-12-SE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-000725-12-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-DE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-PL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-HU   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Allogenic eASCs 5 million cells/ml suspension for injection. CX601   
   TiGenix S.A.U.
      2012   Phase 3   EUCTR2011-006064-43-DE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
   TiGenix, S.A.U.
      2012   Phase 3   EUCTR2011-006064-43-AT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Allogenic eASCs 5 million/ml suspension for injection.   
   TiGenix, S.A. Unipersonal
      2012   Phase 3   EUCTR2011-006064-43-BE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
      2012   -   EUCTR2011-006064-43-NL   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Allopurinol   
   SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
      2018   Phase 4   EUCTR2016-004112-35-SE   Sweden;
Allopurinol Sandoz 100 mg, tabletten   
   Meander Medical Center
      2016   Phase 4   EUCTR2016-001638-84-NL   Netherlands;
Alofisel   
   MILLENNIUM PHARMACEUTICALS, INC.
      2019   Phase 4   EUCTR2019-000333-39-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Millennium Pharmaceuticals, Inc (MPI)
      2020   Phase 4   EUCTR2019-000333-39-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2020   Phase 4   EUCTR2017-002491-10-FR   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-ES   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-CZ   Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
      2019   Phase 4   EUCTR2019-000333-39-CZ   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Takeda Development Center Americas, Inc
      2020   Phase 4   EUCTR2019-000333-39-BE   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2020-003193-48-NL   Israel;Italy;Japan;Netherlands;Poland;Spain;
      2020   Phase 4   EUCTR2017-002491-10-DE   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
      2020   Phase 4   EUCTR2017-002491-10-AT   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
      -   Phase 3   EUCTR2020-003193-48-PL   Israel;Japan;Netherlands;Poland;
   TiGenix, S.A.U.
      2021   Phase 3   EUCTR2017-000725-12-SE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-000725-12-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-DE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-PL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-HU   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Also referred to as 'MEDI2070'   
   AstraZeneca AB
      2021   Phase 2;Phase 3   EUCTR2018-004346-42-HU   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Also referred to as MED2070   
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2019-001866-14-IT   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2021   Phase 3   EUCTR2019-001866-14-PL   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001866-14-HU   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001866-14-DE   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Also referred to as MEDI2070   
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2019-001866-14-IT   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2021   Phase 3   EUCTR2019-001866-14-PL   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001866-14-HU   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001866-14-DE   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Amgevita   
   University Medical Center Groningen
      2021   Phase 4   EUCTR2020-001811-26-BE   Belgium;Netherlands;
      2020   Phase 4   EUCTR2020-001811-26-NL   Netherlands;
Amgevita 40 mg Injektionslösung im Fertigpen   
   Universitätsklinikum Erlangen
      2019   Phase 4   EUCTR2019-003662-40-DE   Germany;
Amgevita 40 mg Injektionslösung in einer Fertigspritze   
   Universitätsklinikum Erlangen
      2019   Phase 4   EUCTR2019-003662-40-DE   Germany;
Amgevita 40Mg Solution for Injection   
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2019   Phase 4   NCT04131322   Spain;
Amoxicillin   
   Ishikawa Dai
      2017   -   JPRN-jRCTs031180415   Japan;
   Juntendo university school of medicineDepartment of gastroenterology
      2017   -   JPRN-UMIN000025846   Japan;
Andecaliximab   
   Gilead Sciences
      2015   Phase 2   NCT02405442   Australia;Canada;Czech Republic;Czechia;France;Germany;Hungary;Iceland;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
AndoSan   
   Oslo University Hospital
      2011   Phase 2/Phase 3   NCT01496053   Norway;
Anti TNF   
   University Hospital, Lille
      2017   -   NCT02872506   -
Anti TNF Alfa.   
   Carmel Medical Center
      2014   -   NCT01881464   Israel;
Anti TNF humanized antibody Fab fragment-PEG conjugate   
   UCB PHARMA S.A.
      2008   -   EUCTR2007-003239-21-FR   France;
Anti TNF therapy including infliximab   
   Janssen Biotech, Inc.
      2007   -   NCT00606346   Canada;United States;
Anti-CD3 Monoclonal antibody   
   PDL BioPharma, Inc
      2005   -   EUCTR2004-004388-31-DE   Germany;
   PDL BioPharma, Inc.
      2005   -   EUCTR2004-004387-72-DE   Germany;
   Protein Design Labs, Inc.
      2005   -   EUCTR2004-004387-72-AT   Austria;Germany;
Anti-IL-23 monoclonal antibody   
   Allergan Limited
      2017   Phase 2   EUCTR2015-000609-38-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2013   Phase 2   EUCTR2012-004098-26-HU   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-FR   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-ES   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-DE   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-CZ   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
   MedImmune Limited
      2016   Phase 2   EUCTR2015-000609-38-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK
      2016   Phase 2   EUCTR2015-000609-38-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Anti-IL-6 mAb   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2012   -   EUCTR2011-004763-72-IT   Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-004763-72-NL   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-HU   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-GB   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-DE   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-CZ   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-AT   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Anti-Interferon-gamma monoclonal antibody   
   Facet Biotech
      2002   Phase 2   NCT00072943   Canada;United States;
Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Huma   
   ALLERGAN LIMITED
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody   
   ALLERGAN LIMITED
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2019-001866-14-IT   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Allergan Limited
      2021   Phase 3   EUCTR2019-001866-14-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Allergan Ltd.
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-BG   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2021   Phase 3   EUCTR2019-001866-14-PL   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001866-14-HU   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001866-14-DE   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2018-004346-42-HU   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001866-14-GB   Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004346-42-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Astrazeneca AB
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Anti-Interleukin-6 Monoclonal Antibody   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2012   -   EUCTR2011-004763-72-IT   Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-004763-72-NL   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-HU   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-GB   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-DE   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-CZ   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-AT   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Anti-MAdCAM antibody   
   Pfizer Inc.
      2013   -   EUCTR2012-002030-37-BE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;United Kingdom;
   SHIRE HUMAN GENETIC THERAPIES, INC
      2019   Phase 3   EUCTR2017-000617-23-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Shire Human Genetic Therapies, Inc.
      2019   Phase 3   EUCTR2017-000617-23-GR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000576-29-GR   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
      2019   Phase 3   EUCTR2017-000574-11-GR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-ES   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000576-29-HU   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
      2018   Phase 3   EUCTR2017-000576-29-ES   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;France;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
      2018   Phase 3   EUCTR2017-000576-29-BE   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
      -   Phase 3   EUCTR2017-000617-23-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000575-88-CZ   Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
Anti-TNF   
   University of Maryland, Baltimore
      2011   -   NCT02619552   United States;
Anti-TNF Drug   
   Hospices Civils de Lyon
      2021   -   NCT03712826   France;
   Schneider Children's Medical Center, Israel
      2019   -   NCT03681652   Israel;
Anti-TNF Therapy   
   Takeda
      2017   -   NCT03090139   Argentina;China;Colombia;Korea, Republic of;Mexico;Russian Federation;Saudi Arabia;Singapore;Taiwan;Turkey;
Anti-TNF discontinuation: Physiological saline solution   
   Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
      2017   Phase 4   NCT02994836   Spain;
Anti-TNF: Infliximab (Infusion)   
   Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
      2017   Phase 4   NCT02994836   Spain;
Anti-TNF:Adalimumab (Subcutaneus)   
   Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
      2017   Phase 4   NCT02994836   Spain;
Anti-thymocyte globulin (rabbit)   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
Antibiotics   
   St Vincent's Hospital Melbourne
      2021   Phase 2/Phase 3   NCT04970446   -
Anticorpo monoclonale anti IL-23   
   ASTRAZENECA
      2013   Phase 2   EUCTR2012-004098-26-IT   Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
Anticorpo monoclonale anti-IL-23   
   MEDIMMUNE, LLC
      2016   Phase 2   EUCTR2015-000609-38-IT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Anticorpo monoclonale umano anti-Interleuchina-23 Immunoglobulina G2 (IgG2)   
   ALLERGAN LIMITED
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Antithymocyte immunoglobulin (rabbit)   
   WOLFSON DIGESTIVE DISEASES CENTRE
      2007   -   EUCTR2005-003337-40-IT   Italy;United Kingdom;
Apheresis catheter placement   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
Apixaban 2.5 milligram   
   McMaster University
      2021   Early Phase 1   NCT03935451   Canada;
Application of Adalimumab   
   Gerhard Rogler
      2009   -   NCT01012570   Switzerland;
Artesunate   
   Sanjay Gandhi Postgraduate Institute of Medical Sciences
      2021   Phase 2   NCT04713631   India;
Atorvastatin   
   Region Skåne
      2006   -   EUCTR2005-000496-17-SE   Sweden;
   Skane University Hospital
      2006   Phase 2   NCT00454545   Sweden;
Autologous ADIpose derived stromal vascular fraction   
   ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
      2019   Phase 2   EUCTR2019-001948-21-FR   France;
Autologous CD34-selected peripheral blood stem cells transplant   
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
Autologous Stem Cell Transplantation   
   Northwestern University
      2005   Phase 2   NCT00271947   United States;
Autologous mesenchymal stromal cell   
   Emory University
      2012   Phase 1   NCT01659762   United States;
Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population   
   TxCell
      2014   Phase 2   EUCTR2014-001295-65-IT   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-DE   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-BE   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-AT   Austria;Belgium;Germany;Italy;
Autologous stem cell transplant   
   Icahn School of Medicine at Mount Sinai
      2017   Phase 2   NCT03219359   United States;
Azathioprin   
   PIBD-Net
      2017   Phase 3   EUCTR2016-000522-18-DE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
   PIBDNet
      2018   Phase 4   EUCTR2016-000522-18-CZ   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Azathioprin-ratiopharm   
   Abbott GmBH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprin-ratiopharm 25mg Filmtabletten   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 3   EUCTR2010-020137-10-LT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020137-10-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020137-10-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-NL   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020137-10-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020137-10-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprin-ratiopharm 50 mg Filmtabletten   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 3   EUCTR2010-020137-10-LT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020137-10-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020137-10-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-NL   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020137-10-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020137-10-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprine   
    Dental University Gastroenterology
   AbbVie (prior sponsor, Abbott)
      2011   Phase 3   NCT01235689   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
   Academic Medical Center, department of Gastroenterology and hepatology
      2008   -   EUCTR2008-001131-35-NL   Netherlands;
   Centocor B.V.
      2005   Phase 3   EUCTR2004-002815-10-GB   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002815-10-ES   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-SE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DK   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-AT   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
   Department of Gastroenterology and Hepatology, Kyoto University Hospital
      2011   -   JPRN-UMIN000005689   Japan;
   Department of Gastroenterology, Nanfang Hospital, Southern Medical University
      2016   -   ChiCTR1800020305   China;
   Department of Internal Medicine, School of Medicine, Keio University
      2013   -   JPRN-UMIN000009596   Japan;
      2011   Phase 4   JPRN-UMIN000005146   Japan;
   Dr. Falk Pharma GmbH
      2002   Phase 3   NCT00946946   Austria;Germany;
   Erasmus Medical Center
      2015   Phase 4   NCT02517684   Belgium;Denmark;Finland;Italy;Netherlands;Poland;
      2013   Phase 4   NCT01880307   Italy;Netherlands;
   GETAID
      2018   Phase 4   EUCTR2014-002311-41-NL   Belgium;France;Germany;Netherlands;Sweden;United Kingdom;
      2015   Phase 4   EUCTR2014-002311-41-DE   Australia;France;Germany;Netherlands;Sweden;United Kingdom;
      2014   -   EUCTR2014-002311-41-FR   France;Sweden;United Kingdom;
   Gastroenterology Research of America
      2013   Phase 3   NCT01817972   United States;
   Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
      2012   Phase 3   NCT01564823   Spain;
   Indiana University
      2015   -   NCT02413047   United States;
   Jinling Hospital, China
      2009   -   NCT01015391   China;
   Lower GI disease, Hyogo College of Medicine
      2007   Phase 2,3   JPRN-UMIN000004427   Japan;
   Massachusetts General Hospital
      2005   Phase 3   NCT00098111   United States;
   Novartis Pharma Services AG
      2005   Phase 2   EUCTR2005-001148-22-SK   Slovakia;
   PIBD net
      2018   Phase 4   EUCTR2016-000522-18-GB   Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
   PIBDnet (Pediatric Inflammatory Bowel Disease Network)
      -   Phase 4   EUCTR2016-000522-18-PL   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
   Region Örebro län
      2021   Phase 4   EUCTR2019-002942-19-DK   Denmark;
   SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
      2018   Phase 4   EUCTR2016-004112-35-SE   Sweden;
   Schneider Children's Medical Center, Israel
      2019   -   NCT03681652   Israel;
   Shanghai Research Institute of Acupuncture and Meridian
      2016   Phase 1 study   ChiCTR-IIR-16007751   China;
   Sixth Affiliated Hospital, Sun Yat-sen University
      2021   -   NCT04761952   -
      2017   Phase 3   NCT03185611   China;
   Tokyo Medical &
   University of Edinburgh
      2015   -   EUCTR2014-002311-41-GB   Belgium;France;Germany;Sweden;United Kingdom;
   Zhu Weiming
      2018   -   NCT04160325   China;
Azathioprine (AZA) caps   
   Centocor Ortho Biotech Services, L.L.C.
      2005   Phase 3   NCT00094458   Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Azathioprine (AZA) or 6-mercaptopurine (6-MP)   
   ZonMw: The Netherlands Organisation for Health Research and Development
      2007   -   NCT00521950   Netherlands;
Azathioprine - ratiopharm   
   Abbott GmBH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprine / 6 Mercaptopurine   
   PIBD-Net
      2017   Phase 4   NCT02852694   France;
Azathioprine OR Mesalazine   
   Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
      2002   Phase 3   NCT00976690   France;
Azathioprine in case of endoscopic recurrence   
   Universitaire Ziekenhuizen Leuven
      2005   Phase 2   NCT02247258   Belgium;Czech Republic;Greece;
Azathioprine individualised dose   
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   Phase 2   NCT00113503   Canada;United States;
Azathioprine or 6-mercaptopurine   
   ZonMw: The Netherlands Organisation for Health Research and Development
      2007   -   NCT00521950   Netherlands;
Azathioprine or adalimumab and infliximab   
   Tokyo Medical and Dental University
      2014   Phase 3   NCT02332356   Japan;
Azathioprine weight-based dose   
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   Phase 2   NCT00113503   Canada;United States;
Azathioprine+enteral nutrition   
   Jinling Hospital, China
      2012   -   NCT01823042   China;
Azatioprina   
   GETECCU
      2011   -   EUCTR2011-000885-36-ES   Spain;
Azithromycin   
   Erasmus MC
      2014   -   EUCTR2012-005226-29-PL   Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
   University of North Carolina, Chapel Hill
      2021   Phase 2   NCT04186247   Canada;Israel;Netherlands;United States;
   Wolfson Medical Center
      2013   -   EUCTR2012-005226-29-BE   Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
      -   -   EUCTR2012-005226-29-NL   Canada;Israel;Netherlands;United States;
Azithromycin + Metronidazole   
   Prof. Arie Levine
      2012   Phase 4   NCT01596894   Israel;
B. theta   
   4D Pharma
      2015   Phase 1   EUCTR2014-005666-29-GB   United Kingdom;
BFAHF-2   
   Icahn School of Medicine at Mount Sinai
      2021   Phase 1   NCT03992469   United States;
BI 655066 10 mg/ml   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2015-001834-15-NL   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
      2015   Phase 2   EUCTR2015-001834-15-DE   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-001834-15-BE   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
   Boehringer Ingelheim España, S.A.
      2015   Phase 2   EUCTR2015-001834-15-ES   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
      2014   Phase 2   EUCTR2013-002902-29-ES   Belgium;Canada;France;Ireland;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
   Boehringer Ingelheim bv
      2015   Phase 2   EUCTR2013-002902-29-NL   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm.V
      2014   Phase 2   EUCTR2013-002902-29-BE   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
BI 655066 90 mg/ml   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2015-001834-15-NL   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
      2015   Phase 2   EUCTR2015-001834-15-DE   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-001834-15-BE   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
   Boehringer Ingelheim España, S.A.
      2015   Phase 2   EUCTR2015-001834-15-ES   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
      2014   Phase 2   EUCTR2013-002902-29-ES   Belgium;Canada;France;Ireland;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
   Boehringer Ingelheim bv
      2015   Phase 2   EUCTR2013-002902-29-NL   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm.V
      2014   Phase 2   EUCTR2013-002902-29-BE   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
BI 655130   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2021   Phase 2   EUCTR2020-005770-99-IT   Aruba;Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Boehringer Ingelheim
      2021   Phase 2   EUCTR2020-005770-99-NL   Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-001673-93-BE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-001673-93-AT   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim AB
      2021   Phase 2   EUCTR2020-005770-99-SE   Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Boehringer Ingelheim B.V
      2021   Phase 2   EUCTR2020-005770-99-DK   Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2017-003090-34-DK   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim Ltd
      2021   Phase 2   EUCTR2020-005770-99-IE   Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Boehringer Ingelheim Netherlands BV
      2019   Phase 2   EUCTR2017-003090-34-NL   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim Norway KS
      2022   Phase 2   EUCTR2020-005770-99-NO   Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2019-001673-93-DE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
      2019   Phase 2   EUCTR2017-003090-34-DE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2019-001673-93-HU   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
      2019   Phase 2   EUCTR2017-003090-34-HU   Austria;Belgium;Germany;Hungary;Netherlands;
      2019   Phase 2   EUCTR2017-003090-34-AT   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim S.A.
      2021   Phase 2   EUCTR2019-001673-93-ES   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   SCS Boehringer Ingelheim Comm.V
      2018   Phase 2   EUCTR2017-003090-34-BE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
BI 695501   
   Boehringer Ingelheim
      2016   Phase 3   NCT02871635   Belarus;Bosnia and Herzegovina;Croatia;Czechia;Germany;Greece;Israel;Poland;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim International GmbH
      2017   Phase 3   EUCTR2016-000612-14-HR   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000612-14-GR   Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000612-14-GB   Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000612-14-DE   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000612-14-CZ   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
BI 706321   
   BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      2021   Phase 2   EUCTR2020-004527-16-IT   Belgium;Czechia;France;Italy;Poland;Spain;United States;
   Boehringer Ingelheim
      2021   Phase 2   NCT04978493   Poland;United States;
BIBR 796 BS,   
   Boehringer Ingelheim
      2001   Phase 2   NCT02209792   -
BLI-1300 high dose   
   Braintree Laboratories
      2011   Phase 2   NCT01442363   United States;
BLI-1300 low dose   
   Braintree Laboratories
      2011   Phase 2   NCT01442363   United States;
BMS-188667   
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2006-003371-13-IE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2008   -   EUCTR2006-003371-13-PL   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2008   -   EUCTR2006-003371-13-CZ   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   Phase 3   EUCTR2006-003371-13-FR   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-NL   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-GB   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
BMS-936557   
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-002981-19-PL   Belgium;France;Hungary;Poland;South Africa;United States;
      2012   -   EUCTR2011-002981-19-HU   Belgium;France;Hungary;Poland;South Africa;United States;
      2012   -   EUCTR2011-002981-19-BE   Belgium;France;Hungary;Poland;South Africa;United States;
BMS-936557 (Anti-IP-10 Antibody)   
   Bristol-Myers Squibb
      2011   Phase 2   NCT01466374   Belgium;France;Hungary;Israel;Poland;Puerto Rico;South Africa;United States;
BMS-945429   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2012   -   EUCTR2011-004763-72-IT   Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-004763-72-NL   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-HU   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-GB   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-DE   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-CZ   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-004763-72-AT   Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
   CSL Behring
      2012   Phase 2   NCT01545050   Australia;Austria;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
BMS-986165   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2021   Phase 2   EUCTR2020-004461-40-IT   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-IT   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb
      2021   Phase 2   NCT04877990   Australia;Brazil;China;Germany;Hungary;Italy;Japan;Poland;Romania;Russian Federation;United Kingdom;United States;
      2018   Phase 2   NCT03599622   Australia;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2020-004461-40-DE   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2017-001976-48-NL   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2017-001976-48-BE   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-001976-48-DK   Australia;Belgium;Bouvet Island;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-GB   Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb international Corporation
      2020   Phase 2   EUCTR2017-001976-48-FR   Australia;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-001976-48-PT   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-PL   Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-HU   Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-ES   Australia;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-DE   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
BMS986165   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2018   Phase 2   EUCTR2017-001976-48-IT   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2020-004461-40-DE   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2017-001976-48-NL   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-001976-48-DK   Australia;Belgium;Bouvet Island;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-GB   Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb international Corporation
      2020   Phase 2   EUCTR2017-001976-48-FR   Australia;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-001976-48-PT   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-PL   Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-HU   Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-ES   Australia;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001976-48-DE   Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
BT-11   
   Landos Biopharma Inc.
      2021   Phase 2   EUCTR2019-000824-17-SK   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
      2021   Phase 2   EUCTR2019-000824-17-HR   Albania;Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Moldova, Republic of;Netherlands;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
      2021   Phase 2   EUCTR2019-000824-17-BG   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
      2020   Phase 2   EUCTR2018-005086-39-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2019   Phase 2   EUCTR2018-005086-39-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2019   Phase 2   EUCTR2018-005086-39-HU   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2019   Phase 2   EUCTR2018-005086-39-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
BT-11 (Omilancor)   
   Landos Biopharma Inc.
      2021   Phase 2   NCT05057273   -
BT-11 1,   
   Landos Biopharma Inc.
      2021   Phase 2   NCT03870334   Bulgaria;Poland;United States;
BT-11 Active   
   Landos Biopharma Inc.
      2018   Phase 1   NCT03860571   United States;
Bacteriophage preparation   
   Intralytix, Inc.
      2019   Phase 1/Phase 2   NCT03808103   United States;
Bacteriotherapy   
   David Suskind
      2012   Phase 1   NCT01757964   United States;
Beta carotene from Dunaliella algae   
   Bnai Zion Medical Center
      2002   Phase 3   NCT00275418   Israel;
Betamethasone   
   The Sixth Affiliated Hospital of Sun Yat-sen University
      2019   -   ChiCTR1900023696   China;
Bezlotoxumab   
   David Binion, MD
      2021   Phase 4   NCT04626947   United States;
Bif195 capsules   
   Hvidovre University Hospital
      2021   -   NCT04842149   Denmark;
Bifidobacterium infantis 35624   
   University College Cork
      2002   Phase 2/Phase 3   NCT00510978   Ireland;
Biological samplings   
   Hospices Civils de Lyon
      2011   -   NCT02504255   France;
Biosimilar   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada;
Biosimilar infliximab   
   Diakonhjemmet Hospital
      2014   Phase 4   NCT02148640   Norway;
Bleomycin   
   The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      2020   Phase 0   ChiCTR2000031344   China;
Blood and stools samples   
   University Hospital, Lille
      2015   -   NCT02851134   France;
Blood sample   
   Centre Hospitalier Universitaire, Amiens
      2021   Phase 3   NCT05040464   France;
Blood sampling   
   Centre Hospitalier Universitaire Dijon
      2013   -   NCT02859675   France;
Blood sampling from infant   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from mother   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States;
Blue light photopheresis   
   University Hospital, Akershus
      2019   Phase 1/Phase 2   NCT04164849   Norway;
Bone Marrow Derived Mesenchymal Stem cells (MSCs)   
   Leiden University Medical Center
      2010   -   EUCTR2009-015680-14-NL   Netherlands;
Bone Marrow MSC Derived Extracellular Vesicle Isolate   
   Direct Biologics, LLC
      2022   Phase 1   NCT05130983   -
Boulardii   
   University Clinic Dr Dragisa Misovic-Dedinje
      2019   -   NCT03941418   -
Brazikumab   
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2019-001866-14-IT   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab IV Infusion   
   Allergan
      2016   Phase 2   NCT02574637   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Brazikumab Induction Dose   
   AstraZeneca
      2020   Phase 3   NCT03961815   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab Maintenance Dose   
   AstraZeneca
      2020   Phase 3   NCT03961815   Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab SC Injection   
   Allergan
      2016   Phase 2   NCT02574637   Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Brazikumab high dose   
   AstraZeneca
      2018   Phase 2/Phase 3   NCT03759288   Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab low dose   
   AstraZeneca
      2018   Phase 2/Phase 3   NCT03759288   Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Breast milk sampling   
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02154425   France;Netherlands;Switzerland;United States;
Brepocitinib   
   Pfizer Inc.
      2018   Phase 2   EUCTR2017-003359-43-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 2   EUCTR2017-003359-43-PL   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-DE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-BE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-AT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Budenofalk   
   Dr. Falk Pharma GmbH
      2007   -   EUCTR2004-001213-34-GB   Czech Republic;United Kingdom;
   University Medical Center Utrecht
      2009   -   EUCTR2007-005455-42-NL   Netherlands;
Budenofalk 3mg gastro-resistant capsules   
   Dr. Falk Pharma GmbH
      2009   -   EUCTR2008-006957-42-SK   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-LV   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-LT   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
      2009   -   EUCTR2008-006957-42-HU   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-DE   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
      2009   -   EUCTR2008-006957-42-CZ   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-BG   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
Budenofalk 9mg gastro-resistant granules   
   Dr. Falk Pharma GmbH
      2009   -   EUCTR2008-006957-42-SK   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-LV   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-LT   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
      2009   -   EUCTR2008-006957-42-HU   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-DE   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
      2009   -   EUCTR2008-006957-42-CZ   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
      2009   -   EUCTR2008-006957-42-BG   Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
Budesonide   
   AstraZeneca
      -   Phase 2   JPRN-JapicCTI-080566   -
   AstraZeneca AB
      -   -   EUCTR2011-003743-22-DE   Canada;Germany;Italy;Poland;United States;
   AstraZeneca K.K.
      -   Phase 3   EUCTR2014-004132-20-Outside-EU/EEA   Japan;
   Dr. Falk Pharma GmbH
      2009   Phase 3   NCT01086553   Germany;
      2007   -   EUCTR2004-001213-34-GB   Czech Republic;United Kingdom;
      2004   Phase 3   NCT00300118   Germany;
      2004   Phase 3   EUCTR2004-001213-34-SK   Czech Republic;Slovakia;United Kingdom;
      2004   -   EUCTR2004-001213-34-CZ   Czech Republic;United Kingdom;
   Hillel Yaffe Medical Center
      2020   -   NCT04233463   Israel;
   Osaka University Graduate School of MedicineDepartment of Gastroenterology and Hepatology
      2018   -   JPRN-UMIN000031839   Japan;
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
   Royal Liverpool University Hospital
      2014   Phase 2   NCT01783106   United Kingdom;
   Takehara Tetsuo
      2018   Phase 2   JPRN-jRCT1051190043   Japan;
   Tohoku University Hospital, Division of Gastroenterology
      2018   -   JPRN-UMIN000030884   Japan;
Budesonide ( Zentacort Capsules 3mg )   
   ZERIA Pharmaceutical Co., Ltd.
      2017   -   JPRN-JapicCTI-184152   -
Bupivacaine/epinephrine/dexamethasone   
   Cedars-Sinai Medical Center
      2018   Phase 4   NCT03723447   United States;
By demand   
   Hospital Galdakao-Usansolo
      2020   -   NCT04188990   Spain;
C326, IL-6 Inhibitory Avimer protein   
   Avidia
      2006   Phase 1   NCT00353756   Australia;
CC-5013   
   Celgene Corporation
      2002   Phase 2   NCT00446433   France;Israel;United Kingdom;United States;
CCX282-B   
   ChemoCentryx
      2006   Phase 2   NCT00306215   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Netherlands;Poland;South Africa;Sweden;United Kingdom;
      2004   Phase 2   NCT00102921   United States;
   ChemoCentryx, Inc
      2007   -   EUCTR2005-003827-38-SE   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
      2007   -   EUCTR2005-003827-38-HU   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
      2007   -   EUCTR2005-003827-38-FR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
      2007   -   EUCTR2005-003827-38-DE   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Hungary;Sweden;United Kingdom;
      2007   -   EUCTR2005-003827-38-BG   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
      2007   -   EUCTR2005-003827-38-BE   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
      2007   -   EUCTR2005-003827-38-AT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-003827-38-GB   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Hungary;Sweden;United Kingdom;
      2006   -   EUCTR2005-003827-38-DK   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
      2006   -   EUCTR2005-003827-38-CZ   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
CD   
   Fukuoka University Chikushi Hospital
      2011   -   JPRN-UMIN000005946   Japan;
   Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine
      2012   -   JPRN-UMIN000013534   Japan;
   Icahn School of Medicine at Mount Sinai
      2019   -   NCT03850600   United States;
   NHS Greater Glasgow and Clyde
      2020   -   NCT04225689   United Kingdom;
   Nanfang Hospital, Southern Medical University
      2019   -   ChiCTR1900027370   China;
   Shikamura Mitsuhiro
      2022   Phase 3   JPRN-jRCT2071210031   Australia;Belgium;Bosnia;China;Croatia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russia;Slovakia;Spain;Ukraine;United Kingdom;United States;
   The 7th Medical Center of the PLA General Hospital (Army general hospital)
      2019   Phase 0   ChiCTR1900022728   China;
   The First Hospital Affiliated to Sun Yat sen University
      2020   -   ChiCTR2000029543   China;
   University of Glasgow
      2014   -   NCT02426567   United Kingdom;
   University of Miami
      2019   -   NCT04213729   United States;
CD-C-Food   
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   -   NCT04976491   China;
CD7 CAR T-cells   
   Zhejiang University
      2022   Early Phase 1   NCT05239702   China;
CDP6038   
   UCB BIOSCIENCES GmbH
      2012   Phase 2   EUCTR2011-002517-11-BG   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Serbia;
      2012   -   EUCTR2011-002517-11-HU   Czech Republic;Germany;Hungary;Serbia;
      2012   -   EUCTR2011-002517-11-DE   Czech Republic;Germany;Hungary;Serbia;
      2012   -   EUCTR2011-002517-11-CZ   Czech Republic;Germany;Hungary;Serbia;
CDP870   
   UCB AE
      2006   -   EUCTR2006-002027-16-GR   Greece;
   UCB Celletech
      2008   -   EUCTR2007-001913-41-IT   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
   UCB Celltech
      2008   -   EUCTR2007-002716-26-IT   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-002716-26-EE   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-002716-26-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-002716-26-BE   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
      2008   -   EUCTR2007-002716-26-AT   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
      2008   -   EUCTR2007-001913-41-EE   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-DE   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-BE   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-AT   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-002716-26-LV   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-002716-26-HU   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
      2007   -   EUCTR2007-002716-26-FI   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-001913-41-LV   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-001913-41-HU   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-001913-41-FI   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      -   -   EUCTR2014-004381-24-Outside-EU/EEA   Australia;Canada;New Zealand;United States;
   UCB Japan Co., Ltd.
      -   -   EUCTR2014-004400-30-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-004399-42-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-004354-34-Outside-EU/EEA   Japan;
   UCB PHARMA
      2007   -   EUCTR2006-001729-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   UCB PHARMA S.A.
      2008   -   EUCTR2007-003239-21-FR   France;
   UCB Pharma S.A
      2007   -   EUCTR2005-003977-25-DE   Belgium;Germany;
   UCB Pharma S.A.
      2007   -   EUCTR2006-003871-11-DE   Germany;
      2007   -   EUCTR2006-001729-24-SE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-003870-88-DE   Germany;
      2006   -   EUCTR2005-004104-37-DE   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
   UCB Pharma SA
      2007   -   EUCTR2006-001729-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   UCB S.A
      2007   Phase 3   EUCTR2006-001729-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-001729-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2005-003977-25-BE   Belgium;Germany;
   UCB S.A.
      2007   Phase 3   EUCTR2006-001729-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-001729-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-001729-24-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004104-37-GB   Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004104-37-ES   Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-001729-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-SE   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-DK   Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-BE   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-AT   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
CHOLECALCIFEROL CONCENTRATE   
   Academic Medical Center
      2013   Phase 3   EUCTR2013-002838-20-NL   Belgium;Netherlands;
CHOLECALCIFEROL CONCENTRATE (WATER-DISPERSIBLE FORM)   
   Academic Medical Center
      2014   Phase 3   EUCTR2013-002838-20-BE   Belgium;Netherlands;
CNTO1275   
   JANSSEN CILAG INTERNATIONAL NV
      2019   Phase 3   EUCTR2018-002629-51-IT   Austria;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-IT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002918-43-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2016   Phase 2   EUCTR2016-000634-21-IT   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   JANSSEN-CILAG INTERNATIONAL N.V.
      2011   -   EUCTR2010-022759-42-IT   Australia;Brazil;Bulgaria;Canada;Croatia;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;South Africa;Spain;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2020   Phase 3   EUCTR2018-002629-51-GB   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002629-51-SE   Austria;Czech Republic;Czechia;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002629-51-FR   France;Germany;Netherlands;Spain;Sweden;United States;
      2019   Phase 3   EUCTR2018-002629-51-AT   Austria;France;Germany;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-002629-51-ES   France;Germany;Netherlands;Spain;Sweden;United States;
      2018   Phase 3   EUCTR2017-004209-41-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-002918-43-SK   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 3   EUCTR2016-002918-43-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-SE   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-PT   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-GB   Belgium;Germany;Netherlands;Portugal;Spain;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2017   Phase 3   EUCTR2016-002918-43-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2017   Phase 1   EUCTR2016-001956-22-PL   Belgium;Canada;France;Germany;Poland;United States;
      2017   Phase 1   EUCTR2016-001956-22-DE   Belgium;Canada;France;Germany;Poland;United States;
      2017   Phase 1   EUCTR2016-001956-22-BE   Belgium;Canada;France;Germany;Poland;United States;
      2012   Phase 3   EUCTR2010-022760-12-NL   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022760-12-BE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022758-18-BE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-IT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-IS   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-IE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-HU   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-GB   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-FR   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-ES   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-DK   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-DE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-CZ   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-BG   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022760-12-AT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022759-42-GB   Australia;Brazil;Bulgaria;Canada;Croatia;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022758-18-GB   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022759-42-NL   Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022759-42-IS   Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022759-42-HU   Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022759-42-ES   Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022759-42-DE   Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022759-42-BG   Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-IS   Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Italy;Spain;United Kingdom;
      2011   -   EUCTR2010-022758-18-IE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-HU   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-ES   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-DK   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-DE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-CZ   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   -   EUCTR2010-022758-18-AT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
      -   Phase 1   EUCTR2016-001956-22-FR   Belgium;Canada;France;Germany;Poland;United States;
   Janssen-Cilag International NV
      2021   Phase 3   EUCTR2020-004457-76-PL   Argentina;France;Japan;Poland;Russian Federation;Turkey;United States;
      2021   Phase 3   EUCTR2019-004225-24-HU   Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004225-24-DE   Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004225-24-BE   Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
      2021   Phase 3   EUCTR2018-002629-51-CZ   Austria;Czech Republic;Czechia;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002629-51-NL   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2017-002195-13-PT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2017-002195-13-GB   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-000634-21-FR   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-PL   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-NL   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-LV   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-LT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-HR   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-GR   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-ES   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-DE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-CZ   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-BE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-AT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000634-21-PL   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000634-21-HU   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000634-21-GB   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000634-21-DE   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004457-76-FR   Argentina;Belgium;France;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004225-24-PL   Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004225-24-Outside-EU/EEA   Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004225-24-GB   Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
CNTO1959   
   JANSSEN CILAG INTERNATIONAL NV
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-IT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
   Janssen-Cilag International NV
      2019   Phase 2;Phase 3   EUCTR2017-002195-13-PT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2017-002195-13-GB   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-SK   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-PL   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-NL   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-LV   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-LT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-HR   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-GR   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-ES   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-DE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-CZ   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-BE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-002195-13-AT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
CP-461   
   Astellas Pharma Inc
      2002   Phase 2   NCT00042055   United States;
CP-690,550   
   PFIZER
      2008   -   EUCTR2008-003571-45-IT   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
   Pfizer
      2012   Phase 2   NCT01470599   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;United States;
      2012   Phase 2   NCT01393899   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;United States;
      2011   Phase 2   NCT01393626   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
      2008   Phase 2   NCT00615199   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom;United States;
   Pfizer Limited, Ramsgate Road,Sandwich,Kent CT13 9NJ
      2009   -   EUCTR2008-003571-45-GB   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
   Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ
      2009   -   EUCTR2008-003571-45-CZ   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-003571-45-SK   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-003571-45-FR   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   -   EUCTR2008-003571-45-NL   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2008-003571-45-HU   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2008-003571-45-BE   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
   Pfizer S.A
      2008   Phase 2   EUCTR2008-003571-45-ES   Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
CP-690,550-10   
   Pfizer Inc
      2012   Phase 2   EUCTR2011-003622-27-CZ   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2013   Phase 2   EUCTR2011-003622-27-NL   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2013   Phase 2   EUCTR2011-003622-27-HR   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
      2013   Phase 2   EUCTR2011-003622-27-AT   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
      2012   Phase 2   EUCTR2011-003622-27-HU   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   Phase 2   EUCTR2011-003622-27-GR   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2012   Phase 2   EUCTR2011-003622-27-ES   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2012   Phase 2   EUCTR2011-003622-27-BG   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-003622-27-SE   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA
      2012   Phase 2   EUCTR2011-003622-27-DE   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;Netherlands Antilles;South Africa;Spain;Sweden;Ukraine;United States;
   Pfizer Inc.
      2012   Phase 2   EUCTR2011-001754-28-CZ   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001733-16-CZ   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2013   Phase 2   EUCTR2011-001754-28-HR   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
      2013   -   EUCTR2011-001733-16-HR   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
      2012   Phase 2   EUCTR2011-001754-28-BG   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001754-28-NL   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001754-28-HU   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001754-28-GR   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001754-28-ES   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001754-28-AT   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001733-16-NL   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001733-16-HU   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;Norway;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001733-16-GR   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001733-16-BG   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001733-16-AT   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
      2011   -   EUCTR2011-001754-28-SE   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2011   -   EUCTR2011-001733-16-SE   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
      2011   -   EUCTR2011-001733-16-ES   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
   Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA
      2012   Phase 2   EUCTR2011-001754-28-DE   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
      2012   -   EUCTR2011-001733-16-DE   Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
CPSI-2364   
   Ferring Pharmaceuticals
      2009   Phase 1   NCT00950105   United States;
CROWN   
   Prometheus Laboratories
      2016   Phase 2   NCT02793778   United States;
CT-P13   
   CELLTRION INC.
      2019   Phase 3   EUCTR2019-001087-30-IT   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   Celltrion
      2016   Phase 1   NCT02883452   Korea, Republic of;
      2014   Phase 3   NCT02096861   United States;
   Celltrion, Inc
      2019   Phase 3   EUCTR2019-001087-30-PL   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-LV   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-HU   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-HR   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-GR   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-FR   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-ES   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-DE   Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-CZ   Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-BG   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-AT   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   Celltrion, Inc.
      2014   Phase 3   EUCTR2013-004497-10-RO   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004497-10-NL   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004497-10-IT   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004497-10-HU   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004497-10-GB   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004497-10-ES   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004497-10-DK   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004497-10-BE   Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Pfizer
      2015   -   NCT02539368   Belgium;Czech Republic;Czechia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
CT-P13 SC (Infliximab)   
   Celltrion
      2019   Phase 3   NCT03945019   Poland;United States;
CTLA4Ig   
   Bristol-Myers Squibb International Corporation
      2008   Phase 3   EUCTR2006-003371-13-IE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2008   -   EUCTR2006-003371-13-PL   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2008   -   EUCTR2006-003371-13-CZ   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   Phase 3   EUCTR2006-003371-13-FR   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-NL   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-GB   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
CURCUMA LONGA RHIZOMA   
   CHU de Clermont-Ferrand
      2014   Phase 3   EUCTR2014-000261-51-FR   France;
Caffeine   
   Janssen Research & Development, LLC
      2018   Phase 1   NCT03358706   Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
   Takeda
      2016   Phase 4   NCT02760615   United States;
Calcitonin nasal spray (salmon)   
   Children's Hospital Boston
      2004   -   NCT00114803   United States;
Calcitriol   
   Atlanta VA Medical Center
      2007   -   NCT00427804   United States;
Caltrate Pill   
   Second Affiliated Hospital of Wenzhou Medical University
      2020   Early Phase 1   NCT04276636   China;
      2014   -   NCT04606017   China;
Cannabidiol   
   Meir Medical Center
      2010   Phase 1/Phase 2   NCT01037322   Israel;
   University of Illinois at Chicago
      2018   Phase 2/Phase 3   NCT03467620   -
Cannabidiol , synthetic form   
   Stero Biotechs Ltd.
      2019   Phase 2   NCT04056442   Israel;
Cannabis, Medical   
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Capsule endoscopy   
   Innovaderm Research Inc.
      2012   Phase 4   NCT01556672   Canada;
Capsule fecal microbiota material (cap-FMT)   
   University of Minnesota
      2022   Phase 1   NCT05248191   United States;
Celebrex   
   University of Pittsburgh
      2003   Phase 4   NCT00177866   United States;
Cellulose   
   Ciim Plus, d.o.o.
      2018   -   NCT04370535   Slovenia;
Certican   
   Novartis Pharma Services AG
      2005   Phase 2   EUCTR2005-001148-22-SK   Slovakia;
Certolizumab   
   Baylor College of Medicine
      2011   -   NCT01582568   United States;
Certolizumab Pegol (CDP870)   
   UCB Pharma
      2004   Phase 3   NCT00152425   -
      2003   Phase 3   NCT00152490   -
   UCB Pharma SA
      2004   Phase 3   NCT00160706   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Ukraine;United States;
      2004   Phase 3   NCT00160524   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Latvia;Lithuania;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Tunisia;Ukraine;United States;
Certolizumab Pegol /Cimzia   
   UCB Celltech
      -   -   EUCTR2014-004381-24-Outside-EU/EEA   Australia;Canada;New Zealand;United States;
   UCB Japan Co., Ltd.
      -   -   EUCTR2014-004400-30-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-004399-42-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-004354-34-Outside-EU/EEA   Japan;
Certolizumab pegol   
   Atlanta Gastroenterology Associates
      2009   Phase 4   NCT01024647   United States;
   Gastroenterology Research of America
      2013   Phase 3   NCT01817972   United States;
   Shafran Gastroenterology Center
      2010   -   NCT01053559   United States;
   UCB AE
      2006   -   EUCTR2006-002027-16-GR   Greece;
   UCB Biopharma SRL
      2021   Phase 3   NCT04643483   -
   UCB Celletech
      2008   -   EUCTR2007-001913-41-IT   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
   UCB Celltech
      2008   -   EUCTR2007-002716-26-IT   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-002716-26-EE   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-002716-26-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-002716-26-BE   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
      2008   -   EUCTR2007-002716-26-AT   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
      2008   -   EUCTR2007-001913-41-EE   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-DE   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-BE   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2008   -   EUCTR2007-001913-41-AT   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-002716-26-LV   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-002716-26-HU   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
      2007   -   EUCTR2007-002716-26-FI   Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-001913-41-LV   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-001913-41-HU   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
      2007   -   EUCTR2007-001913-41-FI   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
   UCB PHARMA
      2007   -   EUCTR2006-001729-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   UCB Pharma
      2010   Phase 2   NCT01190410   Australia;Canada;United States;
      2007   Phase 3   NCT00358683   -
      2007   Phase 3   NCT00356408   Canada;Germany;United States;
      2007   Phase 3   NCT00354367   -
      2007   Phase 3   NCT00307931   Greece;
      2006   Phase 3   NCT00349752   Belgium;Canada;Germany;United States;
      2006   Phase 3   NCT00308581   Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
      2006   Phase 3   NCT00297648   Belgium;France;Germany;
      2006   Phase 2   NCT00329420   Japan;
   UCB Pharma S.A
      2007   -   EUCTR2005-003977-25-DE   Belgium;Germany;
   UCB Pharma S.A.
      2007   -   EUCTR2006-003871-11-DE   Germany;
      2007   -   EUCTR2006-001729-24-SE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-003870-88-DE   Germany;
      2006   -   EUCTR2005-004104-37-DE   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
   UCB Pharma SA
      2007   -   EUCTR2006-001729-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   UCB S.A
      2007   Phase 3   EUCTR2006-001729-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-001729-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2005-003977-25-BE   Belgium;Germany;
   UCB S.A.
      2007   Phase 3   EUCTR2006-001729-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-001729-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-001729-24-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004104-37-GB   Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004104-37-ES   Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-001729-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-SE   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-DK   Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-BE   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004104-37-AT   Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
Certolizumab pegol (CDP870)   
   UCB Pharma
      2006   Phase 3   NCT00333788   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Certolizumab pegol (CDP870, CZP)   
   UCB Pharma
      2008   Phase 3   NCT00552058   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Certolizumab pegol (CZP)   
   UCB Japan Co. Ltd.
      2006   Phase 2   NCT00329550   Japan;
Certolizumab pegol (rINN)   
   UCB PHARMA S.A.
      2008   -   EUCTR2007-003239-21-FR   France;
ChAdOx2 HAV   
   University of Oxford
      2017   Phase 1   NCT03027193   United Kingdom;
Chenodiol   
   University Medical Center Utrecht
      2009   -   EUCTR2009-013348-35-NL   Netherlands;
Chenofalk   
   University Medical Center Utrecht
      2009   -   EUCTR2009-013348-35-NL   Netherlands;
Chimeric IgG1 monoclonal antibody   
   Centocor B.V.
      2005   Phase 3   EUCTR2004-002815-10-GB   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-SE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DK   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DE   Denmark;Germany;Spain;Sweden;United Kingdom;
Cholecalciferol   
   Boston Children’s Hospital
      2008   -   NCT00621257   United States;
   University Hospital Birmingham NHS Foundation Trust
      2019   Phase 4   NCT03718182   United Kingdom;
   University of California, Los Angeles
      2010   Phase 1   NCT01046773   United States;
Cholecalciferol 10,000 IU   
   University of Michigan
      2015   Phase 4   NCT02208310   United States;
Cholecalciferol 400 IU   
   University of Michigan
      2015   Phase 4   NCT02208310   United States;
Cholestagel   
   LMU München, Campus Großhadern
      2011   -   EUCTR2009-010727-91-DE   Germany;
   University College London
      2009   Phase 2   EUCTR2009-010163-16-GB   United Kingdom;
Chondroitin sulfate   
   University Hospital Case Medical Center
      2011   Phase 1/Phase 2   NCT01245088   United States;
Cimzia   
   Milton S. Hershey Medical Center
      2013   Phase 4   NCT01696942   United States;
   UCB BIOSCIENCES GmbH
      2008   Phase 3   NCT00552344   Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
   UCB Pharma
      2009   -   NCT00844285   United States;
Cimzia 200 mg solution for injection   
   Ghent University Hospital
      2012   Phase 3   EUCTR2009-017998-37-BE   Belgium;
Ciprofloxacin   
   Assistance Publique - Hôpitaux de Paris
      2015   Phase 2   NCT02620007   France;
   Children's Hospital of Philadelphia
      2018   Phase 2   NCT03476317   United States;
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
   Foundation for Liver Research
      2008   Phase 3   NCT00736983   Netherlands;
   Mount Sinai Hospital, Canada
      2006   Phase 2   NCT00257699   Canada;
   Royal Liverpool University Hospital
      2014   Phase 2   NCT01783106   United Kingdom;
   University of North Carolina, Chapel Hill
      2008   Phase 2   NCT00609973   United States;
   University of Pennsylvania
      2016   Phase 2   NCT02765256   United States;
Ciprofloxacin hydrochloride   
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
Clarithromycin   
   Royal Liverpool University Hospital
      2000   Phase 3   NCT00269386   United Kingdom;
Clofarabine   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Coffee   
   University Hospital Heidelberg
      2010   -   NCT01231217   Germany;
Colecalciferol   
   Academic Medical Center
      2013   Phase 3   EUCTR2013-002838-20-NL   Belgium;Netherlands;
Colecalciferol D3 (Vigantol Oil)   
   Imperial College London
      2008   Phase 4   NCT00672763   United Kingdom;
Colesevelam   
   Florian Beigel
      2010   Phase 4   NCT01203254   Germany;
   LMU München, Campus Großhadern
      2011   -   EUCTR2009-010727-91-DE   Germany;
ColoVit capsule   
   University Medical Center Groningen
      2021   -   NCT04913467   Netherlands;
Colonoscopic fecal microbiota material (colo-FMT)   
   University of Minnesota
      2022   Phase 1   NCT05248191   United States;
Colony-purified Bacteroides thetaiotaomicron (B.theta)   
   4D Pharma
      2015   Phase 1   EUCTR2014-005666-29-GB   United Kingdom;
Companion diagnostic (CDx)   
   Prometheus Biosciences, Inc.
      2021   Phase 2   NCT05013905   United States;
Computed Tomography   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Continuous Mononuclear Cell Collection (CMNC)   
   University Hospital, Akershus
      2019   Phase 1/Phase 2   NCT04164849   Norway;
Contrast Enhanced Ultrasound   
   University of Michigan
      2015   Phase 1/Phase 2   NCT02061163   United States;
Contrast enhanced ultrasound   
   Yonsei University
      2020   Phase 4   NCT04660136   Korea, Republic of;
Cortecosteroid   
   Children's Hospital Medical Center, Cincinnati
      2005   Phase 2   NCT00109473   United States;
Corticosteroid   
   Jinling Hospital, China
      2014   Phase 4   NCT02056418   China;
   Yale University
      2015   Phase 4   NCT02392286   United States;
CosmoFer 50mg/ml solution for infusion or injection   
   Barts Health NHS Trust
      2011   Phase 4   EUCTR2010-023797-39-GB   United Kingdom;
Crohn's Disease   
   Ferring Pharmaceuticals
      2005   Phase 4   NCT00225810   Czech Republic;
Crohn's disease exclusion diet   
   Hospital Italiano de Buenos Aires
      2021   -   NCT05034458   Argentina;
Crohn's disease exclusion diet (CDED)   
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2/Phase 3   NCT05284136   France;Netherlands;
Crohns Disease Exclusion Diet + PEN   
   Prof. Arie Levine
      2016   -   NCT02231814   Israel;
Curcumin   
   Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research
      2014   -   JPRN-UMIN000015770   Japan;
   Sanjay Gandhi Postgraduate Institute of Medical Sciences
      2021   Phase 2   NCT04713631   India;
   Seattle Children's Hospital
      2009   Phase 1   NCT00889161   United States;
   University Hospital, Clermont-Ferrand
      2014   Phase 3   NCT02255370   France;
Cx401   
   CELLERIX S.A.
      2009   -   EUCTR2008-004286-25-DE   Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
      2009   -   EUCTR2008-004286-25-BE   Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
Cx601   
   MILLENNIUM PHARMACEUTICALS, INC.
      2019   Phase 4   EUCTR2019-000333-39-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Millennium Pharmaceuticals, Inc (MPI)
      2020   Phase 4   EUCTR2019-000333-39-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2020   Phase 4   EUCTR2017-002491-10-FR   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-ES   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-CZ   Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
      2019   Phase 4   EUCTR2019-000333-39-CZ   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Takeda Development Center Americas, Inc
      2020   Phase 4   EUCTR2019-000333-39-BE   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2020-003193-48-NL   Israel;Italy;Japan;Netherlands;Poland;Spain;
      2020   Phase 4   EUCTR2017-002491-10-DE   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
      2020   Phase 4   EUCTR2017-002491-10-AT   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
      -   Phase 3   EUCTR2020-003193-48-PL   Israel;Japan;Netherlands;Poland;
   TiGenix, S.A. Unipersonal
      2012   Phase 3   EUCTR2011-006064-43-BE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
      2012   -   EUCTR2011-006064-43-NL   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
   TiGenix, S.A.U.
      2017   Phase 3   EUCTR2017-000725-12-ES   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Tigenix S.A.U.
      2017   Phase 3   NCT03279081   Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Puerto Rico;Spain;Sweden;United Kingdom;United States;
      2009   Phase 1/Phase 2   NCT01372969   Spain;
Cyclophosphamide   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
   Fred Hutchinson Cancer Research Center
      2012   Phase 2   NCT01570348   United States;
   Icahn School of Medicine at Mount Sinai
      2017   Phase 2   NCT03219359   United States;
   Northwestern University
      2019   Phase 2   NCT04154735   United States;
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
   WOLFSON DIGESTIVE DISEASES CENTRE
      2007   -   EUCTR2005-003337-40-IT   Italy;United Kingdom;
Cyclophosphamide monohydrate   
   Barts Health NHS Trust
      2017   Phase 3   EUCTR2017-002545-30-GB   United Kingdom;
Cyltezo   
   Boehringer Ingelheim International GmbH
      2017   Phase 3   EUCTR2016-000612-14-HR   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000612-14-DE   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000612-14-CZ   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
Cytochrome P450 (CYP) Substrates   
   AbbVie
      2020   Phase 1   NCT04254783   Germany;Israel;United States;
Cytoxan   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
D9421-C   
   AstraZeneca
      -   Phase 3   JPRN-JapicCTI-121765   -
   AstraZeneca K.K.
      -   Phase 3   EUCTR2014-004132-20-Outside-EU/EEA   Japan;
D9421-C capsule   
   AstraZeneca
      2012   Phase 3   NCT01514240   Japan;
D9421-C,   
   AstraZeneca
      2006   Phase 2   NCT00573469   Japan;
DB adalimumab 40 mg eow   
   Abbott
      2002   Phase 3   NCT00055497   United States;
DB adalimumab 40 mg ew   
   Abbott
      2002   Phase 3   NCT00055497   United States;
DEXA scan   
   University of Texas Southwestern Medical Center
      2006   -   NCT00286689   United States;
DLX105   
   Delenex Therapeutics AG
      2012   Phase 2   NCT01624376   Switzerland;
DOXYCYCLINE HYCLATE   
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
DR-6MP   
   Teva GTC
      2011   Phase 2   NCT01433432   Israel;
Darvadstrocel   
   MILLENNIUM PHARMACEUTICALS, INC.
      2019   Phase 4   EUCTR2019-000333-39-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Millennium Pharmaceuticals, Inc (MPI)
      2020   Phase 4   EUCTR2017-002491-10-FR   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-ES   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-CZ   Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
   Millennium Pharmaceuticals, Inc.
      2019   Phase 3   NCT04075825   Belgium;Czechia;France;Hungary;Israel;Italy;Poland;Spain;United States;
   Shikamura Mitsuhiro
      2021   Phase 3   JPRN-jRCT2033200314   Israel;Italy;Japan;Netherlands;Poland;Spain;
   Takeda
      2021   Phase 3   NCT04701411   Israel;Japan;Netherlands;Poland;Spain;
      2021   -   NCT05113095   Japan;
      2020   Phase 4   NCT04118088   Austria;Czechia;France;Germany;Israel;Spain;
      2019   Phase 3   NCT03706456   Japan;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2020-003193-48-NL   Israel;Italy;Japan;Netherlands;Poland;Spain;
      2020   Phase 4   EUCTR2017-002491-10-DE   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
      2020   Phase 4   EUCTR2017-002491-10-AT   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
      -   Phase 3   EUCTR2020-003193-48-PL   Israel;Japan;Netherlands;Poland;
   Takeda Pharmaceutical Company Limited
      2019   Phase 3   JPRN-JapicCTI-184145   Japan;
   TiGenix, S.A.U.
      2021   Phase 3   EUCTR2017-000725-12-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Decortin   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 3   EUCTR2010-020137-10-LT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020137-10-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020137-10-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-NL   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020137-10-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
   Abbott GmBH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020137-10-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Dehydroepiandrosterone [DHEA]   
   Inflabloc Pharmaceuticals
      2005   Phase 2   NCT00106314   Canada;United States;
Dekristol 20.000 ie   
   Jørgen Agnholt
      2013   Phase 3   EUCTR2013-000971-34-DK   Denmark;
Delayed Release 6 mercaptopurine   
   Teva GTC
      2010   Phase 1/Phase 2   NCT01094613   Israel;
      2008   Phase 1   NCT00774982   Israel;
Delayed Release 6MP or Calcitriol vs. Purinethol   
   Teva GTC
      2006   Phase 1/Phase 2   NCT00287170   Israel;
Denosumab   
   University of Manitoba
      2015   Phase 1/Phase 2   NCT02321280   Canada;
Deucravacitinib   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2021   Phase 2   EUCTR2020-004461-40-IT   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2020-004461-40-DE   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Dexamethasone   
   Erydel
      2009   Phase 3   NCT01277289   Italy;Romania;Spain;
Dexamethasone sodium phosphate 250 mg/ 10 ml   
   ERYDEL S.P.A.
      2009   -   EUCTR2008-007329-38-IT   Italy;Spain;
      2009   -   EUCTR2008-007329-38-ES   Italy;Spain;
Dextromethorphan   
   Janssen Research & Development, LLC
      2018   Phase 1   NCT03358706   Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
   Takeda
      2016   Phase 4   NCT02760615   United States;
Diet 1   
   University of Washington
      2017   -   NCT03012542   United States;
Diet 2   
   University of Washington
      2017   -   NCT03012542   United States;
Dietary therapy   
   Rush University Medical Center
      2006   Phase 1/Phase 2   NCT00343642   United States;
Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon   
   Italfarmaco S.p.A.
      2005   Phase 2   EUCTR2004-004854-19-SK   Slovakia;
Dietician designed diet   
   St Vincent's Hospital Melbourne
      2021   Phase 2/Phase 3   NCT04970446   -
Diflucan   
   Cliniques Universitaires Saint Luc
      2008   -   EUCTR2008-003167-39-BE   Belgium;
Diphenhydramine   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
Dipyridamole   
   Guangzhou Women and Children's Medical Center
      2021   Phase 0   ChiCTR2100048717   China;
Doxycycline   
   Royal Liverpool University Hospital
      2014   Phase 2   NCT01783106   United Kingdom;
E-Device   
   UCB Biopharma S.P.R.L.
      2017   Phase 3   NCT03357471   United States;
E6011   
   EA Pharma Co., Ltd.
      2019   Phase 2   NCT03733314   Czechia;Hungary;Japan;Poland;Russian Federation;
      2019   Phase 2   EUCTR2018-002109-70-HU   Czech Republic;Hungary;Japan;Poland;
      2019   Phase 2   EUCTR2018-002109-70-CZ   Czech Republic;Czechia;Hungary;Japan;Poland;Russian Federation;
      2014   Phase 1/Phase 2   NCT02039063   Japan;
   Eisai Inc.
      2014   Phase 1   NCT02249078   -
EB8018   
   Millennium Pharmaceuticals, Inc (a wholly owned subsidiary
      2020   Phase 2   EUCTR2019-000886-19-FR   France;Germany;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000886-19-GB   Austria;France;Germany;Netherlands;United Kingdom;United States;
   Millennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)
      2020   Phase 2   EUCTR2019-000886-19-NL   Austria;France;Germany;Netherlands;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000886-19-AT   Austria;France;Germany;Netherlands;United Kingdom;United States;
   Takeda Development Center Americas,Inc.
      2019   Phase 2   EUCTR2019-000886-19-DE   Austria;France;Germany;Netherlands;United Kingdom;United States;
EB8018 (First-in-class FimH blocker)   
   Enterome
      2018   Phase 1   NCT03709628   Austria;France;Germany;Italy;
EEN   
   Sun Yat-sen University
      2013   -   NCT02887287   China;
   The Second Hospital of Nanjing Medical University
      2016   -   NCT02897661   China;
EEN (Nestle Modulen®)   
   Duzce University
      2021   Phase 3   NCT04921033   Turkey;
EEN intervention group   
   Shaare Zedek Medical Center
      2020   -   NCT04239248   Israel;
EGG WHITE PROTEIN   
   Lument AB
      2019   Phase 2   EUCTR2019-002093-32-SE   Sweden;
EMEA/H/C/000240   
   Santeon
      2015   Phase 4   EUCTR2015-001954-14-NL   Netherlands;
EMEA/H/C/002576   
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
EMEA/H/C/002778   
   Department of medical gastroenterology, Herlev Hospital
      2016   Phase 4   EUCTR2012-002702-51-NO   Denmark;Finland;Norway;Sweden;
ENDOXAN BAXTER   
   WOLFSON DIGESTIVE DISEASES CENTRE
      2007   -   EUCTR2005-003337-40-IT   Italy;United Kingdom;
ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2016   Phase 4   EUCTR2015-003270-32-IT   Italy;
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2021   Phase 3   EUCTR2020-004301-31-IT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
ERB-041   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2004   Phase 1   NCT00245947   -
ERY-DEX   
   ERYDEL S.P.A.
      2009   -   EUCTR2008-007329-38-IT   Italy;Spain;
      2009   -   EUCTR2008-007329-38-ES   Italy;Spain;
EU/1/03/268/002   
   LMU München, Campus Großhadern
      2011   -   EUCTR2009-010727-91-DE   Germany;
EU/1/99/116/003   
   Academic Medical Center, department of Gastroenterology and hepatology
      2008   -   EUCTR2008-001131-35-NL   Netherlands;
EUA with seton placement if necessary   
   Vanderbilt University Medical Center
      2008   Phase 4   NCT00517296   United States;
EUS   
   Vanderbilt University Medical Center
      2008   Phase 4   NCT00517296   United States;
Early immunosuppressants (azathioprine, methotrexate)   
   Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
      2005   Phase 4   NCT00546546   France;
Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml   
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
Efmarodocokin alfa   
   Genentech, Inc.
      2018   Phase 2   EUCTR2017-004997-32-IE   Bulgaria;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Egg Albumen Powder   
   Lument AB
      2019   Phase 2   EUCTR2019-002093-32-SE   Sweden;
Eicosapentaenoic acid   
   Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
      2014   -   NCT02179372   Italy;
Empagliflozin   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 1   NCT05078879   United States;
Endopath from Itamar medical - FDA approved device.   
   Carmel Medical Center
      2014   -   NCT01881464   Israel;
Endoscopic balloon dilatation   
   St Vincent's Hospital Melbourne
      2017   Phase 4   NCT03220841   Australia;
Entecavir   
   Saitama Medical University
      2016   -   JPRN-UMIN000020029   Japan;
Enteral nutrition   
   Jinling Hospital, China
      2014   Phase 4   NCT02056418   China;
   Zhu Weiming
      2012   -   NCT01820247   China;
Enteral nutrition.   
   Jinling Hospital, China
      2012   -   NCT01823029   China;
Entocort   
   ASTRAZENECA
      2011   Phase 3   EUCTR2011-003743-22-IT   Canada;Germany;Italy;United States;
   AstraZeneca K.K.
      -   Phase 3   EUCTR2014-004132-20-Outside-EU/EEA   Japan;
   Padagis LLC
      2011   Phase 3   NCT01453946   Canada;Germany;Italy;Poland;United States;
      2011   Phase 3   NCT01444092   Canada;Germany;Italy;Poland;United States;
Entocort CR   
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
Entocort® Kapseln   
   AstraZeneca AB
      -   -   EUCTR2011-003743-22-DE   Canada;Germany;Italy;Poland;United States;
      -   -   EUCTR2011-003742-40-DE   Canada;Germany;Italy;Poland;United States;
Entyvio   
   AMC MEDICAL RESEARCH B.V.
      2017   Phase 3   EUCTR2015-000555-24-IT   France;Italy;Netherlands;Spain;
   Academic Medical Center Amsterdam
      2016   Phase 4   EUCTR2015-000555-24-NL   Netherlands;
      2016   Phase 4   EUCTR2015-000555-24-FR   France;Netherlands;Spain;
      2016   Phase 4   EUCTR2015-000555-24-ES   Netherlands;Spain;
   Academic Medical Center, Gastroenterology
      2017   Phase 4   EUCTR2014-005376-29-HU   Belgium;Hungary;Netherlands;
      2015   Phase 4   EUCTR2014-005376-29-BE   Belgium;Netherlands;
      2015   -   EUCTR2014-005376-29-NL   Netherlands;
   TAKEDA DEVELOPMENT CENTRE EUROPE LTD
      2016   Phase 3   EUCTR2015-000481-58-IT   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Takeda Development Centre Europe Limited
      2017   Phase 4   EUCTR2016-000678-40-BG   Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
      2016   Phase 4   EUCTR2016-000678-40-LV   Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
      2016   Phase 4   EUCTR2016-000678-40-HU   Australia;Bulgaria;Czech Republic;Czechia;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
      2016   Phase 4   EUCTR2016-000678-40-EE   Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
      2016   Phase 4   EUCTR2016-000678-40-CZ   Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
   Takeda Development Centre Europe, Ltd.
      2018   Phase 2   EUCTR2017-002231-41-PL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002231-41-NL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002231-41-BE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002182-21-PL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002182-21-NL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002182-21-BE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 4   EUCTR2015-000852-12-BE   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002231-41-HU   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002231-41-GB   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002231-41-DE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-HU   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-GB   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-FR   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-DE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-000852-12-NL   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-000852-12-GB   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-000852-12-FR   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-000852-12-ES   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-NL   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-HR   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-SK   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-SE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-NL   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-LT   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-HU   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-GB   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-ES   Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-DK   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-DE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-CZ   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-BG   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-BE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 2   EUCTR2017-002231-41-FR   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
Epanova   
   Tillotts Pharma AG
      2003   Phase 3   NCT00613197   Belgium;
Epanova™ (Omega-3 Free Fatty Acids)   
   Tillotts Pharma AG
      2002   Phase 3   NCT00074542   Canada;United States;
Epaxal Berna (virosomal hepatitis A vaccine)   
   Asan Medical Center
      2011   Phase 4   NCT01341808   Korea, Republic of;
Ergocalciferol   
   Boston Children’s Hospital
      2008   -   NCT00621257   United States;
Erythropoietin   
   Jinling Hospital, China
      2012   -   NCT01823029   China;
Etiprednol dicloacetate   
   Teva Branded Pharmaceutical Products R&D, Inc.
      2002   Phase 2   NCT00035503   Canada;United States;
Etrasimod   
   Arena Pharmaceuticals
      2020   Phase 2/Phase 3   NCT04173273   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United States;
   Samia Hassan El-Shishtawy
      2021   Phase 2/Phase 3   NCT05033340   -
Etrasimod L-arginine   
   ARENA PHARMACEUTICALS, INC.
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-IT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Arena Pharmaceuticals Inc.
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-004775-40-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-PT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-NO   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-NL   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-LT   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-HU   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-GR   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-GB   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-FR   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-ES   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-CZ   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002895-14-BG   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Etrolizumab   
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 3   EUCTR2014-003855-76-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003824-36-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Hoffmann-La Roche
      2018   Phase 1   NCT03478956   Belgium;Germany;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   NCT02403323   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Luxembourg;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   NCT02394028   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Luxembourg;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Evaluation of biological predictive factors of clinical response to ustekinumab   
   Hospices Civils de Lyon
      2018   -   NCT03351647   France;
Everolimus   
   Novartis Pharma Services AG
      2005   Phase 2   EUCTR2005-001148-22-SK   Slovakia;
Exclusive Enteral Nutrition   
   Children's Hospital of Fudan University
      2022   Phase 4   NCT04530877   -
      2017   -   NCT03755583   China;
   McMaster University
      2018   Phase 4   NCT03833596   Canada;
   Tel-Aviv Sourasky Medical Center
      2020   Phase 3   NCT04398836   Israel;
Exclusive Enteral Nutrition Therapy   
   Jinling Hospital, China
      2013   -   NCT02233062   China;
Expanded allogenic adipose-derived adult stem cells   
   Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
      2009   Phase 1/Phase 2   NCT00999115   Spain;
Expanded autologous adipose-derived adult stem cells (eASCs)   
   Tigenix S.A.U.
      2008   Phase 3   NCT01378390   Austria;Netherlands;Spain;
Expanded human allogenic mesemchymal adult stem cells extracted from adipose tissue (eASCs)   
   TiGenix, S.A. Unipersonal
      2012   -   EUCTR2011-006064-43-NL   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Expanded human allogenic mesenchymal adult stem cells extractd from adipose tissue (eASCs)   
   CELLERIX S.A.
      2012   Phase 3   EUCTR2011-006064-43-IT   Austria;Belgium;Germany;Israel;Italy;Netherlands;Spain;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose   
   MILLENNIUM PHARMACEUTICALS, INC.
      2019   Phase 4   EUCTR2019-000333-39-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs   
   Millennium Pharmaceuticals, Inc (MPI)
      2020   Phase 4   EUCTR2017-002491-10-FR   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-ES   Austria;Czech Republic;France;Germany;Spain;United Kingdom;
      2020   Phase 4   EUCTR2017-002491-10-CZ   Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
   Takeda Development Center Americas, Inc.
      2020   Phase 4   EUCTR2017-002491-10-DE   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
      2020   Phase 4   EUCTR2017-002491-10-AT   Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs)   
   Millennium Pharmaceuticals, Inc (MPI)
      2020   Phase 4   EUCTR2019-000333-39-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000333-39-CZ   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Takeda Development Center Americas, Inc
      2020   Phase 4   EUCTR2019-000333-39-BE   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2020-003193-48-NL   Israel;Italy;Japan;Netherlands;Poland;Spain;
      -   Phase 3   EUCTR2020-003193-48-PL   Israel;Japan;Netherlands;Poland;
   TiGenix S.A.U.
      2012   Phase 3   EUCTR2011-006064-43-DE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
   TiGenix, S.A. Unipersonal
      2012   Phase 3   EUCTR2011-006064-43-BE   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
   TiGenix, S.A.U.
      2021   Phase 3   EUCTR2017-000725-12-SE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-000725-12-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-DE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-PL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-HU   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-ES   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-006064-43-AT   Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Extracorporeal Photopheresis   
   Mallinckrodt
      2004   Phase 2   NCT00221026   Austria;Belgium;Germany;United States;
FE 999301   
   University Hospital Schleswig-Holstein (UKSH)
      2016   Phase 2   EUCTR2016-000205-36-DE   Germany;
FFP104   
   Fast Forward Pharmaceuticals
      2016   Phase 1/Phase 2   NCT02465944   Belgium;Netherlands;
   Fast Forward Pharmaceuticals, B.V.
      2016   Phase 2   EUCTR2015-001678-17-NL   Belgium;Netherlands;
      2015   Phase 2   EUCTR2015-001678-17-BE   Belgium;Netherlands;
FITC-Adalimumab   
   University of Erlangen-Nürnberg Medical School
      2011   Phase 1/Phase 2   NCT01275508   Germany;
FMT   
   Children's Hospital Los Angeles
      2017   Phase 1/Phase 2   NCT03194529   United States;
   St Vincent's Hospital Melbourne
      2021   Phase 2/Phase 3   NCT04970446   -
   Yanling Wei
      2015   Phase 2   NCT02335281   China;
FOS   
   Hospital Universitari Vall d'Hebron Research Institute
      2014   -   NCT02539849   Spain;
Faecal Microbiota Transplantation   
   St Vincent's Hospital Melbourne
      2018   -   NCT03477032   Australia;
Faecal microbiota transplantation   
   Torkell Ellingsen
      2022   Phase 2   NCT04924270   -
Fecal Microbial Transplantation   
   Beth Israel Deaconess Medical Center
      2013   Phase 1   NCT01847170   United States;
   Stony Brook University
      2017   Early Phase 1   NCT03267238   United States;
Fecal Microbial transplant   
   Seattle Children's Hospital
      2015   Phase 1/Phase 2   NCT02272868   United States;
Fecal Microbiota Transplant   
   Children's Hospital of Philadelphia
      2015   -   NCT02636517   United States;
   Stacy A. Kahn
      2017   Phase 1/Phase 2   NCT02330211   United States;
   University of Alberta
      2014   Phase 1/Phase 2   NCT02199561   Canada;
Fecal Microbiota Transplant (FMT)   
   Boston Medical Center
      2015   Phase 2   NCT02417974   United States;
   Stacy A. Kahn
      2015   Phase 1/Phase 2   NCT02330653   United States;
   University of Alberta
      2017   Phase 2   NCT03078803   Canada;
Fecal Microbiota Transplantation   
   Stanford University
      2022   Phase 1   NCT03747718   United States;
Fecal Microbiota Transplantation (FMT)   
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 3   NCT04997733   France;
   Children's Mercy Hospital Kansas City
      2014   Phase 1   NCT02108821   United States;
Fecal microbiota   
   ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS (AP-HP)
      2019   Phase 3   EUCTR2019-003816-29-FR   France;
Fecal microbiota transplantation   
   Gulhane Military Medical Academy
      2015   Phase 3   NCT02575040   Turkey;
Ferric Carboxy Maltose   
   Shield Therapeutics
      2016   Phase 3   NCT02680756   Belgium;France;Germany;Hungary;Spain;United States;
Ferric carboxymaltose   
   Vifor Inc.
      2008   Phase 3   NCT00810030   Austria;Russian Federation;
Ferrous sulphate   
   Barts Health NHS Trust
      2011   Phase 4   EUCTR2010-023797-39-GB   United Kingdom;
   Queen Mary University of London
      2011   Phase 4   NCT01991314   United Kingdom;
Fibrin glue injection in fistula   
   Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
      2003   Phase 3   NCT00723047   Belgium;France;
Filgotinib   
   GILEAD SCIENCES INCORPORATED
      2018   Phase 3   EUCTR2016-002763-34-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001367-36-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
   Gilead Sciences
      2018   Phase 1   NCT03417778   Germany;New Zealand;United States;
      2017   Phase 3   NCT02914600   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 2   NCT03077412   Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   NCT03046056   Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Spain;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02914561   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Filgrastim   
   Barts Health NHS Trust
      2017   Phase 3   EUCTR2017-002545-30-GB   United Kingdom;
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
Fish oil   
   The First Affiliated Hospital of Sun Yat-sen University
      2011   -   ChiCTR-TRC-11001321   China;
Flagyl   
   GETECCU
      2011   -   EUCTR2011-000885-36-ES   Spain;
Flixabi   
   University Medical Center Groningen
      2021   Phase 4   EUCTR2020-001811-26-BE   Belgium;Netherlands;
      2020   Phase 4   EUCTR2020-001811-26-NL   Netherlands;
   University Southampton Hospital NHS Foundation Trust
      2018   Phase 4   EUCTR2018-001546-33-GB   United Kingdom;
Fluconazole   
   Children's Hospital of Philadelphia
      2018   Phase 2   NCT03476317   United States;
   University Hospital, Lille
      2008   Phase 2   NCT02997059   France;
   University of Pennsylvania
      2016   Phase 2   NCT02765256   United States;
Fludarabine   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
   Northwestern University
      2019   Phase 2   NCT04154735   United States;
Fludarabine Phosphate   
   Fred Hutchinson Cancer Research Center
      2012   Phase 2   NCT01570348   United States;
Fludarabine phosphate   
   Barts Health NHS Trust
      2017   Phase 3   EUCTR2017-002545-30-GB   United Kingdom;
Fluorescence endoscopy and spectroscopy   
   University Medical Center Groningen
      2020   Phase 1   NCT04112212   Netherlands;
FolateScan (Technetium Tc 99mEC20)   
   Mayo Clinic
      2006   Phase 2   NCT00588393   United States;
Foralumab   
   Tiziana Life Sciences, PLC
      2021   Phase 1   NCT05028946   -
Fosfato sodico de dexametasona   
   ERYDEL S.P.A.
      2009   -   EUCTR2008-007329-38-ES   Italy;Spain;
Fosfomycin   
   Ishikawa Dai
      2017   -   JPRN-jRCTs031180415   Japan;
Fully humanised, recombinant monoclonal antibody (IgG1)   
   University of Birmingham
      2018   Phase 1   EUCTR2018-002001-65-GB   United Kingdom;
G-CSF   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00025805   United States;
   Northwestern University
      2019   Phase 2   NCT04154735   United States;
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
G321605   
   Galapagos NV
      2014   -   EUCTR2014-001892-30-HU   Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
      2014   -   EUCTR2014-001892-30-BE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
GED-0301   
   CELGENE CORPORATION
      2017   Phase 3   EUCTR2015-001924-40-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-IT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-001693-18-IT   Italy;
   Celgene
      2017   Phase 3   NCT02974322   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   NCT02641392   Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   NCT02685683   Italy;
      2015   Phase 3   NCT02596893   Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;Former Serbia and Montenegro;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 1   NCT02367183   Australia;Canada;Hungary;Slovakia;United States;
   Celgene Corporation
      2017   Phase 3   EUCTR2015-001963-37-FI   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001925-18-FI   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-NL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-LV   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-HR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-GR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-FR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-ES   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-SE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-PT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-LV   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-HR   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-GR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-GB   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Oman;Pakistan;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-ES   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-DK   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-DE   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-BG   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-BE   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-AT   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-SK   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-SE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-PT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-LV   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-HU   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-HR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-GR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-GB   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-ES   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-DK   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-DE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-BG   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-BE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-AT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001963-37-EE   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001925-18-EE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001925-18-NO   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001924-40-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   GIULIANI
      2013   -   EUCTR2011-002640-27-DE   Germany;Italy;
      2012   -   EUCTR2011-005678-47-IT   Italy;
      2011   -   EUCTR2011-002640-27-IT   Germany;Italy;
GLPG0634   
   Galapagos NV
      2014   Phase 2   NCT02048618   Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
      2014   Phase 2   EUCTR2013-002857-32-GB   Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
      2014   Phase 2   EUCTR2013-002857-32-DE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
      2014   Phase 2   EUCTR2013-002857-32-CZ   Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
      2014   -   EUCTR2013-002857-32-PL   Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
      2014   -   EUCTR2013-002857-32-HU   Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
      2014   -   EUCTR2013-002857-32-BE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
GLPG1205   
   Galapagos NV
      2014   -   EUCTR2014-001892-30-HU   Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
      2014   -   EUCTR2014-001892-30-BE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
GS-5745   
   GILEAD SCIENCES INCORPORATED
      2015   Phase 2   EUCTR2015-001249-10-IT   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;South Africa;Spain;United Kingdom;United States;
   Gilead Sciences, Inc
      2016   Phase 2   EUCTR2015-001249-10-IS   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-001249-10-HU   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-001249-10-GB   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;New Zealand;South Africa;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-001249-10-ES   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-001249-10-DE   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-001249-10-CZ   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
GS-6034   
   GILEAD SCIENCES INCORPORATED
      2018   Phase 3   EUCTR2016-002763-34-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-001367-36-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003153-15-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
   Galapagos NV
      2017   Phase 3   EUCTR2016-002763-34-SK   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-BG   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-SK   Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-DE   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-BG   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003179-23-BE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-003179-23-AT   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-003153-15-BE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-003153-15-AT   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-PT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-IS   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-GR   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-ES   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-CZ   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002763-34-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-PT   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-NO   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-IS   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-HU   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-HR   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-GR   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-ES   Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-001367-36-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-PL   Austria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-HU   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-GB   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-FR   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-ES   Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-DE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003179-23-CZ   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003153-15-PL   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003153-15-HU   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003153-15-GB   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003153-15-ES   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003153-15-DE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003153-15-CZ   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
GSK1070806   
   University of Birmingham
      2019   Phase 1/Phase 2   NCT03681067   United Kingdom;
      2018   Phase 1   EUCTR2018-002001-65-GB   United Kingdom;
GSK1605786   
   GlaxoSmithKline
      2011   Phase 1   NCT01489943   United States;
      2010   Phase 1   NCT01611805   Australia;
GSK1605786 ChemoCentryx: formulation A   
   GlaxoSmithKline
      2010   Phase 1   NCT01114607   United States;
GSK1605786 GSK direct-fill: formulation C   
   GlaxoSmithKline
      2010   Phase 1   NCT01114607   United States;
GSK1605786 GSK modified-process: formulation D   
   GlaxoSmithKline
      2010   Phase 1   NCT01114607   United States;
GSK1605786 GSK tablet: formulation E   
   GlaxoSmithKline
      2010   Phase 1   NCT01114607   United States;
GSK1605786 GSK: formulation B   
   GlaxoSmithKline
      2010   Phase 1   NCT01114607   United States;
GSK1605786 capsule   
   GlaxoSmithKline
      2013   Phase 1   NCT01827631   China;
GSK1605786A   
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2010-022384-35-IT   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-IT   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022382-10-IT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;South Africa;Spain;Sweden;United Kingdom;United States;
   GlaxoSmithKline
      2011   Phase 3   NCT01536418   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01318993   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01316939   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   NCT01277666   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2010-022383-12-BG   Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022382-10-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-SK   Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-AT   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022382-10-SK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-022382-10-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022383-12-SE   Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022383-12-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2011   -   EUCTR2010-022383-12-DK   Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2010-022384-35-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-022384-35-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022384-35-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022384-35-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022384-35-PL   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-022384-35-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022384-35-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2010-022384-35-AT   Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022383-12-PL   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022384-35-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022384-35-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022384-35-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022383-12-NO   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2010-022383-12-GB   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2010-022383-12-BE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022382-10-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022382-10-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022384-35-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022384-35-HU   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022384-35-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022384-35-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022383-12-HU   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022383-12-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022382-10-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022382-10-NL   Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-022382-10-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022382-10-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022382-10-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2010-022382-10-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2010-022382-10-NO   Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      -   -   EUCTR2010-022383-12-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2011-002817-12-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002817-12-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002817-12-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2011-002817-12-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002817-12-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002817-12-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002817-12-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-002817-12-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002817-12-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-002817-12-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-002817-12-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-002817-12-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
GSK2330811   
   GlaxoSmithKline
      2021   Phase 2   NCT04151225   -
Glatiramer acetate   
   Tel-Aviv Sourasky Medical Center
      2008   Phase 2   NCT00731172   Israel;
Glucose   
   The First Affiliated Hospital of Sun Yat-sen University
      2011   -   ChiCTR-TRC-11001321   China;
Glutamine   
   All India Institute of Medical Sciences, New Delhi
      2005   Phase 1   NCT00838149   India;
Gold   
   The 7th Medical Center of the PLA General Hospital (Army general hospital)
      2019   Phase 0   ChiCTR1900022728   China;
   The First Affiliated Hospital of Anhui Medical University
      2020   Phase 0   ChiCTR2000037094   China;
   The First Hospital Affiliated to Sun Yat sen University
      2020   -   ChiCTR2000029543   China;
   West China Hospital, Sichuan University
      2013   -   ChiCTR-DDT-14004999   China;
Golimumab   
   Janssen Research & Development, LLC
      2022   Phase 2   NCT05242471   Italy;
   Janssen Scientific Affairs, LLC
      2013   Phase 4   NCT01804166   United States;
Green Tea   
   University Hospital Heidelberg
      2010   -   NCT01231217   Germany;
Group 2 ustekinumab   
   Janssen Research & Development, LLC
      2011   Phase 3   NCT01369342   Australia;Belgium;Brazil;Bulgaria;Canada;Croatia;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   NCT01369329   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Serbia;South Africa;Spain;United Kingdom;United States;
Group 3: ustekinumab approximately   
   Janssen Research & Development, LLC
      2011   Phase 3   NCT01369342   Australia;Belgium;Brazil;Bulgaria;Canada;Croatia;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
      2011   Phase 3   NCT01369329   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Serbia;South Africa;Spain;United Kingdom;United States;
Growth hormone   
   Children's Hospital Medical Center, Cincinnati
      2005   Phase 2   NCT00109473   United States;
Guselkumab   
   Janssen Pharmaceutical K.K.
      2020   Phase 3   NCT04397263   Japan;
      2020   Phase 3   JPRN-JapicCTI-205298   Japan;
      2018   Phase 2-3   JPRN-JapicCTI-183950   Japan, North America;
   Janssen Research & Development, LLC
      2022   Phase 2   NCT05242471   Italy;
   University of California, San Diego
      2013   -   NCT02103361   United States;
Guselkumab Dose 1   
   Janssen Research & Development, LLC
      2022   Phase 3   NCT05197049   Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2/Phase 3   NCT03466411   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 2   
   Janssen Research & Development, LLC
      2022   Phase 3   NCT05197049   Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2/Phase 3   NCT03466411   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 3   
   Janssen Research & Development, LLC
      2022   Phase 3   NCT05197049   Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2/Phase 3   NCT03466411   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 4   
   Janssen Research & Development, LLC
      2018   Phase 2/Phase 3   NCT03466411   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 5   
   Janssen Research & Development, LLC
      2018   Phase 2/Phase 3   NCT03466411   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
HM201   
   Syneos Health
      2021   Early Phase 1   NCT05088369   -
HMPL-004   
   Hutchison Medipharma Limited
      2006   Phase 2   NCT00655733   United States;
HMPL004-6599   
   Nutrition Science Partners Limited
      2018   Phase 1   NCT03597971   Australia;
HUMAN ALBUMIN AS MACROAGGREGATES   
   ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
      2019   Phase 2   EUCTR2019-001948-21-FR   France;
HUMAN PLASMA FOR FRACTIONATION   
   Fundación FISEVI
      2012   -   EUCTR2011-006127-38-ES   Spain;
      2012   -   EUCTR2011-004820-37-ES   Spain;
HUMIRA   
   Abbott GmbH & Co. KG
      2008   -   EUCTR2006-004814-41-IT   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
   Abbott GmbH & Co. KG (Abbott)
      -   Phase 3   EUCTR2006-002078-23-SK   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   Boehringer Ingelheim
      2016   Phase 3   NCT02871635   Belarus;Bosnia and Herzegovina;Croatia;Czechia;Germany;Greece;Israel;Poland;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
   GETAID
      2014   Phase 4   EUCTR2013-003199-11-FR   Belgium;France;
   University of Leuven, Division of Gastroenterology
      2007   Phase 4   EUCTR2006-006632-22-BE   Belgium;
HUMIRA (adalimumab)   
   Boehringer Ingelheim International GmbH
      2017   Phase 3   EUCTR2016-000612-14-HR   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000612-14-GR   Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000612-14-GB   Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000612-14-DE   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000612-14-CZ   Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL   
   UMBERTO I - POLICLINICO DI ROMA
      2017   Phase 4   EUCTR2016-000522-18-IT   Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
HUMIRA 40 mg solución inyectable en jeringa precargada   
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
HUMIRA 40Mg Solution for Injection   
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2019   Phase 4   NCT04131322   Spain;
HUMIRA ®   
   Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
      2019   Phase 4   EUCTR2019-000717-37-ES   Spain;
HUMIRA*SC 2SIR+F 40MG 0,8ML+2T   
   Abbott GmBH Co KG
      2005   -   EUCTR2004-002163-24-IT   Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
   Abbott GmBH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Abbott GmbH Co.KG
      2006   -   EUCTR2005-005291-32-IT   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
HYDROXYCHLOROQUINE SULPHATE   
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
Hematopoietic stem cell transplantation   
   University of California, Los Angeles
      2014   Phase 0   NCT01932658   United States;
Herpes Zoster Vaccine   
   University of Alabama at Birmingham
      2016   Phase 2   NCT02538341   United States;
      2013   Phase 2   NCT02538757   United States;
Hextend   
   Spectrum Health Hospitals
      2007   Phase 3   NCT00467922   United States;
High Oligosaccharide Group   
   University of British Columbia
      2015   -   NCT02193750   Australia;Canada;
High dose TSO   
   Dr. Falk Pharma GmbH
      2010   Phase 2   NCT01279577   Germany;
High serine diet   
   University of Michigan
      2021   -   NCT04795960   United States;
High-dose Cyclophosphamide   
   Johns Hopkins University
      2015   Phase 1/Phase 2   NCT01836289   United States;
HuM291   
   PDL BioPharma, Inc
      2005   -   EUCTR2004-004388-31-DE   Germany;
   PDL BioPharma, Inc.
      2005   -   EUCTR2004-004387-72-DE   Germany;
   Protein Design Labs, Inc.
      2005   -   EUCTR2004-004387-72-AT   Austria;Germany;
Hulio   
   University Medical Center Groningen
      2021   Phase 4   EUCTR2020-001811-26-BE   Belgium;Netherlands;
      2020   Phase 4   EUCTR2020-001811-26-NL   Netherlands;
Human Anti-IL-12 Antibody   
   Centocor BV
      2009   Phase 2   EUCTR2008-000649-77-FR   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-000649-77-ES   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-NL   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-GB   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-DE   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-BE   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2008-000649-77-AT   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40   
   Centocor BV
      2009   Phase 2   EUCTR2008-000649-77-FR   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-000649-77-ES   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-NL   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-GB   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-DE   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-000649-77-BE   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2008-000649-77-AT   Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Human Placenta-Derived Cells PDA001 Intravenous Infusion   
   Celularity Incorporated
      2010   Phase 2   NCT01155362   United States;
Human Umbilical Cord Mesenchymal Stem Cells   
   Shanghai East Hospital
      2022   -   NCT05262829   China;
Human anti-IP10 monoclonal antibody   
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-002981-19-PL   Belgium;France;Hungary;Poland;South Africa;United States;
      2012   -   EUCTR2011-002981-19-HU   Belgium;France;Hungary;Poland;South Africa;United States;
      2012   -   EUCTR2011-002981-19-BE   Belgium;France;Hungary;Poland;South Africa;United States;
Human umbilical cord mesenchymal stem cells (UC-MSCs)   
   CryoCord Sdn Bhd
      2022   Phase 1   NCT05039411   Malaysia;
Humira   
   Abbott GmbH & Co. KG
      2008   -   EUCTR2006-004814-41-NL   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2006-004814-41-CZ   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2006-004814-41-BE   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2004-002163-24-GB   Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-004814-41-FR   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2005-005291-32-SE   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-NL   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-DE   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-BE   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2006   -   EUCTR2005-005291-32-AT   Austria;Belgium;Germany;Italy;Netherlands;Sweden;
      2005   -   EUCTR2004-002934-20-BE   Belgium;
      2005   -   EUCTR2004-002163-24-DE   Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
      2004   -   EUCTR2004-002163-24-SE   Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-002163-24-ES   Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-002163-24-DK   Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2006-004814-41-Outside-EU/EEA   -
   Abbott GmbH & co. KG
      2004   -   EUCTR2004-002163-24-BE   Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
   Abbott Laboratories
      2004   -   EUCTR2004-002163-24-HU   Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
   Academic Medical Center
      2019   Phase 4   EUCTR2018-002064-15-NL   Netherlands;
      2013   Phase 4   EUCTR2013-002932-25-NL   Netherlands;
   Department of medical gastroenterology, Herlev Hospital
      2009   Phase 4   EUCTR2009-009926-94-DK   Denmark;
   Fundació Clínic per a la Recerca Biomèdica
      2013   Phase 3   EUCTR2012-001723-12-ES   Spain;
   GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
      2015   Phase 4   EUCTR2013-003199-11-BE   Belgium;France;
   GETECCU
      2011   -   EUCTR2011-000885-36-ES   Spain;
   Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
      2012   -   EUCTR2011-003966-34-ES   Spain;
      2011   Phase 3   EUCTR2011-003966-34-BE   Belgium;Spain;
   IBD Center LMU Munich
      2008   -   EUCTR2008-004926-18-DE   Germany;
   PIBD-Net
      2017   Phase 3   EUCTR2016-000522-18-DE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
   PIBDNet
      2018   Phase 4   EUCTR2016-000522-18-BE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
      2017   Phase 4   EUCTR2016-000522-18-NL   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
      -   Phase 4   EUCTR2016-000522-18-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
   Region Örebro län
      2021   Phase 4   EUCTR2019-002942-19-DK   Denmark;
   Robarts Clinical Trials
      2015   Phase 4   EUCTR2014-001050-41-DE   Canada;Germany;United Kingdom;United States;
   Royal Liverpool University Hospital
      2012   -   EUCTR2011-006084-22-GB   United Kingdom;
   University Hospital Southampton NHS Foundation Trust
      2019   Phase 4   EUCTR2018-004967-30-GB   United Kingdom;
   University Maastricht
      2019   Phase 4   EUCTR2017-004588-11-NL   Netherlands;
   University Medical Center Groningen
      2021   Phase 4   EUCTR2020-001811-26-BE   Belgium;Netherlands;
      2020   Phase 4   EUCTR2020-001811-26-NL   Netherlands;
Humira (adalimumab original)   
   Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
      2019   Phase 4   EUCTR2019-000717-37-ES   Spain;
Humira (adalimumab)   
   Radboud University Medical Centre
      2017   Phase 4   EUCTR2016-003321-42-NL   Netherlands;
Humira 20 mg solution for injection in pre-filled syringe   
   AbbVie Deutschland GmbH & Co. KG
      2009   Phase 3   EUCTR2007-006494-90-CZ   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   Abbott GmbH & Co. K.G.
      -   -   EUCTR2007-006494-90-Outside-EU/EEA   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   Abbvie Deutschland GmbH & Co. K.G.
      2008   Phase 3   EUCTR2007-006494-90-BE   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira 40 mg injekcní roztok v predplnené injekcní stríkacce   
   PIBDNet
      2018   Phase 4   EUCTR2016-000522-18-CZ   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Humira 40 mg solution for injection in pre-filled pen   
   Abbott GmbH & Co. KG
      2009   -   EUCTR2006-004814-41-GB   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
Humira 40 mg solution for injection in pre-filled syringe   
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 3   EUCTR2013-004034-15-IT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004034-15-GB   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004034-15-FR   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004034-15-DK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2015   Phase 3   EUCTR2013-004034-15-DE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2015   Phase 3   EUCTR2013-004034-15-BE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2015   Phase 3   EUCTR2013-001746-33-FR   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2015   Phase 3   EUCTR2013-001746-33-BE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2015   Phase 3   EUCTR2010-020137-10-LT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004034-15-SK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004034-15-HU   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2014   Phase 3   EUCTR2013-004034-15-ES   Austria;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2014   Phase 3   EUCTR2013-004034-15-AT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
      2014   Phase 3   EUCTR2013-001746-33-SK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-NL   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-IT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-ES   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-DK   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-DE   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   Phase 3   EUCTR2013-001746-33-AT   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
      2014   -   EUCTR2013-001746-33-HU   Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
      2012   Phase 3   EUCTR2010-020137-10-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020137-10-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-SE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-NL   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020137-10-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020137-10-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
      2009   Phase 3   EUCTR2007-006494-90-CZ   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   AbbVie Farmacéutica S.L.U.
      2014   Phase 4   EUCTR2013-004781-34-ES   Spain;
   Abbott GmbH & Co. K.G.
      2009   Phase 3   EUCTR2007-006494-90-GB   Belgium;Czech Republic;United Kingdom;
      -   -   EUCTR2007-006494-90-Outside-EU/EEA   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2006-004814-41-GB   Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
   Abbvie Deutschland GmbH & Co. K.G.
      2008   Phase 3   EUCTR2007-006494-90-BE   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira 40 mg/0.8 ml solution for injection   
   AbbVie GK
      -   -   EUCTR2015-004121-13-Outside-EU/EEA   Japan;
   Abbott Deutschland GmbH & Co. KG
      -   -   EUCTR2014-004560-38-Outside-EU/EEA   Japan;
      -   -   EUCTR2014-004531-39-Outside-EU/EEA   Japan;
Humira 40mg/0.4ml pre-filled syringe   
   PIBD net
      2018   Phase 4   EUCTR2016-000522-18-GB   Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
Humira 40mg/0.8ml solution for injection for paediatric use   
   AbbVie Deutschland GmbH & Co. KG
      2009   Phase 3   EUCTR2007-006494-90-CZ   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   Abbott GmbH & Co. K.G.
      -   -   EUCTR2007-006494-90-Outside-EU/EEA   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
   Abbvie Deutschland GmbH & Co. K.G.
      2008   Phase 3   EUCTR2007-006494-90-BE   Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira pre-filled PEN   
   Abbott GmbH & Co. KG
      2007   -   EUCTR2006-002078-23-SE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2007   -   EUCTR2006-002078-23-PT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2007   -   EUCTR2006-002078-23-GR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002078-23-FI   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-ES   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-DK   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
   Abbott GmbH & Co. KG (Abbott)
      2010   -   EUCTR2006-002078-23-IE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2007   -   EUCTR2006-002078-23-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Slovakia;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2006-002078-23-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-NO   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-DE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-BE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-002078-23-AT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
Humira®   
   ALLERGAN LIMITED
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Allergan Ltd.
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-BG   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   AstraZeneca
      2018   Phase 2/Phase 3   NCT03759288   Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2021   Phase 2;Phase 3   EUCTR2018-004346-42-HU   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-CZ   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-DE   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004346-42-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Astrazeneca AB
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   JANSSEN CILAG INTERNATIONAL NV
      2018   Phase 3   EUCTR2017-004209-41-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2018   Phase 3   EUCTR2017-004209-41-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   Janssen-Cilag International NV
      2018   Phase 3   EUCTR2017-004209-41-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004209-41-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
Hydroxychloroquine   
   Royal Liverpool University Hospital
      2014   Phase 2   NCT01783106   United Kingdom;
ICG-guided bowel perfusion assessment   
   Leiden University Medical Center
      2020   Phase 3   NCT04712032   Netherlands;
IGG2 ANTIBODIES   
   EA Pharma Co., Ltd.
      2019   Phase 2   EUCTR2018-002109-70-HU   Czech Republic;Hungary;Japan;Poland;
      2019   Phase 2   EUCTR2018-002109-70-CZ   Czech Republic;Czechia;Hungary;Japan;Poland;Russian Federation;
IM90838   
   Immunic AG
      2019   Phase 2   EUCTR2018-001895-39-NL   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001895-39-HR   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001895-39-CZ   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001895-39-BG   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''.   
   PFIZER INC.
      2011   -   EUCTR2010-023034-23-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Hungary;Israel;Italy;New Zealand;Sweden;Switzerland;United Kingdom;United States;
IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form   
   PFIZER INC.
      2012   -   EUCTR2011-000722-30-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;New Zealand;Sweden;Switzerland;United Kingdom;United States;
IMU-838   
   Immunic AG
      2019   Phase 2   EUCTR2018-001895-39-NL   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001895-39-HR   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001895-39-CZ   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001895-39-BG   Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
ITF 2357   
   ITALFARMACO
      2008   -   EUCTR2007-000189-19-IT   Belgium;Italy;Netherlands;
ITF2357   
   Italfarmaco
      2007   Phase 1/Phase 2   NCT00792740   Belgium;
   Italfarmaco S.p.A.
      2007   -   EUCTR2007-000189-19-NL   Belgium;Italy;Netherlands;
      2007   -   EUCTR2007-000189-19-BE   Belgium;Italy;Netherlands;
      2005   Phase 2   EUCTR2004-004854-19-SK   Slovakia;
Ileocecal resection   
   University Hospital, Lille
      2017   -   NCT02872506   -
Ileocolonoscopy   
   Universitaire Ziekenhuizen Leuven
      2005   Phase 2   NCT02247258   Belgium;Czech Republic;Greece;
Immune Ablation and Hematopoietic Stem Cell Support   
   Richard Burt, MD
      2001   Phase 1   NCT00278577   United States;
Immunonutrition   
   Istituto Clinico Humanitas
      2020   -   NCT04014517   -
Immunosuppressor/TNFalpha   
   University Hospital, Grenoble
      2018   -   NCT03623932   France;
Immunosuppressors (Thiopurines or Methotrexate)   
   Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
      2021   Phase 4   NCT05072782   -
Impact   
   Lawson Health Research Institute
      2016   -   NCT02742597   Canada;
   NHS Greater Glasgow and Clyde
      2020   -   NCT04273399   United Kingdom;
Imraldi   
   University Hospital Southampton NHS Foundation Trust
      2019   Phase 4   EUCTR2018-004967-30-GB   United Kingdom;
Imuran   
   Academic Medical Center, department of Gastroenterology and hepatology
      2008   -   EUCTR2008-001131-35-NL   Netherlands;
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
   Centocor B.V.
      2005   Phase 3   EUCTR2004-002815-10-GB   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002815-10-ES   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-SE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DK   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-AT   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
   Novartis Pharma Services AG
      2005   Phase 2   EUCTR2005-001148-22-SK   Slovakia;
   PIBDNet
      2017   Phase 4   EUCTR2016-000522-18-NL   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
   University of Edinburgh
      2015   -   EUCTR2014-002311-41-GB   Belgium;France;Germany;Sweden;United Kingdom;
Imurel   
   GETAID
      2015   Phase 4   EUCTR2014-002311-41-SE   France;Germany;Netherlands;Sweden;United Kingdom;
   GETECCU
      2011   -   EUCTR2011-000885-36-ES   Spain;
   Marianne Kiszka-Kanowitz
      2013   Phase 3   EUCTR2013-001503-37-DK   Denmark;
   PIBDNet
      2018   Phase 4   EUCTR2016-000522-18-BE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
      -   Phase 4   EUCTR2016-000522-18-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
   Region Örebro län
      2021   Phase 4   EUCTR2019-002942-19-DK   Denmark;
   SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
      2018   Phase 4   EUCTR2016-004112-35-SE   Sweden;
InVita D3   
   Academic Medical Center
      2013   Phase 3   EUCTR2013-002838-20-NL   Belgium;Netherlands;
Increlex 10mg/ml solution for injection   
   Greater Glasgow & Clyde NHS
      2011   Phase 2   EUCTR2010-022215-19-GB   United Kingdom;
   Queen Mary, University of London
      2008   -   EUCTR2007-004269-16-GB   United Kingdom;
Indocyanine green   
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
      2017   -   ChiCTR-INR-17012532   China;
   Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
      2020   Phase 0   ChiCTR2000035737   China;
Inflectra   
   CELLTRION INC.
      2019   Phase 3   EUCTR2019-001087-30-IT   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   CUB- Hopital Erasme
      2016   Phase 4   EUCTR2015-004618-10-BE   Belgium;
   Celltrion, Inc
      2019   Phase 3   EUCTR2019-001087-30-PL   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-LV   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-HU   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-HR   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-GR   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-FR   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-ES   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-DE   Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-CZ   Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-BG   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-AT   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   Department of medical gastroenterology, Herlev Hospital
      2016   Phase 4   EUCTR2012-002702-51-NO   Denmark;Finland;Norway;Sweden;
   Erasmus Medical Center
      2015   Phase 4   EUCTR2014-005702-37-NL   Netherlands;
   Pfizer
      2018   -   NCT03801928   Canada;United States;
   University Medical Center Groningen
      2021   Phase 4   EUCTR2020-001811-26-BE   Belgium;Netherlands;
      2020   Phase 4   EUCTR2020-001811-26-NL   Netherlands;
Inflectra 100 mg powder for concentrate for solution for infusion   
   Santeon
      2015   Phase 4   EUCTR2015-001954-14-NL   Netherlands;
Infliximab   
   Academic Medical Center
      2019   Phase 4   EUCTR2018-002064-15-NL   Netherlands;
      2014   -   EUCTR2013-001029-17-NL   Netherlands;
      2013   Phase 4   EUCTR2013-002932-25-NL   Netherlands;
   Academic Medical Center, department of Gastroenterology and hepatology
      2008   -   EUCTR2008-001131-35-NL   Netherlands;
   Beth Israel Deaconess Medical Center
      2021   Phase 4   NCT04835506   United States;
   Biogen
      2018   -   NCT03662919   France;
   CHRU de Lille
      2008   -   EUCTR2006-004784-58-FR   Belgium;France;Germany;United Kingdom;
   Centocor B.V.
      2005   Phase 3   EUCTR2004-002815-10-GB   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002815-10-ES   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-SE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DK   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-AT   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
   Centocor, Inc.
      2003   Phase 3   NCT00207675   -
      2000   Phase 3   NCT00207766   -
      2000   Phase 3   NCT00207662   -
      1996   Phase 3   NCT00269841   -
      1995   Phase 2/Phase 3   NCT00269854   -
   Chiba University Hospital
      2012   Phase 2   JPRN-UMIN000015297   Japan;
      2012   Phase 2   JPRN-UMIN000007806   Japan;
   Children's Hospital Medical Center, Cincinnati
      2019   -   NCT04131504   United States;
   Children's Hospital of Fudan University
      2022   Phase 4   NCT04530877   -
   Clinical Research Group of inflammatory bowel disease in Japan
      2009   Phase 4   JPRN-UMIN000002604   Japan;
   Copenhagen University Hospital at Herlev
      2013   Phase 4   NCT01817426   Denmark;Finland;Norway;Sweden;
   Daping Hospital, Army Medical University (Third Military Medical University)
      2018   -   ChiCTR1800019958   China;
   Department of Gastroenterology and Hepatology, Kyoto University Hospital
      2011   -   JPRN-UMIN000005689   Japan;
   Department of Gastroenterology, Nanfang Hospital, Southern Medical University
      2016   -   ChiCTR1800020305   China;
   Department of Lower Gastroenterology, Hyogo College of Medicine
      2012   Phase 4   JPRN-UMIN000006889   Japan;
   Erasmus Medical Center
      2015   Phase 4   NCT02517684   Belgium;Denmark;Finland;Italy;Netherlands;Poland;
      2013   Phase 4   NCT01880307   Italy;Netherlands;
   Ernest Seidman
      2014   -   NCT02453607   Canada;
   Fukuoka University Chikushi Hospital
      2021   -   JPRN-UMIN000043165   Japan;
   Graduate School of Medical Sciences, Kyushu University
      2009   -   JPRN-UMIN000010293   Japan;
   Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
      2012   Phase 4   NCT01442025   France;
      2005   Phase 3   NCT00571337   Belgium;France;
   Hikma Pharmaceuticals LLC
      2018   -   NCT03452501   Saudi Arabia;
   Hvidovre University Hospital
      2014   -   NCT02060318   Denmark;
   IBD Center, Sapporo Kosei General Hospital
      2014   -   JPRN-UMIN000014006   Japan;
   IRCCS Burlo Garofolo
      2018   Phase 3   NCT03221166   Italy;
   Ishida Tetsuya
      2020   Phase 3   JPRN-jRCT2031200117   Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Latvia;Poland;Spain;US;
   Janssen Biotech, Inc.
      2010   Phase 3   NCT01190839   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Netherlands;New Zealand;Poland;Spain;United Kingdom;United States;
   Janssen Korea, Ltd., Korea
      2007   -   NCT00724529   Korea, Republic of;
   Janssen Scientific Affairs, LLC
      2013   Phase 4   NCT01804166   United States;
   Johnson & Johnson (China) Investment Ltd.
      2020   -   NCT04312659   China;
   Klinikum Westbrandenburg GmbH
      2015   -   NCT02522169   -
   Lower GI disease, Hyogo College of Medicine
      2007   Phase 2,3   JPRN-UMIN000004427   Japan;
   Massachusetts General Hospital
      2019   -   NCT04655729   United States;
   Merck Sharp & Dohme Corp.
      2012   -   NCT01349920   Moldova, Republic of;United Kingdom;
      2010   -   NCT00988832   United Kingdom;
      2006   -   NCT00727298   Germany;
      2005   -   NCT00705471   -
      2004   -   NCT00724958   Austria;
      2003   Phase 3   NCT00796250   -
   Mikami Yohei
      2019   -   JPRN-jRCT1031190056   Japan;
   Nanfang Hospital of Southern Medical University
      2014   -   NCT02088944   -
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01355614   Germany;Switzerland;
   Oregon Health and Science University
      2010   -   NCT01266785   United States;
   Renji Hospital, School of Medicine, Shanghai Jiaotong University
      2020   Phase 0   ChiCTR2000029323   China;
   Royal Liverpool University Hospital
      2012   -   EUCTR2011-006084-22-GB   United Kingdom;
   Saitama Medical University
      2011   -   JPRN-UMIN000006232   Japan;
   Saitama Medical center
      2014   -   JPRN-UMIN000012790   Japan;
   Samsung Medical Center
      2009   Phase 3   NCT01661257   Korea, Republic of;
   Second Affiliated Hospital of Wenzhou Medical University
      2017   -   NCT04272788   China;
   Sheba Medical Center
      2005   -   NCT00252369   Israel;
   Sixth Affiliated Hospital, Sun Yat-sen University
      2021   -   NCT04761952   -
   The First Affiliated Hospital of Sun Yat-sen University
      2019   -   ChiCTR1900026091   China;
   The Jikei University School of MedicineDivision of Gastroenterology and Hepatology
      2012   Phase 4   JPRN-UMIN000008043   Japan;
   Tohoku University Graduate School of Medicine (Tohoku University Hospital)
      2012   -   JPRN-UMIN000007343   Japan;
   University Hospitals Cleveland Medical Center
      2008   -   NCT00791557   United States;
   University Medical Center Groningen
      2021   Phase 4   NCT04646187   Belgium;Netherlands;Spain;
   University Southampton Hospital NHS Foundation Trust
      2018   Phase 4   EUCTR2018-001546-33-GB   United Kingdom;
   University of Alberta
      2015   -   NCT02847884   Canada;
   University of Leuven Hospitals
      2009   Phase 4   EUCTR2006-004784-58-GB   Belgium;France;Germany;United Kingdom;
   University of Pittsburgh
      2005   Phase 4   NCT00688636   United States;
   University of Rochester
      2007   Phase 4   NCT00462072   United States;
   University of Toyama
      2017   -   JPRN-UMIN000026330   Japan;
   University of Western Ontario, Canada
      2014   Phase 4   NCT01960426   United States;
   Vanderbilt-Ingram Cancer Center
      2006   -   NCT00897312   -
Infliximab (IFX alone)   
   Children's Memorial Health Institute, Poland
      2008   Phase 3   NCT01559142   Poland;
Infliximab (Remicade)   
   Centocor, Inc.
      2002   -   NCT00261976   Argentina;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Infliximab (Remicade): 100 mg of lyophilized infliximab   
   First Department of Medicine, University of Szeged
      2014   -   EUCTR2013-005629-21-HU   Hungary;
Infliximab 5 mg/kg body weight infused over 2 hours   
   Janssen Inc.
      2012   Phase 4   NCT01181765   Canada;
Infliximab 5 mg/kg every 6 weeks   
   Merck Sharp & Dohme Corp.
      2008   Phase 4   NCT00752622   Canada;
Infliximab 7 mg/kg every 8 weeks   
   Merck Sharp & Dohme Corp.
      2008   Phase 4   NCT00752622   Canada;
Infliximab CT-P13   
   Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
      2021   Phase 4   NCT05072782   -
Infliximab [infliximab biosimilar 3]   
   Pfizer
      2019   -   NCT03884439   Japan;
Infliximab and adalimumab   
   Regionshospitalet Viborg, Skive
      2009   -   NCT02322008   -
Infliximab and azathioprine combination at week 0   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2017   -   NCT03393247   China;
Infliximab and azathioprine combination at week 14   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2017   -   NCT03393247   China;
Infliximab and immunosuppressives   
   Children's Hospital of Fudan University
      2022   Phase 4   NCT05043870   -
Infliximab infusion   
   Centocor Ortho Biotech Services, L.L.C.
      2005   Phase 3   NCT00094458   Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab   
   Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
      2019   Phase 4   NCT03885713   Spain;
Infliximab therapeutic drug monitoring   
   Imelda GI Clinical Research Center
      2018   Phase 4   NCT04775732   Belgium;
Infliximab with azathioprine (IIFX + AZA)   
   Children's Memorial Health Institute, Poland
      2008   Phase 3   NCT01559142   Poland;
Infliximab+azathioprine   
   Belgian IBD Research Group
      2001   Phase 4   NCT00554710   Belgium;
Infliximab, adalimumab, certolizumab pegol   
   Oslo University Hospital
      2013   -   NCT02073526   Norway;
Infliximab, azathioprine   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2016   -   NCT02998827   -
Infliximab-Biosimilar   
   Onze Lieve Vrouwe Gasthuis
      2015   Phase 4   NCT02452151   -
Infliximab-Innovator   
   Onze Lieve Vrouwe Gasthuis
      2015   Phase 4   NCT02452151   -
Injection of iron   
   Jinling Hospital, China
      2012   -   NCT01823029   China;
Innovator infliximab   
   Diakonhjemmet Hospital
      2014   Phase 4   NCT02148640   Norway;
Inositol   
   National Cancer Institute (NCI)
      2010   Phase 1/Phase 2   NCT01111292   United States;
Instillation of fibrin glue   
   Sheba Medical Center
      2005   -   NCT00252369   Israel;
Interferon beta-1a   
   EMD Serono
      2001   Phase 2   NCT00304252   Germany;Italy;Sweden;Switzerland;United Kingdom;
Interleukin-2 (aldesleukin).   
   Boston Children's Hospital
      2021   Phase 1/Phase 2   NCT04263831   United States;
Intestinal surgery for Crohn's Disease   
   Sir Run Run Shaw Hospital
      2019   Phase 4   NCT03901937   China;
Intralipid   
   Mayo Clinic
      2018   -   NCT03773237   United States;
   Radboud University
      2014   Phase 4   NCT02349594   Netherlands;
Iron sulphate 200mg coated tablets   
   Barts Health NHS Trust
      2011   Phase 4   EUCTR2010-023797-39-GB   United Kingdom;
Iron supplement 300-600 mg/day   
   University Health Network, Toronto
      2002   Phase 2   NCT00152841   Canada;
Iron(III)- hydroxide dextran complex   
   Barts Health NHS Trust
      2011   Phase 4   EUCTR2010-023797-39-GB   United Kingdom;
Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.   
   Montreal Heart Institute
      2022   Phase 2   NCT05049525   -
J695   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2000   Phase 1   NCT00007163   United States;
J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0   
   Abbott
      2009   -   EUCTR2008-004919-36-SE   Austria;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-DK   Austria;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-BE   Austria;Belgium;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-AT   Austria;Denmark;Sweden;
JNJ-40346527-AAC   
   Provention Bio, Inc.
      2018   Phase 2   EUCTR2017-003017-25-PL   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
      2018   Phase 2   EUCTR2017-003017-25-HU   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
      2018   Phase 2   EUCTR2017-003017-25-ES   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
      2018   Phase 2   EUCTR2017-003017-25-DE   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
      2018   Phase 2   EUCTR2017-003017-25-AT   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
JNJ-64304500   
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2020-002701-26-IT   Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
   Janssen Research & Development, LLC
      2021   Phase 2   NCT04655807   Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
      2016   Phase 2   NCT02877134   Belgium;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Serbia;Ukraine;United Kingdom;United States;
JNJ-64304500-AAA   
   JANSSEN CILAG INTERNATIONAL NV
      2016   Phase 2   EUCTR2016-000634-21-IT   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   Janssen-Cilag International NV
      2019   Phase 2   EUCTR2016-000634-21-FR   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000634-21-PL   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000634-21-HU   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000634-21-GB   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000634-21-DE   Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
JNJ-67864238   
   JANSSEN CILAG INTERNATIONAL NV
      2019   Phase 2   EUCTR2019-003335-37-IT   Argentina;Germany;Italy;Poland;Russian Federation;United States;
   Janssen Research & Development, LLC
      2019   Phase 2   NCT04102111   Argentina;France;Germany;Italy;Poland;Russian Federation;Ukraine;United States;
   Janssen-Cilag International NV
      2020   Phase 2   EUCTR2019-003335-37-DE   Argentina;Germany;Italy;Poland;Russian Federation;United States;
JNJ-78934804   
   Janssen Research & Development, LLC
      2022   Phase 2   NCT05242471   Italy;
Kanamycin   
   Hyogo college of medicine
      2014   Phase 2   JPRN-UMIN000013369   Japan;
Kenacort   
   University Medical Center Utrecht
      2009   -   EUCTR2007-005455-42-NL   Netherlands;
Kremezin®, Spherical Adsorptive Carbon   
   Ocera Therapeutics, Inc.
      2007   -   EUCTR2005-005363-28-HU   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2007   -   EUCTR2005-005363-28-AT   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   Phase 3   EUCTR2005-005363-28-GB   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-005363-28-DE   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-005363-28-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
      2006   -   EUCTR2005-005363-28-BE   Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
L 44   
   Lument AB
      2019   Phase 2   EUCTR2019-002093-32-SE   Sweden;
L01BA   
   PIBDNet
      2017   Phase 4   EUCTR2016-000522-18-NL   Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
LDP-02   
   Millennium Pharmaceuticals, Inc.
      2000   Phase 2   NCT00655135   -
LY3074828   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2021   Phase 3   EUCTR2019-002687-27-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Eli Lilly and Company
      2022   Phase 3   EUCTR2019-002687-27-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002687-27-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002687-27-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002687-27-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002687-27-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-002687-27-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002687-27-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002687-27-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004614-18-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004614-18-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004614-18-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004614-18-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004614-18-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002204-84-PL   Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002204-84-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002204-84-HU   Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002204-84-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002204-84-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002204-84-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002204-84-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
   Lilly S.A.
      2019   Phase 3   EUCTR2018-004614-18-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Lactated Ringers   
   Spectrum Health Hospitals
      2007   Phase 3   NCT00467922   United States;
Lactobacillus salivarius UCC118   
   University College Cork
      2002   Phase 2/Phase 3   NCT00510978   Ireland;
Lactulose/Rhamnose solution   
   MediBeacon
      2019   Early Phase 1   NCT03962998   United States;
Lap TAP Bupivacaine/Epinephrine   
   Cedars-Sinai Medical Center
      2015   -   NCT02538679   -
Laquinimod   
   Teva Pharmaceutical Industries
      2010   Phase 2   NCT00737932   Belgium;France;Israel;Italy;Netherlands;Poland;South Africa;Spain;United Kingdom;
   Teva Pharmaceutical Industries Ltd.
      2008   -   EUCTR2008-004276-49-IT   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Laquinimod Capsules   
   Teva Pharmaceutical Industries Ltd.
      2008   Phase 2   EUCTR2008-004276-49-GB   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-004276-49-FR   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-004276-49-BE   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2008-004276-49-NL   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Laquinimod Cápsulas   
   Teva Pharmaceutical Industries Ltd.
      2008   Phase 2   EUCTR2008-004276-49-ES   Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Leucine   
   Showa Inan General Hospital
      2020   -   NCT04535882   Japan;
Leukapheresis   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
Lipitor   
   University College London
      2009   Phase 2   EUCTR2009-010163-16-GB   United Kingdom;
Liposomal bupivacaine   
   Cedars-Sinai Medical Center
      2018   Phase 4   NCT03723447   United States;
Losartan   
   Takeda
      2016   Phase 4   NCT02760615   United States;
Low dose TSO   
   Dr. Falk Pharma GmbH
      2010   Phase 2   NCT01279577   Germany;
Low dose naltrexone   
   Santa Barbara Cottage Hospital
      2013   Phase 2   NCT01810185   United States;
Low serine diet   
   University of Michigan
      2021   -   NCT04795960   United States;
Low-dose IL-2 administration   
   Nationwide Children's Hospital
      2013   Phase 2   NCT02676622   -
Lumbar puncture   
   Shire
      2012   Phase 1   NCT01387594   Austria;Belgium;France;Germany;Netherlands;
Lumentin 44   
   Lument AB
      2019   Phase 2   EUCTR2019-002093-32-SE   Sweden;
Lymphocyte immune globulin   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
MB-102   
   MediBeacon
      2019   Early Phase 1   NCT03962998   United States;
MDGN-002   
   Aevi Genomic Medicine, LLC, a Cerecor company
      2017   Phase 1   NCT03169894   United States;
MDX-1100   
   Bristol-Myers Squibb International Corporation
      2012   -   EUCTR2011-002981-19-PL   Belgium;France;Hungary;Poland;South Africa;United States;
      2012   -   EUCTR2011-002981-19-HU   Belgium;France;Hungary;Poland;South Africa;United States;
      2012   -   EUCTR2011-002981-19-BE   Belgium;France;Hungary;Poland;South Africa;United States;
MEDI2070   
   ASTRAZENECA
      2013   Phase 2   EUCTR2012-004098-26-IT   Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
   Allergan
      2013   Phase 2   NCT01714726   Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United States;
   Allergan Limited
      2017   Phase 2   EUCTR2015-000609-38-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-CZ   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-004098-26-HU   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-FR   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-ES   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-DE   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
      2013   Phase 2   EUCTR2012-004098-26-CZ   Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
   MEDIMMUNE, LLC
      2016   Phase 2   EUCTR2015-000609-38-IT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   MedImmune Limited
      2016   Phase 2   EUCTR2015-000609-38-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK
      2016   Phase 2   EUCTR2015-000609-38-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-000609-38-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML   
   UMBERTO I - POLICLINICO DI ROMA
      2017   Phase 4   EUCTR2016-000522-18-IT   Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
METHOTREXATE DISODIUM   
   GETAID
      2015   Phase 4   EUCTR2014-002311-41-SE   France;Germany;Netherlands;Sweden;United Kingdom;
MICROBIOTA   
   McMaster Children's Hospital
      2018   Phase 1   NCT03378167   Canada;
MLN0002   
   AMC MEDICAL RESEARCH B.V.
      2017   Phase 3   EUCTR2015-000555-24-IT   France;Italy;Netherlands;Spain;
   Academic Medical Center Amsterdam
      2016   Phase 4   EUCTR2015-000555-24-NL   Netherlands;
      2016   Phase 4   EUCTR2015-000555-24-FR   France;Netherlands;Spain;
      2016   Phase 4   EUCTR2015-000555-24-ES   Netherlands;Spain;
   Academic Medical Center, Gastroenterology
      2015   Phase 4   EUCTR2014-005376-29-BE   Belgium;Netherlands;
   MILLENNIUM PHARMACEUTICALS, INC.
      2011   -   EUCTR2009-016488-12-IT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
      2009   -   EUCTR2008-002783-33-IT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   Millennium Pharmaceuticals, Inc.
      2011   Phase 3   EUCTR2009-016488-12-SK   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
      2011   Phase 3   EUCTR2009-016488-12-BE   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
      2011   -   EUCTR2009-016488-12-NL   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
      2011   -   EUCTR2009-016488-12-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Turkey;United States;
      2011   -   EUCTR2009-016488-12-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
      2011   -   EUCTR2009-016488-12-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Turkey;United States;
      2010   -   EUCTR2009-016488-12-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
      2009   Phase 3   EUCTR2008-002784-14-PT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-002784-14-IE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002784-14-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-002784-14-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-002784-14-EE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002783-33-IS   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-002783-33-GB   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-002783-33-FR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-002783-33-BE   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002784-14-MT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-SK   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-SE   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-PT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-NL   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-MT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-IE   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-HU   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-GR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-EE   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
      2009   -   EUCTR2008-002783-33-CZ   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-BG   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-002783-33-AT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
      2008   -   EUCTR2008-002783-33-LV   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-002783-33-DK   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2021   Phase 3   EUCTR2020-004301-31-IT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2020-004301-31-SK   Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004301-31-LT   Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004301-31-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004301-31-HR   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004301-31-ES   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004301-31-PL   Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004301-31-CZ   Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004301-31-BE   Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Takeda Development Centre Europe Ltd
      2015   Phase 3   EUCTR2014-003509-13-PL   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2014-003509-13-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2014-003509-13-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2015   Phase 3   EUCTR2014-003509-13-BE   Belgium;Canada;Czech Republic;Hungary;Poland;United States;
      2009   Phase 3   EUCTR2008-002784-14-IS   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   Takeda Development Centre Europe Ltd.
      2010   Phase 3   EUCTR2008-002784-14-SE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2008-002784-14-GB   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-002784-14-SK   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002784-14-NL   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002784-14-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002784-14-CZ   Australia;Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
      2009   Phase 3   EUCTR2008-002784-14-BG   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002784-14-BE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002784-14-AT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2008-002784-14-LV   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Takeda Development Centre Europe ltd.
      2009   Phase 3   EUCTR2008-002784-14-HU   Australia;Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Takeda Development Centre Europe, Ltd.
      2018   Phase 2   EUCTR2017-002231-41-PL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002231-41-NL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002231-41-BE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002182-21-PL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002182-21-NL   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002182-21-BE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002231-41-HU   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002231-41-GB   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002231-41-DE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-HU   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-GB   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-FR   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002182-21-DE   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
      -   Phase 2   EUCTR2017-002231-41-FR   Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
MLN0002 (Vedolizumab)   
   Takeda Pharmaceutical Company Limited
      2014   Phase 3   JPRN-JapicCTI-142402   Japan;
MLN0002 SC   
   TAKEDA DEVELOPMENT CENTRE EUROPE LTD
      2016   Phase 3   EUCTR2015-000482-31-IT   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Montenegro;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-IT   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Takeda Development Centre Europe, Ltd.
      2016   Phase 3   EUCTR2015-000482-31-SK   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-SE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-NL   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-LT   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-HU   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-HR   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-GB   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-ES   Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-DK   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-DE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-CZ   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-BG   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000482-31-BE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-SK   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-SE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-NL   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-LT   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-HU   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-GB   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-ES   Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-DK   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-DE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-CZ   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-BG   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000481-58-BE   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
MLN002   
   Takeda Development Centre Europe Limited
      2016   Phase 4   EUCTR2016-000678-40-CZ   Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
MODULEN IBD   
   Assistance Publique - Hôpitaux de Paris
      2014   -   NCT02201693   France;
MODULEN IBD (R) (specific Enteral Nutrition)   
   Hôpital Necker-Enfants Malades
      2005   Phase 4   NCT00265772   France;
MONOCLONAL ANTIBODY ANTI-IGG1   
   Boehringer Ingelheim
      2021   Phase 2   EUCTR2019-001673-93-BE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-001673-93-AT   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2017-003090-34-DK   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim Netherlands BV
      2019   Phase 2   EUCTR2017-003090-34-NL   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2019-001673-93-DE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
      2019   Phase 2   EUCTR2017-003090-34-DE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2019-001673-93-HU   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
      2019   Phase 2   EUCTR2017-003090-34-HU   Austria;Belgium;Germany;Hungary;Netherlands;
      2019   Phase 2   EUCTR2017-003090-34-AT   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   Boehringer Ingelheim S.A.
      2021   Phase 2   EUCTR2019-001673-93-ES   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
   SCS Boehringer Ingelheim Comm.V
      2018   Phase 2   EUCTR2017-003090-34-BE   Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
MSB11022   
   Fresenius Kabi SwissBioSim GmbH
      2019   Phase 1   NCT04018599   United States;
MSC   
   CHU-ULg
      2012   -   EUCTR2011-005966-39-BE   Belgium;
MSC injection 01   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2017   Phase 2/Phase 3   NCT03056664   -
MSC injection 02   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2017   Phase 2/Phase 3   NCT03056664   -
MSC treatment 01   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2016   Phase 2/Phase 3   NCT02532738   -
MSC treatment 02   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2016   Phase 2/Phase 3   NCT02532738   -
MSC-AFP   
   Mayo Clinic
      2018   Phase 1   NCT03449069   United States;
      2017   Phase 1   NCT03220243   United States;
   William A. Faubion, M.D.
      2013   Phase 1   NCT01915927   United States;
MT-1303   
   Mitsubishi Tanabe Pharma Corporation
      2015   Phase 2   NCT02389790   Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2015   Phase 2   NCT02378688   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2014   Phase 1   NCT02148185   Japan;
   Mitsubishi Tanabe Pharma Corporation (MTPC)
      2015   Phase 2   EUCTR2014-002557-19-SK   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
      2015   Phase 2   EUCTR2014-002557-19-PL   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2015   Phase 2   EUCTR2014-002557-19-NL   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2015   Phase 2   EUCTR2014-002557-19-IT   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
      2015   Phase 2   EUCTR2014-002556-77-SK   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2015   Phase 2   EUCTR2014-002556-77-PL   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2015   Phase 2   EUCTR2014-002556-77-NL   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2015   Phase 2   EUCTR2014-002556-77-IT   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
      2014   Phase 2   EUCTR2014-002557-19-HU   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
      2014   Phase 2   EUCTR2014-002557-19-CZ   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
      2014   Phase 2   EUCTR2014-002556-77-HU   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
      2014   Phase 2   EUCTR2014-002556-77-CZ   Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
MTX   
   Centre Hospitalier Universitaire, Amiens
      2021   Phase 3   NCT05040464   France;
   Peking Union Medical College Hospital
      2016   -   ChiCTR-OPC-16008655   China;
MVA HAV   
   University of Oxford
      2017   Phase 1   NCT03027193   United Kingdom;
Magnetic Resonance Enterography (MRE)   
   Mayo Clinic
      2017   Phase 4   NCT03235180   United States;
Maltodextrin   
   Katholieke Universiteit Leuven
      2008   -   NCT01487759   Belgium;
   University of Alberta
      2021   -   NCT04804046   Canada;
      2020   -   NCT03950336   Canada;
Mango polyphenolics   
   Texas A&M University
      2014   -   NCT02227602   United States;
Mannitol   
   Sanming First Affiliated Hospital of Fujian Medical University
      2014   Phase 4 study   ChiCTR-DDT-14004402   China;
Mare´s milk   
   University of Jena
      2000   -   NCT00940576   Germany;
Masitinib mesylate   
   AB Science
      2015   Phase 2;Phase 3   EUCTR2012-004222-25-GR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Morocco;Poland;Romania;Russian Federation;Slovakia;Spain;Tunisia;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2012-004222-25-SK   Belgium;Czech Republic;France;Greece;India;Morocco;Slovakia;Spain;Tunisia;
      2013   Phase 3   EUCTR2012-004222-25-BE   Belgium;Canada;Central African Republic;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Romania;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
Measurement of serum infliximab and anti-infliximab antibodies   
   Copenhagen University Hospital at Herlev
      2009   Phase 4   NCT00851565   Denmark;
Mecasermin [rDNA Origin] 10mg/ml solution   
   Greater Glasgow & Clyde NHS
      2011   Phase 2   EUCTR2010-022215-19-GB   United Kingdom;
Medium chain triglycerides   
   Imperial College London
      2008   Phase 4   NCT00672763   United Kingdom;
Medium dose TSO   
   Dr. Falk Pharma GmbH
      2010   Phase 2   NCT01279577   Germany;
Melphalan   
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
Mensa   
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
Mercaptopurine   
   Lower GI disease, Hyogo College of Medicine
      2007   Phase 2,3   JPRN-UMIN000004427   Japan;
   University of Edinburgh
      2015   -   EUCTR2014-002311-41-GB   Belgium;France;Germany;Sweden;United Kingdom;
Mesalamine   
   Milton S. Hershey Medical Center
      2013   Phase 4   NCT01696942   United States;
Mesalamine, 5-aminosalicylic acid   
   Ferring Pharmaceuticals A/S
      2009   Phase 3   EUCTR2008-002100-26-FR   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-002100-26-GB   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-002100-26-BE   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-002100-26-SE   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-002100-26-DK   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-002100-26-DE   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
Mesalazine   
   AstraZeneca
      -   Phase 3   JPRN-JapicCTI-121765   -
   AstraZeneca K.K.
      -   Phase 3   EUCTR2014-004132-20-Outside-EU/EEA   Japan;
   Dr. Falk Pharma GmbH
      2007   -   EUCTR2004-001213-34-GB   Czech Republic;United Kingdom;
      2004   Phase 3   NCT00300118   Germany;
      2004   Phase 3   EUCTR2004-001213-34-SK   Czech Republic;Slovakia;United Kingdom;
      2004   -   EUCTR2004-001213-34-CZ   Czech Republic;United Kingdom;
      2002   Phase 3   NCT00946946   Austria;Germany;
   Ferring Laegemidler A/S
      2005   -   EUCTR2005-002472-15-SE   Sweden;
   University Medical Center Utrecht
      2009   -   EUCTR2009-011220-62-NL   Netherlands;
   Yanling Wei
      2015   Phase 2   NCT02335281   China;
   Zeria Pharmaceutical Co., Ltd.
      -   Phase 2   JPRN-JapicCTI-111460   -
   Zeria Pharmaceutical Co.,LTD
      2005   Phase 3   JPRN-C000000300   Japan;
   Zeria Pharmaceutical Co.,LTD.
      2005   Phase 2,3   JPRN-C000000301   Japan;
Mesalazine (Mesalamine)   
   Ferring Pharmaceuticals
      2009   Phase 3   NCT00245505   Sweden;
Mesalazine EC   
   Disphar International B.V.
      2005   Phase 3   EUCTR2004-004083-77-SK   Czech Republic;Slovakia;
      2004   -   EUCTR2004-004083-77-CZ   Czech Republic;
Mesalazine Sustained-Release Tablets   
   Xijing Hospital of Digestive Diseases
      2016   Phase 3   NCT02769494   China;
Mesalazine tablets   
   AstraZeneca
      2012   Phase 3   NCT01514240   Japan;
Mesalazine, Tripterygium glycosides   
   Zhu Weiming
      2014   Phase 2/Phase 3   NCT02044952   China;
Mesenchymal Stem Cells   
   Amy Lightner
      2020   Phase 1/Phase 2   NCT04519697   United States;
      2020   Phase 1/Phase 2   NCT04519671   United States;
Mesenchymal Stem Cells (MSC)   
   University of Liege
      2013   Phase 1/Phase 2   NCT01540292   Belgium;
Mesenchymal Stromal Cells   
   University of Liege
      2018   Phase 1/Phase 2   NCT03901235   Belgium;
Mesenchymal cell and fibroblast injection   
   Royan Institute
      2013   Phase 1   NCT01874015   Iran, Islamic Republic of;
Mesenchymal cell transplantation   
   Royan Institute
      2013   Phase 1   NCT01874015   Iran, Islamic Republic of;
Mesenchymal stem cells   
   Amy Lightner
      2021   Phase 1   NCT04791878   United States;
      2020   Phase 1/Phase 2   NCT04519684   United States;
   CHU-ULg
      2012   -   EUCTR2011-005966-39-BE   Belgium;
Mesenchymal stem cells (MSCs)   
   The Cleveland Clinic
      2021   Phase 1   NCT04073472   United States;
Mesenchymal stromal cells (MSC) for infusion   
   R.P.Herrmann
      2010   Phase 2   NCT01090817   Australia;
Mesna   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
   Northwestern University
      2019   Phase 2   NCT04154735   United States;
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
Methacholine   
   Rambam Health Care Campus
      2008   -   NCT01297907   Israel;
Methotrexat   
   PIBD-Net
      2017   Phase 3   EUCTR2016-000522-18-DE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Methotrexate   
   Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University
      2011   -   JPRN-UMIN000005251   Japan;
   Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
      2015   Phase 4   NCT02177071   Australia;Belgium;France;
   Indiana University
      2015   -   NCT02413047   United States;
   PIBD net
      2018   Phase 4   EUCTR2016-000522-18-GB   Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
   PIBD-Net
      2017   Phase 4   NCT02852694   France;
   PIBDNet
      2018   Phase 4   EUCTR2016-000522-18-BE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
      -   Phase 4   EUCTR2016-000522-18-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
   Takeda
      2017   Phase 4   NCT02764762   Canada;United States;
   University of Edinburgh
      2015   -   EUCTR2014-002311-41-GB   Belgium;France;Germany;Sweden;United Kingdom;
   University of North Carolina, Chapel Hill
      2016   Phase 3   NCT02772965   United States;
   University of Western Ontario, Canada
      2005   Phase 3   NCT00132899   Canada;
Methotrexate injection   
   Amsterdam UMC location AMC
      2019   Phase 4   EUCTR2018-003594-95-NL   Netherlands;
Methoxsalen   
   Therakos
      2005   -   EUCTR2004-002693-37-DE   Germany;
      2004   -   EUCTR2004-002693-37-AT   Austria;Germany;
Methoxsalen +ECP   
   Mallinckrodt
      2004   Phase 2   NCT00221026   Austria;Belgium;Germany;United States;
Methyl prednisolone   
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
Methylprednisolone   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
   Icahn School of Medicine at Mount Sinai
      2017   Phase 2   NCT03219359   United States;
Methylprednisolone or budesonide   
   Belgian IBD Research Group
      2001   Phase 4   NCT00554710   Belgium;
Metoject   
   GETAID
      2015   Phase 4   EUCTR2014-002311-41-SE   France;Germany;Netherlands;Sweden;United Kingdom;
Metotrexat   
   GETAID
      2015   Phase 4   EUCTR2014-002311-41-SE   France;Germany;Netherlands;Sweden;United Kingdom;
Metronidazol   
   GETECCU
      2011   -   EUCTR2011-000885-36-ES   Spain;
Metronidazole   
   Erasmus MC
      2014   -   EUCTR2012-005226-29-PL   Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
   Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
      2012   Phase 3   NCT01564823   Spain;
   Hyogo college of medicine
      2014   Phase 2   JPRN-UMIN000013369   Japan;
   Ishikawa Dai
      2017   -   JPRN-jRCTs031180415   Japan;
   Juntendo university school of medicineDepartment of gastroenterology
      2017   -   JPRN-UMIN000025846   Japan;
   Mount Sinai Hospital, Canada
      2006   Phase 2   NCT00257699   Canada;
   S.L.A. Pharma AG
      2007   Phase 1   NCT00774969   United Kingdom;
   University of North Carolina, Chapel Hill
      2021   Phase 2   NCT04186247   Canada;Israel;Netherlands;United States;
   Wolfson Medical Center
      2013   -   EUCTR2012-005226-29-BE   Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
      -   -   EUCTR2012-005226-29-NL   Canada;Israel;Netherlands;United States;
Metronidazole Ointment   
   S.L.A. Pharma AG
      2005   Phase 3   NCT00509639   United Kingdom;United States;
Metronidazole Oral   
   University of Louisville
      2021   Phase 4   NCT04682522   United States;
Midazolam   
   GlaxoSmithKline
      2011   Phase 1   NCT01489943   United States;
   Janssen Research & Development, LLC
      2018   Phase 1   NCT03358706   Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
   Takeda
      2016   Phase 4   NCT02760615   United States;
Mirikizumab   
   Eli Lilly and Company
      2021   Phase 3   NCT04844606   Israel;Japan;Korea, Republic of;United States;
      2020   Phase 3   NCT04232553   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT03926130   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   NCT02891226   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Japan;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
   Yoshimoto Yusuke
      2021   Phase 3   JPRN-jRCT2031210210   Japan;United States;
Mobilization of stem cells to prepare for Leukapheresis   
   Nationwide Children's Hospital
      2013   Phase 2   NCT02676622   -
Moderate Oligosaccharide Group   
   University of British Columbia
      2015   -   NCT02193750   Australia;Canada;
Modulen   
   Hillel Yaffe Medical Center
      2020   -   NCT04233463   Israel;
Mongersen   
   CELGENE CORPORATION
      2017   Phase 3   EUCTR2015-001924-40-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-IT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-001693-18-IT   Italy;
   Celgene Corporation
      2017   Phase 3   EUCTR2015-001963-37-FI   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001925-18-FI   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-NL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-LV   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-HR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-GR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-FR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-ES   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001924-40-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-SE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-PT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-LV   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-HR   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-GR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-GB   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Oman;Pakistan;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-ES   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-DK   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-DE   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-BG   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-BE   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001963-37-AT   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-SK   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-SE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-PT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-LV   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-HU   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-HR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-GR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-GB   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-ES   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-DK   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-DE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-BG   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-BE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001925-18-AT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001963-37-EE   Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001925-18-EE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001925-18-NO   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001924-40-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Monoclonal antibodies   
   MILLENNIUM PHARMACEUTICALS, INC.
      2011   -   EUCTR2009-016488-12-IT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
Monoclonal antibody cA2   
   FDA Office of Orphan Products Development
      1996   Phase 3   NCT00004941   -
Mosapride   
   Department of Gastroenterology, Graduate School of Medicine, Osaka City University
      2012   -   JPRN-UMIN000008199   Japan;
Movprep   
   Lument AB
      2019   Phase 2   EUCTR2019-002093-32-SE   Sweden;
Mycodigest supplement   
   Tel-Aviv Sourasky Medical Center
      2018   -   NCT04329481   Israel;
N-3 Polyunsaturated Fatty Acids   
   Sixth Affiliated Hospital, Sun Yat-sen University
      2021   -   NCT04761952   -
N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium   
   GlaxoSmithKline Research & Development Ltd
      2011   -   EUCTR2010-022382-10-NL   Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2010-022382-10-NO   Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium   
   GlaxoSmithKline Research & Development Ltd
      2011   Phase 3   EUCTR2010-022383-12-NO   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2010-022383-12-GB   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
NI-0401 (anti-CD3 mAB)   
   NovImmune SA
      2006   Phase 1/Phase 2   NCT00630643   -
NNC 0142-0000-0002   
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01203631   Belgium;Canada;France;Hungary;Israel;Poland;Russian Federation;United States;
NNC0114-0006   
   Novo Nordisk A/S
      2013   Phase 2   NCT01751152   Bulgaria;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
NNC0142-0000-0002   
   Novo Nordisk A/S
      2011   Phase 2   EUCTR2010-020836-21-BE   Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
      2011   -   EUCTR2010-020836-21-PL   Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
      2010   -   EUCTR2010-020836-21-HU   Belgium;Hungary;Poland;
NNC142-0002   
   Novo Nordisk A/S
      2011   Phase 2   EUCTR2010-020836-21-BE   Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
      2011   -   EUCTR2010-020836-21-PL   Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
      2010   -   EUCTR2010-020836-21-HU   Belgium;Hungary;Poland;
NO   
   Rambam Health Care Campus
      2008   -   NCT01297907   Israel;
   University of Texas at Austin
      2021   -   NCT04898530   United States;
      2021   -   NCT04617184   United States;
NORMIX*AD 12CPR RIV   
   ALFA WASSERMANN
      2007   -   EUCTR2007-001014-17-IT   France;Germany;Hungary;Italy;
NSP001   
   Provexis Plc
      2009   Phase 2   EUCTR2006-005526-23-GB   United Kingdom;
Naltrexone   
   Milton S. Hershey Medical Center
      2008   Phase 2   NCT00715117   United States;
Naltrexone hydrochloride   
   ErasmusMC
      2020   Phase 2   EUCTR2019-000852-32-NL   Netherlands;
Naltrexone-HCl   
   Milton S. Hershey Medical Center
      2006   Phase 2   NCT00663117   United States;
Nap   
   TiGenix, S.A.U.
      2021   Phase 3   EUCTR2017-000725-12-SE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000725-12-DE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-PL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-HU   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000725-12-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Natalizumab   
   Biogen
      2008   Phase 4   NCT00801125   -
      2008   -   NCT00707512   Puerto Rico;United States;
      2004   Phase 3   NCT00078611   Canada;United States;
      2002   Phase 4   NCT00280956   United States;
      2002   Phase 3   NCT00032786   -
      2002   Phase 2   NCT00055536   United States;
      2002   Phase 2   NCT00055367   United Kingdom;United States;
      2001   Phase 3   NCT00032799   United States;
   Elan Pharma Ltd.
      2005   -   EUCTR2004-003839-31-DK   Denmark;
Neomycin   
   Children's Hospital of Philadelphia
      2018   Phase 2   NCT03476317   United States;
   University of Pennsylvania
      2016   Phase 2   NCT02765256   United States;
Nessuno   
   GILEAD SCIENCES INCORPORATED
      2015   Phase 2   EUCTR2015-001249-10-IT   Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;South Africa;Spain;United Kingdom;United States;
Nitazoxanide   
   Romark Laboratories L.C.
      2005   Phase 2   NCT00130390   United States;
Nivolumab   
   Alliance Foundation Trials, LLC.
      2019   Phase 1   NCT03656627   United States;
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States;
None   
   Abbott
      2009   -   EUCTR2008-004919-36-SE   Austria;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-DK   Austria;Denmark;Sweden;
      2009   -   EUCTR2008-004919-36-BE   Austria;Belgium;Denmark;Sweden;
   Novartis Pharma Services AG
      2009   -   EUCTR2009-011621-14-AT   Austria;Germany;
None at this time   
   Millennium Pharmaceuticals, Inc (a wholly owned subsidiary
      2020   Phase 2   EUCTR2019-000886-19-FR   France;Germany;United Kingdom;United States;
Normal Saline   
   Seattle Children's Hospital
      2015   Phase 1/Phase 2   NCT02272868   United States;
Nutraceutical Combination   
   Columbia University
      2012   Phase 2   NCT01647412   United States;
Nutrition treat   
   Jinling Hospital, China
      2011   -   NCT01540942   China;
Nutritional dietary intervention   
   Hospital Galdakao-Usansolo
      2020   -   NCT04188990   Spain;
NutropinAq 10mg/2ml solution for injection   
   Greater Glasgow & Clyde NHS
      2011   Phase 2   EUCTR2010-022215-19-GB   United Kingdom;
NutropinAq®   
   Greater Glasgow & Clyde NHS
      2011   Phase 2   EUCTR2010-022215-19-GB   United Kingdom;
OL adalimumab   
   Abbott
      2002   Phase 3   NCT00055497   United States;
OPC-6535   
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 2/Phase 3   NCT00989573   Japan;Korea, Republic of;
OPC-6535(Tetomilast)   
   Otsuka Pharmaceutical Co., Ltd.
      2006   Phase 2   NCT00317369   Japan;
OPS-2071   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2020   Phase 2   NCT03850509   Poland;United States;
      2020   Phase 2   EUCTR2019-000176-41-PL   Belgium;Canada;Germany;Italy;Poland;United States;
      2020   Phase 2   EUCTR2019-000176-41-HU   Canada;Germany;Hungary;Italy;Poland;Russian Federation;Ukraine;United States;
      -   Phase 2   EUCTR2019-000176-41-DE   Canada;Germany;Hungary;Italy;Poland;Russian Federation;Ukraine;United States;
   Otsuka Pharmaceutical Development and Commercialization, Inc
      2020   Phase 2   EUCTR2019-000176-41-IT   Belgium;Canada;Germany;Hungary;Italy;Poland;United States;
Oligofructose enriched inulin   
   Katholieke Universiteit Leuven
      2008   -   NCT01487759   Belgium;
Olokizumab   
   UCB BIOSCIENCES GmbH
      2012   Phase 2   EUCTR2011-002517-11-BG   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Serbia;
      2012   -   EUCTR2011-002517-11-HU   Czech Republic;Germany;Hungary;Serbia;
      2012   -   EUCTR2011-002517-11-DE   Czech Republic;Germany;Hungary;Serbia;
      2012   -   EUCTR2011-002517-11-CZ   Czech Republic;Germany;Hungary;Serbia;
Olokizumab (OKZ)   
   UCB BIOSCIENCES GmbH
      2012   Phase 2   NCT01635621   Bulgaria;Czech Republic;Germany;Hungary;Poland;
Omegaven   
   Radboud University
      2014   Phase 4   NCT02349594   Netherlands;
Omeprazole   
   GlaxoSmithKline
      2011   Phase 1   NCT01489943   United States;
   Janssen Research & Development, LLC
      2018   Phase 1   NCT03358706   Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
   Takeda
      2016   Phase 4   NCT02760615   United States;
Only 1 arm: treatment with MSC-AFP   
   William A. Faubion, M.D.
      2017   Phase 1   NCT03014219   United States;
Ontamalimab   
   SHIRE HUMAN GENETIC THERAPIES, INC
      2018   Phase 3   EUCTR2017-000574-11-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Shire
      2019   Phase 3   NCT03627091   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   NCT03566823   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;New Zealand;Portugal;Slovakia;Spain;Turkey;Ukraine;United States;
      2018   Phase 3   NCT03559517   Australia;Austria;Croatia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      2018   Phase 3   NCT03283085   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Shire Human Genetic Therapies, Inc.
      2019   Phase 3   EUCTR2017-000617-23-HR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000617-23-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000575-88-HR   Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-000575-88-GB   Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-SK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-NL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-EE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000617-23-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000576-29-SK   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-000576-29-PT   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-000576-29-EE   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
      2018   Phase 3   EUCTR2017-000576-29-BG   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-000575-88-NL   Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000575-88-LT   Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000575-88-DE   Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000575-88-AT   Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-NL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-HR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-EE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000574-11-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000574-11-SK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000574-11-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000617-23-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000617-23-IE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000576-29-IE   Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
      -   Phase 3   EUCTR2017-000575-88-PL   Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000574-11-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000574-11-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Optison   
   University of Michigan
      2015   Phase 1/Phase 2   NCT02061163   United States;
Oral prednisolone   
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2/Phase 3   NCT05284136   France;Netherlands;
Orencia   
   Bristol-Myers Squibb International Corporation
      2008   -   EUCTR2006-003371-13-PL   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2008   -   EUCTR2006-003371-13-CZ   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-DE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
      2007   -   EUCTR2006-003371-13-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
Originator (legacy) drug   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada;
Ossium vBM-MSC   
   Amy Lightner
      2022   Phase 1/Phase 2   NCT05075811   United States;
Other Biologic Therapies   
   Janssen Scientific Affairs, LLC
      2021   -   NCT04372108   United States;
Other Biological Agent   
   Takeda
      2015   -   NCT02678052   Canada;United States;
Ova-Treg   
   TxCell
      2014   Phase 2   EUCTR2014-001295-65-IT   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-DE   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-BE   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-AT   Austria;Belgium;Germany;Italy;
Ovasave   
   TxCell
      2014   Phase 2   NCT02327221   Austria;Belgium;France;Germany;Italy;United Kingdom;
      2014   Phase 2   EUCTR2014-001295-65-IT   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-DE   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-BE   Austria;Belgium;Germany;Italy;
      2014   Phase 2   EUCTR2014-001295-65-AT   Austria;Belgium;Germany;Italy;
Oxadrop   
   Mayo Clinic
      2006   Phase 1/Phase 2   NCT00587041   United States;
Oxygen   
   Assaf-Harofeh Medical Center
      2013   -   NCT01828190   Israel;
   Daping Hospital, Army Medical University (Third Military Medical University)
      2018   -   ChiCTR1800019958   China;
Ozanimod   
   CELGENE INTERNATIONAL II SàRL
      2018   Phase 3   EUCTR2017-004292-31-IT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002025-19-IT   Canada;Hungary;Italy;Poland;Ukraine;United States;
   Celgene
      2018   Phase 3   NCT03467958   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   NCT03464097   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   NCT03440385   Australia;Austria;Brazil;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2018   Phase 3   NCT03440372   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Moldova, Republic of;Norway;Poland;Romania;Russian Federation;Saudi Arabia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
      2015   Phase 2   EUCTR2015-002025-19-HU   Canada;Hungary;Italy;Poland;Ukraine;United States;
   Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation
      2016   Phase 2   EUCTR2015-002025-19-PL   Canada;Hungary;Poland;Ukraine;United States;
Ozanimod hydrochloride   
   CELGENE INTERNATIONAL II SàRL
      2018   Phase 3   EUCTR2017-004294-14-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Celgene International II Sàrl
      2016   Phase 1   EUCTR2016-003073-18-GB   United Kingdom;
P28GST   
   University Hospital, Lille
      2014   Phase 2   NCT02281916   France;
PDA001   
   Celularity Incorporated
      2013   Phase 1   NCT01769755   United States;
PENTASA Sachet   
   Ferring Pharmaceuticals A/S
      2009   Phase 3   EUCTR2008-002100-26-FR   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-002100-26-GB   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-002100-26-BE   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-002100-26-SE   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-002100-26-DK   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-002100-26-DE   Belgium;Denmark;France;Germany;Sweden;United Kingdom;
PF-00547659   
   PFIZER SLU
      2011   -   EUCTR2010-023437-30-ES   Austria;Belgium;Bulgaria;Germany;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;
   PFIZER, S.L.U.
      2011   -   EUCTR2010-024638-48-ES   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
   Pfizer Inc.
      2013   -   EUCTR2012-002030-37-BE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;United Kingdom;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2010-024638-48-NO   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2012   Phase 2   EUCTR2010-024638-48-DE   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2012   Phase 2   EUCTR2010-024638-48-BG   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2012   Phase 2   EUCTR2010-024638-48-BE   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2012   Phase 2   EUCTR2010-023437-30-BG   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2012   -   EUCTR2010-023437-30-PL   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2011   Phase 2   EUCTR2010-024638-48-SK   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2011   Phase 2   EUCTR2010-024638-48-SE   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2011   Phase 2   EUCTR2010-024638-48-NL   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2011   Phase 2   EUCTR2010-024638-48-AT   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2011   Phase 2   EUCTR2010-023437-30-SE   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2011   Phase 2   EUCTR2010-023437-30-PT   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2011   Phase 2   EUCTR2010-023437-30-NO   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2011   -   EUCTR2010-024638-48-PT   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
      2011   -   EUCTR2010-023437-30-SK   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2011   -   EUCTR2010-023437-30-NL   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2011   -   EUCTR2010-023437-30-DE   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2011   -   EUCTR2010-023437-30-BE   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
      2011   -   EUCTR2010-023437-30-AT   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
      2012   Phase 2   EUCTR2010-024638-48-PL   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
   Shire
      2011   Phase 2   NCT01298492   Austria;Belgium;Bulgaria;Canada;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
PF-00547659 SC injection   
   Shire
      2011   Phase 2   NCT01276509   Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
PF-04236921   
   Pfizer
      2011   Phase 2   NCT01345318   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;New Zealand;Switzerland;United Kingdom;United States;
PF-04236921 SC injection   
   Pfizer
      2011   Phase 2   NCT01287897   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;New Zealand;Romania;Sweden;Switzerland;United Kingdom;United States;
PF-06651600   
   Pfizer
      2018   Phase 2   NCT03395184   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06651600-15   
   PFIZER INC
      2018   Phase 2   EUCTR2017-003359-43-IT   Austria;Belgium;Croatia;Czech Republic;Germany;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;United States;
   Pfizer Inc.
      2018   Phase 2   EUCTR2017-003359-43-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 2   EUCTR2017-003359-43-PL   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-LT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-HR   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-ES   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Lebanon;Lithuania;New Zealand;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-DE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-BE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-AT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06700841   
   Pfizer
      2018   Phase 2   NCT03395184   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06700841-15   
   PFIZER INC
      2018   Phase 2   EUCTR2017-003359-43-IT   Austria;Belgium;Croatia;Czech Republic;Germany;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;United States;
   Pfizer Inc.
      2018   Phase 2   EUCTR2017-003359-43-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 2   EUCTR2017-003359-43-PL   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-LT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-HR   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-ES   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Lebanon;Lithuania;New Zealand;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-DE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-BE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-AT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PL 17901/0122   
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
PL 20532/0012   
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
PLAQUENIL   
   Royal Liverpool & Broadgreen University Hospitals Trust
      2009   Phase 2   EUCTR2008-001137-99-GB   United Kingdom;
PMA-zeolite   
   Ciim Plus, d.o.o.
      2018   -   NCT04370535   Slovenia;
PRA023   
   Prometheus Biosciences, Inc.
      2021   Phase 2   EUCTR2021-000092-37-PL   Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;France;Georgia;Israel;Poland;Russian Federation;Ukraine;United States;
      2021   Phase 2   EUCTR2021-000092-37-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;France;Georgia;Poland;Russian Federation;Ukraine;United States;
PRA023 IV   
   Prometheus Biosciences, Inc.
      2021   Phase 2   NCT05013905   United States;
PROCHYMAL (remestemcel-L)   
   Mesoblast, Inc.
      2010   -   NCT01510431   United States;
PROCHYMAL adult human mesenchymal stem cells   
   Mesoblast, Inc.
      2007   Phase 3   NCT00543374   Canada;United States;
PRV-6527   
   Provention Bio, Inc.
      2018   Phase 2   NCT03854305   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PRV-6527 (JNJ-40346527)   
   Provention Bio, Inc.
      2018   Phase 2   EUCTR2017-003017-25-PL   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
      2018   Phase 2   EUCTR2017-003017-25-ES   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
      2018   Phase 2   EUCTR2017-003017-25-DE   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
      2018   Phase 2   EUCTR2017-003017-25-AT   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PRV-6527(JNJ-40346527)   
   Provention Bio, Inc.
      2018   Phase 2   EUCTR2017-003017-25-HU   Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PTG-200   
   Janssen-Cilag International NV
      2020   Phase 2   EUCTR2019-003335-37-DE   Argentina;Germany;Italy;Poland;Russian Federation;United States;
PURINETHOL - 50 MG COMPRESSE25 COMPRESSE   
   UMBERTO I - POLICLINICO DI ROMA
      2017   Phase 4   EUCTR2016-000522-18-IT   Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
Partial Enteral Nutrition   
   NHS Greater Glasgow and Clyde
      2021   -   NCT04859088   United Kingdom;
Pectin   
   Jinling Hospital, China
      2014   Phase 2   NCT02164877   China;
Pegylated interferon alfa   
   Vanderbilt-Ingram Cancer Center
      2006   -   NCT00897312   -
Pending   
   Reistone Biopharma Company Limited
      2019   Phase 2   EUCTR2018-003303-19-PL   China;Poland;Ukraine;United States;
Pentasa   
   AstraZeneca K.K.
      -   Phase 3   EUCTR2014-004132-20-Outside-EU/EEA   Japan;
   Ferring Pharmaceuticals
      2009   Phase 3   NCT00862121   Belgium;Denmark;France;Germany;Spain;Sweden;United Kingdom;United States;
Pentasa Sachet 1 g prolonged release granules   
   Ferring Laegemidler A/S
      2005   -   EUCTR2005-002472-15-SE   Sweden;
Pentoxifylline   
   University of Miami
      2017   Early Phase 1   NCT02953275   United States;
Peptidic+Probiotic   
   Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2020   -   NCT04305535   Spain;
Peripheral Blood Stem Cell Infusion   
   Cedars-Sinai Medical Center
      2020   Phase 1/Phase 2   NCT04224558   United States;
Pharmacokinetics of certolizumab pegol   
   UCB Biopharma S.P.R.L.
      2020   Phase 1   NCT04163016   Canada;France;Germany;Netherlands;Spain;Switzerland;United States;
Phase1 : CDED/Modulen™IBD® + Maintenance therapy   
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 3   NCT04777656   France;
Phase2 and 3 :   
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 3   NCT04777656   France;
Phylloquinone (vitamin K1)   
   University College Cork
      2008   Phase 4   NCT01235325   Ireland;
Physician standard-of-care   
   Merck Sharp & Dohme Corp.
      2011   -   NCT01218360   Greece;
Pioglitazone   
   GlaxoSmithKline
      2011   Phase 1   NCT01489943   United States;
Placebo   
   Abbott Japan Co., Ltd.
      2007   Phase 2-3   JPRN-JapicCTI-070367   -
      2007   Phase 2-3   JPRN-JapicCTI-070366   -
   Janssen Pharmaceutical K.K.
      2018   Phase 2-3   JPRN-JapicCTI-183950   Japan, North America;
   Takeda Pharmaceutical Company Limited
      2016   Phase 3   JPRN-JapicCTI-163386   Japan, Refer to Othersection;
      2014   Phase 3   JPRN-JapicCTI-142402   Japan;
Plantain NSP   
   Provexis Plc
      2009   Phase 2   EUCTR2006-005526-23-GB   United Kingdom;
Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI)   
   Fundación FISEVI
      2012   -   EUCTR2011-006127-38-ES   Spain;
      2012   -   EUCTR2011-004820-37-ES   Spain;
Pnemovax   
   Statens Serum Institut
      2013   -   EUCTR2012-002867-86-DK   Denmark;
Pneumovax   
   Statens Serum Institut
      2013   Phase 4   NCT01947010   Denmark;
      2013   -   EUCTR2012-002867-86-DK   Denmark;
Polaprezinc   
   Kawasaki Medical School
      2011   -   JPRN-UMIN000005970   Japan;
Polyethylene Glycol 3350   
   Children's Hospital of Philadelphia
      2018   Phase 2   NCT03476317   United States;
   University of Pennsylvania
      2016   Phase 2   NCT02765256   United States;
Pomegranate   
   IRCCS Azienda Ospedaliero-Universitaria di Bologna
      2017   -   NCT03000101   Italy;
Posaconazole Delayed Release Oral Tablet   
   Cedars-Sinai Medical Center
      2022   Phase 4   NCT04966585   United States;
Positron Emission Tomography   
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Postoperative 3-month exclusive enteral nutrition   
   Zhu Weiming
      2018   -   NCT04160325   China;
Pravastatin   
   University of Virginia
      2004   -   NCT00599625   United States;
Prebiotics   
   University of Alberta
      2020   -   NCT03950336   Canada;
Precedentemente denominato MEDI2070 e AMG 139   
   ALLERGAN LIMITED
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Prednisolon   
   Erasmus Medical Center
      2013   Phase 4   NCT01880307   Italy;Netherlands;
   Hôpital Necker-Enfants Malades
      2005   Phase 4   NCT00265772   France;
Prednisolon Jenapharm   
   4SC AG
      2010   -   EUCTR2008-005903-25-BG   Bulgaria;Germany;
      2009   -   EUCTR2008-005903-25-DE   Bulgaria;Germany;
Prednisolone   
   Central Manchester University Hospitals Foundation Trust
      2011   Phase 2   EUCTR2010-022017-26-GB   United Kingdom;
   Erasmus Medical Center
      2015   Phase 4   NCT02517684   Belgium;Denmark;Finland;Italy;Netherlands;Poland;
   Merck Sharp & Dohme Corp.
      2003   Phase 3   NCT00796250   -
   University Hospital Birmingham
      2008   Phase 4   NCT00609752   United Kingdom;
Prednisone   
   AbbVie (prior sponsor, Abbott)
      2011   Phase 3   NCT01235689   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
   Abbott GmBH & Co. KG
      2010   Phase 3   EUCTR2010-020137-10-IT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Icahn School of Medicine at Mount Sinai
      2016   Phase 4   NCT02324699   United States;
   McMaster University
      2018   Phase 4   NCT03833596   Canada;
   Shanghai Research Institute of Acupuncture and Meridian
      2016   Phase 1 study   ChiCTR-IIR-16007751   China;
Preparative regimen 4-6 weeks after Leukapheresis   
   Nationwide Children's Hospital
      2013   Phase 2   NCT02676622   -
Prevenar 13   
   Statens Serum Institut
      2013   Phase 4   NCT01947010   Denmark;
      2013   -   EUCTR2012-002867-86-DK   Denmark;
Previously referred to as MEDI2070 and AMG 139, AGN-151-598   
   ALLERGAN LIMITED
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Allergan Limited
      2021   Phase 3   EUCTR2019-001866-14-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Allergan Ltd.
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-BG   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   AstraZeneca AB
      2019   Phase 2;Phase 3   EUCTR2018-004346-42-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001866-14-GB   Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2018-004346-42-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
   Astrazeneca AB
      2020   Phase 2;Phase 3   EUCTR2018-004346-42-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Probiotic   
   The Baruch Padeh Medical Center, Poriya
      2013   Phase 4   NCT01765998   Israel;
Probiotic - VSL#3   
   University of Alberta
      2003   Phase 3   NCT00175292   Canada;
Probiotic Mixture   
   Massachusetts General Hospital
      2017   -   NCT03266484   United States;
Probiotics   
   The Baruch Padeh Medical Center, Poriya
      2012   Phase 4   NCT01078935   -
Prochymal®   
   Mesoblast, Inc.
      2007   Phase 3   NCT00482092   Australia;Canada;New Zealand;United States;
Prochymal™ adult human mesenchymal stem cells   
   Mesoblast, Inc.
      2006   Phase 2   NCT00294112   United States;
Promethazine   
   University of Pennsylvania
      2016   Phase 2   NCT02765256   United States;
Prucalopride   
   University of British Columbia
      2016   Phase 4   NCT02806206   Canada;
Puri Nethol   
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
Puri-Nethol   
   GETAID
      2015   Phase 4   EUCTR2014-002311-41-SE   France;Germany;Netherlands;Sweden;United Kingdom;
Puri-nethol   
   Region Örebro län
      2021   Phase 4   EUCTR2019-002942-19-DK   Denmark;
QAX567   
   Gerhard Rogler
      2011   Phase 2   NCT01316601   Switzerland;
QAX576   
   Novartis Pharma AG
      2011   -   EUCTR2010-019973-13-DE   Germany;Switzerland;
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01355614   Germany;Switzerland;
QBECO   
   Qu Biologics Inc.
      2013   Phase 1/Phase 2   NCT01809275   Canada;
QBECO-SSI   
   Qu Biologics Inc.
      2018   Phase 2   NCT03472690   Canada;
RAD001   
   Novartis Pharma Services AG
      2005   Phase 2   EUCTR2005-001148-22-SK   Slovakia;
RCTB-401   
   SBL Vaccin AB
      2005   -   EUCTR2005-002048-25-SE   Sweden;
REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy;
REMSINA   
   Celltrion, Inc
      2019   Phase 3   EUCTR2019-001087-30-CZ   Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
RHB-104   
   RedHill Biopharma Limited
      2017   Phase 3   NCT03009396   Canada;Czechia;Israel;New Zealand;Poland;Serbia;United States;
      2013   Phase 3   NCT01951326   Australia;Bulgaria;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Serbia;Slovakia;United States;
   RedHill Biopharma Ltd.
      2019   Phase 3   EUCTR2016-005199-90-SK   Australia;Canada;Czech Republic;Israel;New Zealand;Poland;Serbia;Slovakia;United States;
      2017   Phase 3   EUCTR2015-001179-36-SK   Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
      2017   Phase 3   EUCTR2015-001179-36-CZ   Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
      2017   Phase 3   EUCTR2015-001179-36-BG   Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
      2015   Phase 3   EUCTR2015-001179-36-PL   Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
      2015   Phase 3   EUCTR2014-004108-31-HU   Belgium;Czech Republic;Germany;Hungary;Ireland;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
      2015   Phase 3   EUCTR2014-004108-31-CZ   Czech Republic;Hungary;Ireland;Russian Federation;Ukraine;United Kingdom;
RPC0163   
   CELGENE INTERNATIONAL II SàRL
      2016   Phase 2   EUCTR2015-002025-19-IT   Canada;Hungary;Italy;Poland;Ukraine;United States;
RPC1063   
   CELGENE INTERNATIONAL II SàRL
      2018   Phase 3   EUCTR2017-004292-31-IT   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002025-19-IT   Canada;Hungary;Italy;Poland;Ukraine;United States;
   Celgene
      2015   Phase 2   NCT02531113   Canada;Hungary;Italy;Poland;Ukraine;United States;
   Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation
      2016   Phase 2   EUCTR2015-002025-19-PL   Canada;Hungary;Poland;Ukraine;United States;
RPC1063 (equivalent to ozanimod HCl)   
   Celgene International II Sàrl
      2019   Phase 3   EUCTR2017-004295-55-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004295-55-FR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004294-14-FR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004293-33-FR   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2017-004292-31-FR   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-SI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-SE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004295-55-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-SI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-SE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-PT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-PL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-NL   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-LV   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-LT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-IE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-HU   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-HR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-GR   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-GB   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-FI   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-ES   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-DK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-DE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-BG   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-BE   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004294-14-AT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004293-33-SK   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-SI   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-SE   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-PT   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-PL   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-NL   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-LT   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-HU   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-GR   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-FI   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-ES   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-BG   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004293-33-AT   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004292-31-PL   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-LV   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-IE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-HR   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-GB   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-ES   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-DK   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-DE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-CZ   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-BG   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004292-31-BE   Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004295-55-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004293-33-DE   Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
RPC1063 equiv to ozanimod HCI   
   CELGENE INTERNATIONAL II SàRL
      2018   Phase 3   EUCTR2017-004295-55-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RPC1063 equiv. to ozanimod HCI   
   CELGENE INTERNATIONAL II SàRL
      2018   Phase 3   EUCTR2017-004294-14-IT   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RR110 (Tamibarotene)   
   R&R Inc.
      2006   Phase 2   NCT00417391   Japan;
RVG 05565   
   Academic Medical Center, department of Gastroenterology and hepatology
      2008   -   EUCTR2008-001131-35-NL   Netherlands;
RVG 07151   
   University Medical Center Utrecht
      2009   -   EUCTR2009-013348-35-NL   Netherlands;
RVG 114681   
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
RVG 116648   
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
RVG00859   
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
RYAH-Medtech Inhaler   
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Rabbit anti-human thymocyte immunoglobulin   
   Barts Health NHS Trust
      2017   Phase 3   EUCTR2017-002545-30-GB   United Kingdom;
Rabbit antithymocyte globulin   
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
Racol   
   Graduate School of Medical Sciences, Kyushu University
      2009   -   JPRN-UMIN000010293   Japan;
Ranolazine   
   Vanderbilt University Medical Center
      2022   Phase 2   NCT04456517   United States;
Rapamycin   
   The Second Hospital of Nanjing Medical University
      2015   -   NCT02675153   China;
Raptiva 100 mg/ml powder and solvent for solution for injection   
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal;
RbATG   
   European Group for Blood and Marrow Transplantation (EMBT)
      2006   -   EUCTR2005-003337-40-GB   United Kingdom;
Received hormone maintenance therapy   
   Fuzhou General Hospital
      2012   Phase 1/Phase 2   NCT02445547   China;
Recombinant Human Interleukin-11 (rhIL-11)   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2002   Phase 2   NCT00040521   United States;
Recombinant growth hormone   
   Greater Glasgow & Clyde NHS
      2011   Phase 2   EUCTR2010-022215-19-GB   United Kingdom;
Recombinant human Insulin-like Growth Factor   
   Greater Glasgow & Clyde NHS
      2011   Phase 2   EUCTR2010-022215-19-GB   United Kingdom;
Red light photopheresis   
   University Hospital, Akershus
      2019   Phase 1/Phase 2   NCT04164849   Norway;
Remicade   
   Academic Medical Center
      2019   Phase 4   EUCTR2018-002064-15-NL   Netherlands;
      2014   -   EUCTR2013-001029-17-NL   Netherlands;
      2013   Phase 4   EUCTR2013-002932-25-NL   Netherlands;
   Academic Medical Center, department of Gastroenterology and hepatology
      2008   -   EUCTR2008-001131-35-NL   Netherlands;
   CHRU de Lille
      2008   -   EUCTR2006-004784-58-FR   Belgium;France;Germany;United Kingdom;
   CUB- Hopital Erasme
      2016   Phase 4   EUCTR2015-004618-10-BE   Belgium;
   Celltrion
      2014   Phase 3   NCT02096861   United States;
   Centocor B.V.
      2005   Phase 3   EUCTR2004-002815-10-GB   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002815-10-ES   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-SE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DK   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-DE   Denmark;Germany;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002815-10-AT   Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
   Department of medical gastroenterology S, Odense University Hospital
      2015   Phase 4   EUCTR2012-002702-51-SE   Denmark;Finland;Norway;Sweden;
      2012   Phase 4   EUCTR2012-002702-51-DK   Denmark;Finland;Norway;Sweden;
   Department of medical gastroenterology, Herlev Hospital
      2016   Phase 4   EUCTR2012-002702-51-NO   Denmark;Finland;Norway;Sweden;
      2015   Phase 4   EUCTR2012-002702-51-FI   Denmark;Finland;Norway;Sweden;
      2009   Phase 4   EUCTR2009-009926-94-DK   Denmark;
   ErasmusMC
      2013   -   EUCTR2012-000645-13-BE   Belgium;Netherlands;
      2012   -   EUCTR2012-000645-13-NL   Belgium;Italy;Netherlands;
   GETAID
      2015   Phase 4   EUCTR2014-002311-41-SE   France;Germany;Netherlands;Sweden;United Kingdom;
   IBD Center LMU Munich
      2008   -   EUCTR2008-004926-18-DE   Germany;
   Janssen Biologics B.V.
      2009   -   EUCTR2008-005237-30-NL   Canada;Netherlands;Sweden;United States;
   Janssen Biologics BV
      2011   -   EUCTR2008-005237-30-SE   Belgium;France;Germany;Hungary;Italy;Netherlands;Sweden;United Kingdom;United States;
   Jørgen Agnholt
      2013   Phase 3   EUCTR2013-000971-34-DK   Denmark;
   Katholieke Universiteit Leuven
      2011   Phase 4   EUCTR2011-002061-38-BE   Belgium;
   Merck Sharp & Dohme Corp.
      2003   -   NCT00705614   -
   Novartis Pharma AG
      2011   -   EUCTR2010-019973-13-DE   Germany;Switzerland;
   Pfizer
      2015   -   NCT02539368   Belgium;Czech Republic;Czechia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
   Region Örebro län
      2021   Phase 4   EUCTR2019-002942-19-DK   Denmark;
   Royal Liverpool University Hospital
      2012   -   EUCTR2011-006084-22-GB   United Kingdom;
   Shradha Agarwal
      2011   -   NCT01438151   United States;
   Univeristy Hospital Na Bulovce
      2009   Phase 3   EUCTR2008-005688-32-CZ   Czech Republic;
   University Medical Center Groningen
      2021   Phase 4   EUCTR2020-001811-26-BE   Belgium;Netherlands;
      2020   Phase 4   EUCTR2020-001811-26-NL   Netherlands;
   University of Edinburgh
      2015   -   EUCTR2014-002311-41-GB   Belgium;France;Germany;Sweden;United Kingdom;
   University of Leuven
      2008   -   EUCTR2006-004784-58-DE   Belgium;France;Germany;United Kingdom;
      2007   -   EUCTR2006-004784-58-BE   Belgium;France;Germany;United Kingdom;
   University of Leuven Hospitals
      2009   Phase 4   EUCTR2006-004784-58-GB   Belgium;France;Germany;United Kingdom;
   University of Leuven Hospitals, Division of Gastroenterology
      2009   -   EUCTR2008-007519-34-SE   Sweden;
   Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie
      2013   -   EUCTR2011-001332-29-AT   Austria;
Remicade (infliximab)   
   Merck Sharp & Dohme Corp.
      2002   -   NCT00818272   Germany;
   Zon MW
      2014   Phase 4   EUCTR2013-002651-15-NL   Netherlands;
Remicade 100 mg powder for concentrate for solution for infusion.   
   Santeon
      2015   Phase 4   EUCTR2015-001954-14-NL   Netherlands;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2014   -   EUCTR2014-002056-40-NO   Norway;
Remisma   
   CELLTRION INC.
      2019   Phase 3   EUCTR2019-001087-30-IT   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Remsima   
   Amsterdam UMC location AMC
      2021   Phase 3;Phase 4   EUCTR2021-000469-33-NL   Netherlands;
   CUB- Hopital Erasme
      2016   Phase 4   EUCTR2015-004618-10-BE   Belgium;
   Celltrion, Inc
      2019   Phase 3   EUCTR2019-001087-30-PL   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-DE   Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
      2019   Phase 3   EUCTR2019-001087-30-BG   Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   Department of medical gastroenterology S, Odense University Hospital
      2015   Phase 4   EUCTR2012-002702-51-SE   Denmark;Finland;Norway;Sweden;
      2012   Phase 4   EUCTR2012-002702-51-DK   Denmark;Finland;Norway;Sweden;
   Department of medical gastroenterology, Herlev Hospital
      2016   Phase 4   EUCTR2012-002702-51-NO   Denmark;Finland;Norway;Sweden;
      2015   Phase 4   EUCTR2012-002702-51-FI   Denmark;Finland;Norway;Sweden;
   GETAID
      2015   Phase 4   EUCTR2014-002311-41-SE   France;Germany;Netherlands;Sweden;United Kingdom;
   Jørgen Agnholt
      2013   Phase 3   EUCTR2013-000971-34-DK   Denmark;
   Taina Sipponen
      2016   Phase 4   EUCTR2016-001278-13-FI   Finland;
   University Medical Center Groningen
      2021   Phase 4   EUCTR2020-001811-26-BE   Belgium;Netherlands;
      2020   Phase 4   EUCTR2020-001811-26-NL   Netherlands;
Remsima (infliximab)   
   Mundipharma Pharmaceuticals B.V.
      2016   Phase 4   EUCTR2014-004904-31-BE   Belgium;Netherlands;
      2015   Phase 4   EUCTR2014-004904-31-NL   Netherlands;
Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning   
   Diakonhjemmet Hospital AS
      2014   -   EUCTR2014-002056-40-NO   Norway;
Remsima and Inflectra   
   Janssen Biologics B.V.
      2009   -   EUCTR2008-005237-30-NL   Canada;Netherlands;Sweden;United States;
RhIGF (Increlex)   
   Nationwide Children's Hospital
      2008   Phase 2/Phase 3   NCT00764699   United States;
RhumAb to Il-17A (IgG1-k-class)   
   Novartis Pharma Services AG
      2009   -   EUCTR2008-008359-40-DE   Austria;Germany;Poland;
RhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class)   
   Novartis Pharma Services AG
      2009   -   EUCTR2008-008359-40-PL   Austria;Germany;Poland;
Ribavirin   
   Vanderbilt-Ingram Cancer Center
      2006   -   NCT00897312   -
Riboflavin Sodium Phosphate Injection   
   Xijing Hospital of Digestive Diseases
      2016   Phase 3   NCT02769494   China;
Riboflavin supplementation   
   University Medical Center Groningen
      2016   -   NCT02538354   Netherlands;
Rifabutin, Clarithromycin, and Clofazimine   
   Medstar Health Research Institute
      2007   Phase 4   NCT00513552   United States;
Rifaximin   
   ALFA WASSERMANN
      2007   -   EUCTR2007-001014-17-IT   France;Germany;Hungary;Italy;
   Assistance Publique - Hôpitaux de Paris
      2015   Phase 2   NCT02620007   France;
   Mayo Clinic
      2019   Phase 2   NCT04254549   United States;
   Northwestern University
      2019   Phase 2   NCT04154735   United States;
   Scott Lee
      2008   Phase 2   NCT00603616   United States;
   Sixth Affiliated Hospital, Sun Yat-sen University
      2017   Phase 3   NCT03185624   China;
      2017   Phase 3   NCT03185611   China;
Rifaximin Delayed Release (DR)   
   Salix Pharmaceuticals, Inc subsidiary of Valeant Pharmaceuticals International Inc
      2015   Phase 3   EUCTR2014-001645-24-CZ   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
   Salix Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2014-001645-24-PL   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
      2015   Phase 3   EUCTR2014-001645-24-DE   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
      2015   Phase 3   EUCTR2014-001644-38-PL   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
      2015   Phase 3   EUCTR2014-001644-38-DE   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
      2014   Phase 3   EUCTR2014-001645-24-HU   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
      2014   Phase 3   EUCTR2014-001645-24-FR   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
      2014   Phase 3   EUCTR2014-001644-38-HU   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
      2014   Phase 3   EUCTR2014-001644-38-FR   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
   Salix Pharmaceuticals, Inc. subsidiary of Valeant Pharmaceuticals International In
      2015   Phase 3   EUCTR2014-001644-38-CZ   Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
Rifaximin EIR   
   Bausch Health Americas, Inc.
      2014   Phase 3   NCT02240121   United States;
      2014   Phase 3   NCT02240108   United States;
Rifaximin delayed release 400 mg film coated tablet   
   ALFASIGMA S.P.A.
      2018   Phase 2   EUCTR2017-002258-36-NL   Belgium;Germany;Italy;Netherlands;Spain;
      2018   Phase 2   EUCTR2017-002258-36-BE   Belgium;Germany;Netherlands;Spain;
      2017   Phase 2   EUCTR2017-002258-36-ES   Germany;Spain;
      2017   Phase 2   EUCTR2017-002258-36-DE   Belgium;Germany;Netherlands;Spain;
Rifaximin delayed release tablets   
   Alfasigma S.p.A.
      2017   Phase 2   NCT03537157   Italy;
Rifaximin+omeprazole+miralax   
   Seattle Children's Hospital
      2015   Phase 1/Phase 2   NCT02272868   United States;
Rifaximin-EIR   
   ALFA WASSERMANN
      2011   -   EUCTR2011-002821-24-IT   Italy;
   ALFASIGMA S.P.A.
      2018   Phase 2   EUCTR2017-002258-36-NL   Belgium;Germany;Italy;Netherlands;Spain;
      2018   Phase 2   EUCTR2017-002258-36-BE   Belgium;Germany;Netherlands;Spain;
      2017   Phase 2   EUCTR2017-002258-36-ES   Germany;Spain;
      2017   Phase 2   EUCTR2017-002258-36-DE   Belgium;Germany;Netherlands;Spain;
   Alfa Wassermann S.p.A.
      2008   -   EUCTR2007-001014-17-DE   France;Germany;Hungary;Italy;
      2007   Phase 2   NCT00528073   France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;
      2007   Phase 2   EUCTR2007-001014-17-HU   France;Germany;Hungary;Italy;
      2007   Phase 2   EUCTR2007-001014-17-FR   France;Germany;Hungary;Italy;
Risankizumab   
   AbbVie
      2020   Phase 3   NCT04524611   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 1   NCT04254783   Germany;Israel;United States;
      2019   -   NCT03914261   Belgium;Israel;Spain;Switzerland;United States;
   AbbVie Deutschland GmbH & Co. KG
      2015   Phase 2   EUCTR2015-001834-15-DE   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 10 mg/ml   
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2014   Phase 2   EUCTR2013-002902-29-DE   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 180 mg SC   
   AbbVie
      2015   Phase 2   NCT02513459   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 600 mg IV   
   AbbVie
      2015   Phase 2   NCT02513459   Belgium;Canada;Germany;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 90 mg/ml   
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2014   Phase 2   EUCTR2013-002902-29-DE   Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab IV   
   AbbVie
      2018   Phase 3   NCT03105102   American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   NCT03105128   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   NCT03104413   American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   NCT02031276   Belgium;Canada;France;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab On-Body Injector (OBI)   
   AbbVie
      2018   Phase 3   NCT03105102   American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Risankizumab SC   
   AbbVie
      2018   Phase 3   NCT03105102   American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   NCT03105128   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   NCT03104413   American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 2   NCT02031276   Belgium;Canada;France;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risedronate   
   University of Alberta
      2010   Phase 4   NCT01215890   Canada;
Ritlecitinib   
   Pfizer Inc.
      2018   Phase 2   EUCTR2017-003359-43-SK   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-CZ   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 2   EUCTR2017-003359-43-PL   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-HU   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-DE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-BE   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
      2018   Phase 2   EUCTR2017-003359-43-AT   Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Rituximab   
   Paul Szabolcs
      2012   Phase 1/Phase 2   NCT00692939   United States;
Rizankisumab   
   AbbVie Deutschland GmbH & Co. KG
      2017   Phase 3   EUCTR2016-003190-17-SK   Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Po